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ABSTRACT 
 
Background: Controlled agglomeration of nanoparticles to micrometer-sized 
composites (i.e. nanoparticle agglomerates) has been suggested as a 
particle-engineering approach to combine the advantages of nanoparticles 
with the aerodynamics of microparticles for pulmonary drug delivery. The 
aim of this thesis was to engineer nanoparticle agglomerates with properties 
suitable for inhaler formulation, for drugs with different physicochemical 
properties. 
 
Methods: Nanoparticle agglomerates of three model drugs, namely 
indometacin, ibuprofen and theophylline, were prepared by coupling wet 
milling and spray drying. In the case of indometacin and ibuprofen, matrix 
formers (i.e. mannitol and L-leucine) were added to the aqueous 
nanosuspensions of the drugs prior to spray drying while for theophylline wet 
milling was carried out in isopropanol in the presence of mannitol. 
Nanoparticle agglomerates were characterised with respect to their particle 
size, morphology, solid state, redispersibility and dissolution, while their in-
vitro aerosolisation performance was determined using the next generation 
impactor. A full factorial design and the fast screening impactor were 
employed in the case of ibuprofen nanoparticle agglomerates while 
computational modelling was used to investigate interactions between the 
crystals of theophylline and mannitol. 
 
Results: Nanosupensions of indometacin and ibuprofen stabilised with 
various polymers/surfactants were successfully prepared by wet milling and 
were further spray dried. Incorporation of matrix formers before spray drying 
resulted in nanoparticle agglomerates with improved redispersibility (ability 
to reform nanoparticles upon hydration), dissolution and higher fine particle 
fractions compared to those without matrix formers. In the case of 
theophylline, mannitol acted as a co-milling agent facilitating the size 
reduction of the drug’s needle-like crystals. Increasing the amount of 
mannitol led to the formation of smaller, more spherical and porous particles 
with enhanced aerosolisation performance. For each drug, the nanoparticle 
agglomerates produced retained the crystallinity of the starting materials 
ensuring the long-term physical stability of the formulations upon storage.  
 
Conclusions: Combining wet milling and spray drying can be used as an 
industrially feasible particle-engineering platform for dry powders for 
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inhalation. By careful selection of formulation and process parameters, this 
platform can be applied to a range of drugs with different physicochemical 
properties. 
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1. GENERAL INTRODUCTION 
 
Drug delivery to the lungs is an effective way of targeting inhaled therapeutic 
aerosols for the treatment of respiratory diseases such as asthma, chronic 
obstructive pulmonary disease (COPD) and cystic fibrosis. In comparison 
with oral or parenteral administration, pulmonary drug delivery results in a 
rapid onset of action as the drug is delivered to its site of action. For 
example, inhalation is the preferred route of administration of salbutamol 
which is a short-acting β-agonist used in the treatment of asthma and COPD. 
According to Du et al. (2002), peak plasma levels were found to be achieved 
considerably earlier for inhaled salbutamol (Ventolin® Inhaler, single dose: 
12 × 100 μg, tmax: 0.22 h) compared to oral administration (oral aqueous 
solution 1.2 mg/100 mL, tmax: 1.8 h). The rapid onset of action of inhaled 
salbutamol can be attributed to its absorption via numerous lung blood 
vessels, while when the drug was orally administered it had to pass through 
more biological barriers before entering the systemic circulation. Additionally, 
pulmonary drug delivery enables local delivery of higher drug concentration 
at the lung tissue while concentrations elsewhere are kept at a minimum. In 
this way, a maximum therapeutic effect can be achieved by administering 
lower inhaled doses compared to those required for systemic administration 
and as a result side effects can be minimised. Moreover, the lungs possess a 
relatively large surface area for drug absorption, lower metabolic activity 
compared to the liver and the gastrointestinal tract, abundance of capillaries 
and thin air-blood barrier. Therefore, the lungs are considered an ideal portal 
of entry for the systemic drug delivery of small molecules but also 
therapeutic biopharmaceuticals as peptides (e.g. insulin), proteins and 
vaccines (Zeng et al., 2001; Patton et al., 2004; Taylor, 2013).  
 
1.1. The human respiratory tract 
 
The respiratory tract is the anatomic part of the human body that is mainly 
involved in the oxygenation of the blood and the removal of carbon dioxide 
from the body. Apart from the gaseous exchange between the inhaled air, 
the blood and the cells, it is responsible for the homeostatic maintenance of 
the blood pH by adjusting the rate of removal of the acid-forming carbon 
dioxide but also for the provision of vocal expression.  
 
The respiratory tract starts at the nose and terminates deep in the lungs at 
an alveolar sac. There are several ways for the classification of the different 
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regions of the respiratory tract. Commonly, it is divided into the upper and 
lower respiratory tract. The upper respiratory tract comprises the nose, nasal 
cavity, throat, pharynx and larynx while the lower respiratory tract consists 
of the trachea, bronchi, bronchioles and the alveoli. Another classification is 
to divide the respiratory tract into the following three regions: 
nasopharyngeal, tracheobronchial and alveolar. More specifically, the 
nasopharyngeal region comprises the airways of the head from the nose to 
the larynx and is often referred to as the extrathoracic airways. The 
tracheobronchial region starts at the larynx and extends via the trachea, 
bronchi, bronchioles and ends at the terminal bronchioles and its main 
function is air-conduction. The alveolar region is the gas-exchange 
compartment comprising the respiratory bronchioles, alveolar ducts and 
alveoli (Taylor and Kellaway, 2001).  
 
In 1963, Edward Weibel proposed a morphometric model of the human lung 
with the main aim to develop a quantitative description of the pulmonary 
anatomy and the correlation of anatomy with physiology (Weibel, 1963). The 
Weibel-A model divides the lungs into 24 compartments, each compartment 
corresponding to a generation of the model. It assumes that each generation 
of the airways branches symmetrically into two equivalent generations and it 
is the most widely used model for the investigation of particle deposition in 
the human lung. According to this model, the tracheobronchial region 
comprises generation 0 (trachea) to 16 (terminal bronchioles) while the 
alveolar region includes generations 17 to 23 (Fig. 1.1).  
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Figure 1.1 Schematic of the human respiratory tract and morphometric model of the 
conducting and respiratory zone according to the Weibel-A model (Kleinstreuer and 
Zhang, 2010) 
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1.2. Inhalation aerosols and particle aerodynamic diameter 
 
With the exceptions of medical gases and administration by pulmonary 
instillation, a drug must be presented as an aerosol in order to be delivered 
to the lungs. In physical pharmacy, an aerosol is defined as a colloidal 
dirspersion of liquids or solids in gases, having sufficiently small size to 
exhibit considerable stability as a suspension (Taylor, 2013). Typically, 
aerosol particles range in diameter from about 10-9 to 10-4 m and the unit of 
micrometre (1 μm = 10-6 m) is used to describe their particle size (Zeng et 
al., 2001).  
 
The most important physical property of an aerosol for inhalation is its 
particle size. This property is the main parameter, which defines the site of 
deposition of aerosol drugs within the respiratory tract and it is usually 
described by the aerodynamic diameter of the particles. The aerodynamic 
diameter is defined as the diameter of a sphere of unit density that has the 
same terminal settling velocity as the particle under consideration. It 
depends on the airflow (particle Reynolds number, Re) and the particulate 
properties including the geometric size, shape and density of the particle. At 
Stokes flow regime of Re < 0.1, the aerodynamic diameter of a particle (da) 
can be calculated using Eq. 1.1: 
 
𝑑𝛼 = 𝑑𝑣 ∗ √
𝜌
𝜒𝜌0 
  . . . Equation 1.1 
where dv is the volume-equivalent diameter, ρ is the particle density, ρ0 is 
the unit density (i.e. 1 g cm-3) and χ is the dynamic shape factor. The 
dynamic shape factor is defined as the ratio of the drag force on a particle to 
the drag force on the particle volume-equivalent sphere at the same velocity. 
For a spherical particle, the dynamic shape is defined as 1 (Chow et al., 
2007).  
 
Most therapeutic aerosols are polydisperse consisting of a wide range of 
particle sizes. The particle size distribution is described by the geometric 
standard deviation (GSD), when size is log-normally distributed. A GSD of 1 
indicates a monodisperse aerosol while a GSD > 1.2 indicates a 
polydispersed aerosol (Traini, 2013).  
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1.3. Particle deposition in the respiratory tract 
 
Deposition occurs when an inhaled particle does not follow airflow 
streamlines and it comes into contact with a respiratory surface from which it 
does not rebound or resuspend. Particles that remain airborne and do not 
deposit throughout the respiratory cycle are exhaled. The main mechanisms 
responsible for particle deposition in the respiratory tract include inertial 
impaction, gravitational sedimentation, Brownian diffusion and to a lesser 
extent interception, and electrostatic precipitation (Fig. 1.2).  
 
 
Figure 1.2 Particle deposition in the airways (Fröhlich and Salar-Behzadi, 2014). 
 
1.3.1. Inertial impaction 
 
Inertial impaction is the predominant mechanism of particle deposition in the 
respiratory tract. Inertia is the tendency of a moving particle to resist 
acceleration. Inertial impaction occurs at the bifurcations of the respiratory 
tract when the airflow changes direction and the particles within the 
airstream follow their original trajectory instead of adjusting to the airflow.  
 
For a particle travelling in an airway, Stokes’ number (Stk) is a 
dimensionless number used to predict impaction driven deposition (Eq. 1.2).    
 
𝑆𝑡𝑘 =
𝜌𝑝∗𝑑
2∗𝑉
18𝜂∗𝑅
 . . . Equation 1.2 
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where ρp is the particle density, d is the particle diameter, V is the air 
velocity, η is the air viscosity and R is the airway radius. The Stokes’ number 
shows that the probability of a particle to deposit due to inertial impaction is 
directly proportional to the particle density, the square of particle diameter 
and the air velocity whereas it is inversely proportional to the airway radius. 
Inertial impaction is a velocity-dependent mechanism and causes most of the 
particles larger than 5 μm and particularly greater than 10 μm to deposit in 
the upper respiratory tract and the large conducting airways (Asgharian and 
Anjilvel, 1994). 
 
1.3.2. Gravitational sedimentation 
 
Gravitational sedimentation refers to the settling of the particles under the 
action of the gravity. The terminal settling velocity (Vt) of particles settling 
under gravity is given by Stokes’ law (Eq. 1.3).  
 
𝑉𝑡 =
(𝜌𝑝−𝜌𝑎)∗𝑑
2∗𝑔
18𝜂∗𝑅
   . . . Equation 1.3 
  
where ρα is the density of the air and g is the gravitational constant. Stoke’s 
law is valid for unit density particles with diameter between 1 to 40 μm and 
if laminar flow within the airways is assumed. According to Eq. 1.3, the 
gravitational sedimentation of a respirable particle is dependent on its size 
and density. Gravitational sedimentation is a time-dependent process and 
deposition by this mechanism increases with increasing residence time of a 
particle in the airways and alveoli (e.g. during slow, steady breathing or 
breath-holding). It is an important deposition mechanism for particles in the 
size range 0.5-3 μm, in the small airways and alveoli (Taylor, 2013).  
 
1.3.3. Brownian diffusion 
Deposition by Brownian diffusion results from the random motions of the 
particles caused by their collisions with gas molecules.  This motion 
transports particles from high to low concentrations causing the movement 
of particles from the aerosol cloud to the airways’ walls. The rate of Brownian 
diffusion (D) is given by Stokes-Einstein equation (Eq. 1.4).  
𝐷 =
𝐾𝐵∗𝑇
3𝜋∗𝜂∗𝑑
  . . . Equation 1.4  
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where KB is the Boltzmann constant and T is the absolute temperature. 
Unlike deposition by inertial impaction and gravitational sedimentation, 
which increase with increasing particle size (Eq. 1.2 and 1.3), deposition by 
Brownian diffusion is inversely proportional to the particle diameter. This 
means that deposition by Brownian diffusion increases with decreasing 
particle size and becomes the predominant mechanism for particles smaller 
than 0.5 μm in the deep lungs (Fig.1.3, Zeng et al.,2001; Taylor, 2013).   
 
 
Figure 1.3 Total deposition of unit-density spheres in the human respiratory tract 
inhaled orally at rest (Heyder, 2004).  
 
1.3.4. Interception 
Interception occurs when a distal end of a particle comes into contact with 
the airway wall despite the fact that its centre of mass remains within the 
streamlines of the gas phase. Although negligible for spherical particles, 
interception can play an important role regarding the deposition of elongated 
particles with small aerodynamic diameter (Johnson and Martonen, 1994).  
1.3.5. Electrostatic precipitation 
 
During aerosolisation, particles may become electrostatically charged. 
Deposition of charged particles by electrostatic precipitation can occur either 
through the induction of an opposing charge on the airways’ surface and 
subsequent electrostatic attraction of via the repulsion between particles of 
the same charge directing them towards the airway walls (Melandri et al., 
1983).  
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1.4. Delivery devices 
 
There are currently three main types of aerosol delivery systems 
commercially available: nebulisers, pressurized metered-dose inhalers 
(pMDIs) and dry powder inhalers (DPIs). The characteristics of these three 
types of devices will be described below. Particular emphasis will be placed 
on DPIs as the formulations prepared in this thesis have been developed for 
this type of device. At this point, it should be highlighted that in recent 
years, the technological innovations in device engineering and formulation 
science have significantly improved the performance of all types of inhalers. 
Factors such as the drug and formulation properties, the device and the 
patient are all of paramount importance and should be addressed in order to 
achieve optimum delivery to the lungs (Fig.1.4).  
 
 
Figure 1.4 Factors that can influence optimal aerosol drug delivery from inhaler 
devices. 
 
1.4.1. Nebulisers  
A nebuliser is a device for converting an aqueous solution or suspension into 
an aerosol for inhalation. The aqueous solution or suspension is contained 
inside nebules. The nebule content is dispensed into the reservoir chamber 
via a jet, ultrasonic or vibrating-mesh nebuliser device. Jet nebulisers 
operate under the Bernouilli’s principle using compressed gas (air or oxygen) 
passing through a Venturi nozzle.  The smaller respirable droplets generated 
during the atomisation are carried on the airstream out of the nebuliser and 
via either a mouthpiece or face mask into the airways of the patient, while 
the larger non-respirable droplets impact on built-in baffles returning to the 
reservoir for renebulisation. In ultrasonic nebulisers the energy of 
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atomisation comes from a piezoelectric crystal, which vibrates at a high 
frequency (1-3 MHz). Modification to ultrasonic nebulisers resulted in the 
development of the recently introduced vibrating-mesh nebulisers, which 
employ plates with multiple apertures through which liquids are extruded to 
generate aerosols (Taylor, 2013). 
Nebulisers have sometimes been used for the delivery of drugs that cannot 
be formulated into pMDIs or DPIs. They are able to deliver high drug doses 
to the lungs, which is especially useful for the pulmonary administration of 
antibiotics (e.g. tobramycin) to patients with cystic fibrosis. Nebulisers can 
be used at any age and for any disease severity as they are simple and 
intuitive devices and the drug can be inhaled during tidal breathing through a 
mouthpiece or facemask. Moreover, as long as there are no physicochemical 
compatibility issues, it is possible to mix more than one medications in the 
nebulisers and thus co-administer them simultaneously (Kamin et al., 2006).  
Regarding the disadvantages of nebulisers, prolonged treatment time is 
required to deliver an adequate dose. Jet nebulisers also require a source of 
compressed air, which together with the need for equipment maintenance 
and cleaning for infection control increase the running cost and have limited 
their use to the treatment of hospitalised or non-ambulatory patients. 
Despite the fact that ultrasonic nebulisers are compact and portable, the rise 
in temperature during their operation may cause degradation of thermolabile 
drugs. The droplets produced by ultrasonic nebulisers have often a higher 
aerodynamic diameter compared to jet nebulisers explaining why they tend 
to be less widely used. The recently introduced vibrating-mesh nebulisers 
manage to overcome many of the aforementioned limitations as they 
generate aerosols with high fine particle fractions (FPF), have very small 
residual volumes (i.e. the volume of solution left in a nebuliser chamber once 
nebulisation has ceased) and treatment times compared to jet and ultrasonic 
nebulisers (Geller, 2005; Alhaddad et al., 2015).  
1.4.2. Pressurised metered-dose inhalers (pMDIs)  
Pressurised metered-dose inhalers (pMDIs) were introduced by Riker 
Laboratories (now 3M Health Care), which in the mid-1950s set out to 
develop formulations of bronchodilators in pressurised containers with multi-
dose capability and reproducible dosing characteristics. In pMDIs, drug is 
either dissolved or dispersed in a liquid propellant or a mixture of propellants 
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together with other excipients including co-solvents, solubilising and 
lubricating agents, which are contained in a pressurised canister with a 
metering valve. Upon actuation of the metering valve, a predetermined dose 
is released as a spray. Upon exiting the canister, the formulation expands 
which is followed by rapid evaporation of the volatile propellant. It is the 
latent heat of evaporation of the volatile propellant that provides the energy 
of atomisation resulting in the breaking-up of the liquid into a fine spray of 
droplets (Newman, 2005; Taylor, 2013).  
The main advantages of pMDIs are their small size, portability, disposability 
and relatively low cost. Many doses (up to 200) are available in the canister 
and dose delivery is reproducible. Moreover, they are quick to use as a dose 
can be delivered in a few seconds, unlike nebulisers, which typically take a 
few minutes. The propellant liquid offers inert conditions and the content of 
the canister are protected from moisture, oxidative and microbiological 
contamination. The aforementioned advantages explain why the pMDIs have 
been the device of choice for the outpatient treatment of asthma and COPD 
(Newman, 2005; Geller, 2005). 
Over the years, a number of drawbacks related to the use of pMDIs have 
been identified (Newman, 2005; Geller, 2005). Most pMDIs only deliver 10-
20% of the stated emitted dose to the lungs, even with a good inhaler 
technique. The main reason for that is the high droplet exit velocity, which 
leads to extensive impaction in the oropharyngeal region. Moreover, as drug 
delivery from pMDIs is highly dependent on patient’s inhaler technique, 
misuse of pMDIs and especially the difficulty of many patients to coordinate 
actuation with inhalation further reduces the amount of the drug that 
reaches the site of action (Fink and Rubin, 2005). Also, some patients suffer 
from the so-called “cold-freon” effect in which the arrival of cold propellant 
spray on the back of the throat causes patients to stop inhaling or to inhale 
by the nose. The use of a spacer between the pMDI and the patient can 
reduce the problem of oropharyngeal deposition and the importance of 
actuation/inhalation coordination. Spacer devices fitted with a facemask have 
been usually employed with a pMDI for administering aerosol inhalation to 
young children. An alternative approach is the use of breath-actuated pMDIs 
which do not release drug until inspiration occurs, and in this way they can 
overcome the coordination problem of conventional pMDIs.  
CHAPTER 1. GENERAL INTRODUCTION 
 
 30 
Another drawback is associated with the propellants used in pMDIs. The 
traditionally used chlorofluorocarbons (CFCs) are considered environmentally 
harmful as they have been linked with the depletion of the stratospheric 
ozone layer and they contribute to global warming. In accordance with the 
Montreal Protocol of 1987, CFCs have been replaced by the non-ozone 
depleting, non-flammable hydrofluoroalkenes (HFA-134a, HFA-227). 
However, the replacement of CFCs with HFAs presented major formulation 
problems as the two types of propellants exhibit different physicochemical 
properties (e.g. polarity, vapour pressure, density etc.). Further replacement 
of HFAs may be required in the future, as these gases have been found to 
contribute to global warming (Leach, 2005).  
 
1.4.3. Dry powder inhalers (DPIs) 
Dry powder inhalers (DPIs) are devices by which a dry powder formulation of 
a drug is delivered for local or systemic effect via the lungs. Their market is 
estimated to reach over USD 31.5 billion in 2018, while they have been 
identified as the most lucrative market segment of the asthma and COPD 
devices market by 2020 (Dhabale, 2014). The main advantages and 
disadvantages of DPIs are presented in Table 1.1. Based on their design, DPI 
devices can be classified into three categories (Fig.1.5).  
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Figure 1.5 Different types of dry powder inhalers. 
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Table 1.1. Advantages and disadvantages of dry powder inhalers (Chrystyn and 
Price, 2009; Taylor, 2013).  
Advantages of DPIs Disadvantages of DPIs 
 Breath-actuated and so no 
need for patient coordination 
required 
 
 Some need to be shaken prior to use 
 Enhanced physicochemical 
stability as the formulation is 
in the solid state 
 
 Dose preparation errors can be 
critical mistakes  
 Ability to deliver high drug 
payloads to the lungs 
 Attention required to orientation of 
the inhaler during dose preparation 
and before inhalation  
 No propellant  Flow-dependent dose emission 
 Most have dose counters 
 
 Need for a fast acceleration rate at 
the start of the inhalation 
 Short treatment time  Poor quality or no dose emitted if 
inhalation is too slow 
 Small and portable  Uncertainty of dose emission during 
acute exacerbations 
  Can result in high oropharyngeal 
deposition 
  More expensive than pMDIs 
  Need to be stored in a cool and dry 
place 
 
The first-generation DPIs were breath-actuated single unit-dose devices. A 
powder-containing capsule is loaded into the device holder prior to use of the 
device, the capsule is opened within the device and the powder is inhaled. 
The spent capsule is discarded after use. The Spinhaler® (Rhône-Poulenc 
Rorer, now Aventis), the first DPI device developed for the delivery of 
sodium cromoglicate, belongs in this category. The drug formulation is 
prefilled into a capsule and loaded into the device on top of a propeller. Two 
pins pierce the walls of the capsule when the patient actuates the device by 
sliding a cam. Once the capsule has been broken, the patient inhales through 
the device causing the propeller to turn and vibrate dispersing the powder 
into the inspired airstream (Chrystyn, 2007). Although, the Spinhaler® is 
discontinued, various other single unit-dose devices are currently on the 
market such as the HandiHaler® (Boehringer-Ingelheim/Pfizer) and the 
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Aerolizer® (Novartis) which is similar to the Cyclohaler® (Teva). The 
Aerolizer® employs four pins located on each side to pierce a capsule. Upon 
inhalation, the powder is deaggregated by a spinning motion via turbulence 
generated by a plastic grid (Coates et al., 2004). Hard gelatin or 
hydroxypropylmethylcellulose (HPMC) capsules have been used for this type 
of DPIs. Although hard gelatin capsules have been the standard for more 
than 40 years in dry powder inhalation, HPMC capsules are currently used in 
the majority of the newly developed medicinal products. HPMC capsules 
contain less water than the gelatin capsules and thus are more suitable for 
moisture sensitive formulations (Jones, 2003). Moreover, HPMC capsules are 
less prone to triboelectrification during spinning and their tendency to 
fragment at extremely low relative humidity when pierced is less compared 
to the gelatin capsules (Birchall et al., 2008). In this way, the risk of 
inhalation of capsule fragments and poor capsule emptying is reduced.  
Single unit-dose inhalers are considered inconvenient to use as many steps 
(i.e. take capsule, load into the device, pierce) are required prior to their 
use. Carrying out all these steps may not be easy for a patient who is 
undergoing an asthma attack or for elderly patients who may lack the 
manual dexterity to accomplish all the required maneuvers (Chrystyn, 2007).  
However, it would be wrong to conclude that their use will be discontinued in 
the future, as they are attractive devices especially in emerging economies 
due to their low cost and ease of manufacturing. According to Harris (2016), 
the development of capsule-based DPIs that use capsules with size larger 
than size 3 and the introduction of an opening rather than piercing 
mechanism that would minimise the risk for creation of fragments, are two 
fields for innovation in the future.  
The second-generation DPIs can be further divided into two categories: the 
multiple dose and the multi-unit devices. The multiple dose DPI devices 
measure the dose from a powder reservoir, and consequently they are also 
known as reservoir systems. The multi-unit dose DPI devices disperse 
individual doses, which are premetered into blisters or disks by the 
manufacturer.  
The Turbohaler® (AstraZeneca) was the first representative of the multiple 
dose DPIs to enter the market and is employed for the administration of β2-
agonists (formoterol, terbutaline) and the corticosteroid budesonide 
separately and in combination. In the Turbohaler®, the drug is formulated as 
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a pellet of a soft aggregate of micronised drug particles with or without 
additional lactose excipient. Other reservoir devices have been developed 
and entered the market including the Clickhaler® (Innovata Biomed), the 
Easyhaler® (Orion Pharma), the Novolizer® (ASTA Medica, now Viatris 
GmbH) and the Pulvinal® (Chiesi). These devices try to minimise the flow-
dependent dose emission that occurs with the Turbohaler®. More specifically, 
the dose emission from the Easyhaler® was found to be relatively consistent 
regardless of the inspiration rate (Palander et al., 2000). Based on the fairly 
consistent dose emission irrespective of the inhalation technique used by 
patients of all groups and the increased patient preference the Easyhaler® 
closely meets the criteria for an ‘ideal inhaler’ (Chrystyn, 2006). It should be 
noted that attention has to be given to the protection of the  formulation 
from moisture when reservoir devices are used. In the case of Turbohaler® 
this is achieved by including a desiccant, while the Easyhaler® has a 
protective case and the hopper is designed so as it is impossible for the 
patient to blow into it. Moreover, it is often important to hold the reservoir 
devices in a vertical position during operation as some of these devices rely 
on gravity to fill the metering dose cup.  
To address issues related with multiple and consistent dose-to-dose delivery, 
multi-unit devices were developed. Multi-unit DPIs include Diskhaler® and 
Accuhaler/Diskus® both developed by GlaxoSmithKline. The Diskhaler® 
employs individual doses contained within blisters (4 or 8 blisters) on a disk. 
Upon actuation, a needle pierces the upper and lower surfaces of a blister 
and as the patient inhales, the contents of the blister are dispersed in the 
airstream. The drug particles are detached from the carrier particles and a 
fraction is delivered to the lungs. On repriming the device, the disk rotates to 
expose the next blister to the piercing needle (Chrystyn, 2007). The 
Diskhaler® has now been withdrawn from the market, but in the past it was 
used for the delivery of drugs such as salbutamol, salmeterol, 
beclometasone, fluticasone propionate and the antiviral drug zanamivir. 
Accuhaler/Diskus® was marketed in the late 1990s as an improvement of the 
Diskhaler®, as it has the advantage of holding additional doses. It contains 
60 doses (one-month therapy assuming one ‘puff’ twice daily dosage) in a 
double-foil strip. Advair/Seretide Diskus® which contains fluticasone 
propionate and salmeterol xinafoate, occupied 5th place on the list of best-
selling medicines for 2013, indicating its wide acceptance among patients 
and physicians (US. Pharmaceutical Sales - Q4 2013, 2014). The recently 
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developed Ellipta® (GlaxoSmithKline) is a multi-unit device which can hold 
sufficient medication for one month (30 doses). It delivers the fixed 
combination of the inhaled corticosteroid fluticasone furoate and the long-
acting β2-agonist vilanterol as a once-daily inhaled maintenance therapy for 
asthma and COPD. The Ellipta® has a three-step operation procedure: ‘open 
the cover’, ‘inhale the dose’ and ‘close the cover’ and it was designed to be 
easily operated by patients of all ages including the elderly. In a recent 
study, Svedsater et al. (2013) found that Ellipta® was associated with high 
patient satisfaction and was preferred to other inhalers (i.e. Diskus® and 
pMDIs) based on interviews of participants with asthma and COPD. 
Ergonomic design, mouthpiece fit, dose counter visibility and ease of 
interpretation emerged as frequently cited drivers of preference for the 
Ellipta®.  
The third-generation DPIs are also known as active devices as they employ 
electrical or mechanichal energy (compressed gas, battery-driven impellers, 
vibrating piezoelectric crystals) to disperse the drug powder (Islam and 
Gladki, 2008). While the efficiency of the passive, breath-actuated devices 
(first and second-generation DPIs) depends on the patient’s inspiratory 
force, the active devices, due to the presence of an energy source, enable 
respiratory force-independent dosing precision and reproducible aerosol 
production (Crowder et al., 2001; Islam and Gladki, 2008). The Exubera® 
(Nektar Therapeutics/Pfizer) was the first approved active DPI using 
compressed air for the pulmonary drug delivery of insulin. While the 
Exubera® was expected to revolutionise the treatment of diabetes and 
increase patient’s adherence, the device was withdrawn by Pfizer in the end 
of 2007 after it was on the market for only a year, due to the very poor sales 
numbers. Detailed commentaries on the reasons of the withdrawal of 
Exubera® and the future of inhaled insulin have been provided by Mack 
(2007) and Heinemann (2008).   
In-vitro studies have demonstrated that active DPIs can produce aerosols 
with fine particle fractions (i.e. the fraction of emitted dose less than a stated 
size, usually 5 μm) of 50-70% (Islam and Clearly, 2012). Moreover, while 
passive devices are commonly used for local respiratory delivery, the active 
devices can play a future role in the delivery of drugs for systemic action, 
which need to deposit more deeply into the lungs.  
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1.4.3.1. Device resistance  
A passive DPI depends on the patient’s inspiratory flow rate for the required 
energy to disperse the powder. The internal resistance of a DPI is a 
consequence of its design, and contains elements of flow restriction to 
increase the kinetic energy of the airflow through the device during an 
inhalation. More specifically, during inhalation from a DPI, the patient’s 
inspiratory effort with the resistance of the device creates turbulent energy, 
which is measured as pressure drop (ΔP in cmH2O) that causes the 
dispersion of the powder (Eq.1.5, Clark and Hollingworth, 1993).  
√𝛥𝑃 = 𝑄 ∗ 𝑅𝐷  . . . Equation 1.5 
where Q is the volumetric flow rate in L min-1  and  RD is the device 
resistance. The resistance of devices can be classified from low (e.g. 
Aerolizer®) to medium/low (e.g. Accuhaler/Diskus®, Ellipta®) to medium/high 
(Turbohaler®) and then to high (e.g. HandiHaler®) (Demoly et al., 2014). 
According to Eq. 1.5, airflow is inversely proportional to device resistance 
indicating that high-resistance devices require low flow to create the required 
pressure drop.   
Most inhalers deliver fine particle fractions between 20 and 30% of the label 
claim between 2 and 4 KPa pressure drop. A common misconception is that 
high resistance DPIs require a high flow rate or considerable inspiratory 
effort in order to be operated correctly limiting the prescription of these 
inhalers to patients with COPD (Hoppentocht et al., 2014). However, studies 
have shown that it is easier to achieve such pressure drop when using high-
resistance inhalers than low-resistance inhalers and that patients were able 
to achieve the required pressure drop even during exacerbations of asthma 
and COPD (Börgstrom, 2001). Moreover, the high flow rates associated with 
low-resistant inhalers lead to the impaction of drug particles in the 
oropharynx, which is at the cost of central and peripheral lung deposition.  
 
1.4.3.2. Dry powder inhaler formulations 
 
Drug particles should exhibit an aerodynamic diameter between 1 and 5 μm 
so as to be delivered to the lungs (Heyder et al., 1986). Such fine drug 
particles exhibit a high surface free energy. In an attempt to minimise their 
surface energy, the particles have the tendency to stick together (cohesion) 
CHAPTER 1. GENERAL INTRODUCTION 
 
 37 
or to any surfaces they encounter (adhesion). Moreover, such fine particles 
tend to suffer from poor flowability and aerosolisation performance as they 
are retained in the device when used alone.  
 
The most commonly applied approach in order to address the above 
challenges is to blend the fine drug particles with an inert carrier consisting 
of coarser particles usually in the size range of 40-150 μm. During blending, 
the micronised drug particles adhere to the surfaces of the carrier particles 
forming adhesive mixtures (Fig.1.6). The carrier particles act as a diluent (a 
typical drug-to-carrier ratio is 1:67.5) but also as a flowability enhancer 
leading to a more reproducible dose metering.  
 
 
Figure 1.6 (a,b) Scanning electron microscopy and (c,d) coherent anti-Stokes 
scattering microscopy images of adhesive mixtures of salmeterol xinafoate (red) and 
lactose carrier (green) after 0.5 (left) and 600 minutes of mixing (right). Scale bars 
represent 20 μm (Fussell et al., 2014).   
 
The dispersion of adhesive mixtures upon inhalation may be regarded as a 
three-step process including: fluidisation of the powder in the airstream, 
detachment of primary or agglomerated drug particles and break-up of 
detached agglomerates into primary particles (Grasmeijer et al., 2015). The 
(b) (a) 
(d) (c) 
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particles that exhibit an aerodynamic diameter in the range of 1-5 μm will be 
deposited in the lungs while larger particles will be impact in the mouth and 
the back of the throat where they are swallowed (Fig.1.7). The degree of 
dispersion achieved depends on the cohesive/adhesive forces and the 
separation forces generated by the kinetic energy of the inhaled airstream. 
The balance between adhesive and cohesive forces should be adjusted to 
ensure sufficient adhesion between carrier particles and drug so as the 
adhesive mixture to be stable during handling and filling but also sufficient 
detachment during aerosolisation.   
 
 
Figure 1.7 Schematic diagram of adhesive mixtures for DPIs. The formulation 
consists of micronised drug particles adhered on the surface of large carrier particles. 
Upon inhalation, drug particles detach from the surface of large carriers and deposit 
in the lungs. The carrier particles impact at the back of the throat. 
 
Lactose is the most widely used carrier in DPIs with various inhalation grades 
of different physicochemical properties available on the market. Apart from 
lactose, a wide range of other generally regarded as safe (GRAS) excipients 
have been studied as carrier for DPIs including D-mannitol, trehalose 
dihydrate, sorbitol, erythritol and D-raffinose. Mannitol, a reducing sugar 
which is less hygroscopic than lactose, has been proposed as the most 
promising alternative carrier to lactose in DPIs (Steckel and Bonzen, 2004; 
Rahimpour et al., 2014).  
 
Many studies have investigated the effect of parameters that can influence 
the aerosolisation performance of adhesive mixtures including the effect of 
carrier particles size distribution, fine excipient particles, carrier surface 
roughness, drug content, and the physicochemical properties of carrier and 
drug. However, general conclusions regarding the effects of these variables 
Carrier residue Detached drug fraction 
Micronised 
drug particles 
Coarse carrier particles  
(e.g. lactose, mannitol)   
Inspiration Force 
(Patient) 
Dispersion 
Fine particles 
reaching the 
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cannot be drawn as inconsistent findings have been reported in the 
literature. The inconsistency of the findings can be attributed to the complex 
interplay among the properties of starting materials, the mixing process and 
the dispersion performance (Grasmeijer et al., 2015).  
 
Over the last three decades, particle engineering for pulmonary drug delivery 
has focused on the design of carrier-free particles (i.e. particles free of 
carrier) for DPIs. Engineering of carrier-free particles has the potential to 
overcome the problems associated with the presence of carrier (most 
commonly lactose) (Healy et al., 2014). In this way, issues of blend 
uniformity can be avoided but also it is possible to deliver high drug payloads 
to the lungs, which is especially useful in the case of antibiotics. Spheroids 
(soft agglomerates) prepared by spheronisation of micronised particles are 
used with the Turbohaler® device where they are loaded as spheroids and 
they break up into individual particles upon inhalation. With a diameter 
around 0.5 mm, the spheroids exhibit enhanced flowability compared to 
micronised drug and they do not suffer from electrostatic charging during 
handling and operation. However, a high variability in the emitted dose has 
been identified as the main limitation of the spheroids (Pilcer and Amighi, 
2010) .   
 
1.5. Particle engineering for pulmonary drug delivery 
 
In attempts to enhance efficiency of delivery from DPIs, various techniques 
have been used to engineer respirable drug particles. These include 
micronisation, crystallisation, spray drying, freeze drying, spray-freeze 
drying, supercritical fluid technology and antisolvent technology (Murnane et 
al., 2014). From the aforementioned techniques, spray drying will be 
considered in depth, as it was one of the key techniques used in the context 
of this thesis.  
 
1.5.1. Spray drying 
Spray drying is a well-established technique, having been used for many 
years in a variety of fields. It was first applied in the dairy and detergents 
industries in the 1920s, and its popularity increased as it was used in the 
manufacture of instant coffee.  Today, dry milk powder, instant soups, coffee, 
detergents and dyes are examples of spray-dried products used in everyday 
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life. However, it remains an active field of research and innovation as particle 
engineering becomes more sophisticated.  
Spray drying is a widely used technique for the formation of pharmaceutical 
particles with size ranging from the nanometre to the micrometre scale. The 
main advantages of spray drying for the production of inhalation particles are 
the ability to manipulate and thus control particle size distribution, shape and 
density as well as flowability and dispersibility of the powders (Van Oort and 
Sacchetti, 1996). 
Spray drying is a one-step manufacturing process where a liquid feed 
(solution, coarse or ultrafine suspension or an emulsion) is converted to a 
dried particulate form (Fig.1.8). The main principles behind spray drying are 
the atomisation of a liquid feed into fine droplets and evaporation of the 
solvent (aqueous or organic) by means of a hot drying gas. For the 
atomisation of the liquid feed a nozzle is used to form droplets in a range of 
5-200 μm. For aqueous feeds with less than 20% of organic solvent, spray 
drying is carried out in the open mode where the drying gas (e.g. 
compressed air) is exhausted in the atmosphere. For concentrations greater 
than 20% organic solvent in the feed, spray drying should be carried out in 
the closed mode, so as to reduce the risk of flammability and explosion when 
organic solvents are heated in the presence of oxygen. In the closed mode, 
the heated inert gas (e.g. nitrogen) is recirculated and an inert loop 
(condenser) is used to convert organic vapours to liquid (Kleinhans et al., 
2007). 
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Figure 1.8 Schematic representation of spray dryer instrumentation. 1: Feeding 
liquid, 2: Drying gas flow, 3: Heater for drying gas, 4: Nozzle, 5: Drying chamber, 6: 
Dried product and process gas flow, 7: Cyclone, 8: Collection vessel, 9: Aspirator and 
10: Exhaust gas, (Peltonen et al. 2010). 
 
The spray drying process consists of a sequence of four steps (Masters, 
1991): 
 Preparation of the liquid feed.  
 Atomization of the feed into a spray through a nozzle and contact with 
the hot drying gas 
 Evaporation of liquid and particle shape formation and drying 
 Separation of the dried product from the drying gas. 
 
Preparation of the liquid feed: The prepared liquid feed must be pumpable, 
homogenised and free from impurities. It can be a solution, suspension or 
emulsion made up from a solvent or a mixture of solvents and the substance 
to spray dry. It is reported that increasing the concentration of solids in the 
liquid feed leads to the formation of larger particles and an increase in the 
effective particle density (i.e. the mass of a particle divided by its volume 
including both open and close pores) (Van Oort and Sacchetti, 1996; 
Elversson and Millqvist-Fureby, 2005). 
Atomisation: This is the process whereby the liquid feed is broken up into a 
collection of droplets. There are many different types of atomizers available 
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(two-fluid or pneumatic, hydraulic pressure, rotary disk atomizer and 
ultrasonic nozzles), with the two-fluid or pneumatic nozzles being the most 
common choice in the spray driers used in the pharmaceutical industry (Fig. 
1.9). This can be explained by the fact that they are suitable for smaller scale 
plants and also they produce smaller sized droplets compared to other types 
of atomisers. In this case, atomisation occurs by rapid expansion of the spray 
gas, which is mixed with the liquid feed either within the nozzle body 
(internal mixing) or at its tip (external mixing). More specifically, the liquid 
feed is pumped at relatively low flow rates and at the discharge orifice is 
impinged by a gas under pressure. As the velocity of the gas is much higher 
than the velocity of the liquid at the orifice, the relative velocity provides the 
work required to create the large surface area of the spray. For a given 
nozzle, the flow rate of the liquid and the gas pressure are the factors 
controlling the particle size distribution of the generated droplets (Van Oort 
and Sacchetti, 1996). 
 
Figure 1.9 Two - fluid (pneumatic) nozzle with external mixing (Kemp et al., 2013). 
 
Drying: The drying of the droplets to solid particles by contact with heated 
gas inside the drying chamber is essentially the step of solvent removal. The 
evaporation of solvent during the droplet drying is described as a coupled 
heat and mass transfer phenomenon, with the difference between the vapour 
pressure of solvent and the partial pressure in the gas phase being the 
driving force of the drying. 
Separation: The final step of spray-drying is the separation of the spray-dried 
particles from the drying gas. Although the primary separation of the dried 
particles from the drying gas takes place at the base of the drying chamber, 
the use of a cyclone is the most commonly used separation technique for the 
recovery of the finer particles from the drying gas. In the cyclone (Fig. 1.10), 
CHAPTER 1. GENERAL INTRODUCTION 
 
 43 
centrifugal forces are applied to the spray-dried particles, which are collected 
in a bottom vessel.  
 
Figure 1.10 Design of the standard Büchi cyclone (Maury et al., 2005). 
 
1.5.1.1. Selection of spray-drying process parameters 
 
The process parameters and their influence on the end product obtained by 
spray drying have been extensively studied with both experimental 
techniques (e.g. the droplet chain and the mono-dispersed spray dryer) but 
also with analytical and numerical models (Vehring, 2008). 
From all these studies, it is evident that spray drying is a method with a high 
interdependency between the process and formulation variables and the 
characteristics of the final product. 
In the past, the selection of spray drying process parameters was based on 
‘one-factor-at-a-time’ studies. These ‘trial and error’ procedures illustrated 
that process parameters (namely inlet temperature, feed flow rate, gas spray 
flow and aspirator flow) combined with formulation parameters (e.g. 
concentration of the liquid feed), influence the product characteristics such as 
the particle size, moisture content and the process yield.   
Recently, the optimisation of spray-drying parameters is carried out by using 
the Quality by Design (QbD) concept characterised as a holistic approach for 
the formulation development (ICH Q8). QbD combines both designing and 
developing formulations and procedures which ensure predefined 
characteristics in the final product, while emphasises the demand of 
regulatory authorities to pharmaceutical industries to acquire a more 
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comprehensive insight into their manufacturing processes (Maltensen et al., 
2008; Lebrun et al., 2012). 
1.5.1.2. Particle formation by spray drying 
 
According to Vehring (2008) there are two dimensionless parameters, which 
were found to influence and explain particle formation by spray drying. The 
first is the Peclet number (Pe) which is the ratio of evaporation rate (k) to the 
diffusion coefficient (Di) of a solute i (Eq.1.6) and the second parameter is 
the initial saturation of excipients: 
𝑃𝑒 =
𝑘
8𝐷𝑖
  . . .  Equation 1.6  
 
 
Figure 1.11 Proposed particle formation for (a) high and (b) changing Peclet number 
(Vehring 2008). 
(a) 
(b) 
Diffusion controlled particle formation 
Particle formation with early phase separation 
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Low Peclet number particle formation: For Peclet numbers equal to or smaller 
than one (Pe≤1), the diffusion of the solute is faster or of the same order, 
compared to the radial velocity of the receding droplet surface. This means 
that the solute remains evenly distributed in the droplet during evaporation. 
Particularly for small Peclet numbers and high solute solubility (to avoid 
supersaturation during drying) the obtained dry particles are expected to be 
spherical with little or no void space and thus their density is close to the true 
density of the dried bulk material. 
High Peclet number particle formation: High Peclet numbers cause 
enrichment of the solute at the surface leading to shell or skin formation. The 
obtained particles are expected to exhibit significantly lower density than the 
true density of the dried bulk material. This is explained by the large void 
space in the particles (Fig. 1.11a). It should be noted that when spray drying 
nanoparticles from suspensions, the nanoparticles are considered to exhibit 
very high Peclet numbers. This may be explained by the fact that 
nanoparticles are considered immobile compared to the receding droplet 
surface (Tsapis et al., 2002).  
Changing Peclet number: The third and most challenging case in terms of 
particle engineering is when the Peclet number changes during the 
evaporation process. While for the two previous cases both the evaporation 
rate and the diffusion coefficient of the solute were considered to be constant 
during the whole process, in reality the diffusion coefficient of a solute is 
changing during droplet evaporation, especially in co-solvent systems, as one 
solvent evaporates faster than the other. For molecules with low solubility in 
the solvent system used and high diffusion coefficient, the initial Peclet 
number will be small and the concentration of the solute will increase without 
any surface enrichment. However, if the initial saturation is efficient, a 
supersaturation will be reached early during the drying process causing the 
precipitation of a separate phase at the surface or throughout the bulk of the 
droplet. The separated phase exhibits much lower mobility than the dissolved 
phase and as a result the diffusion coefficient of the separated phase is much 
lower than the one of the dissolved phase. In other words, the Peclet number 
increases and the separated phase tend to accumulate at the particle surface 
(Fig.1.11b). The approach of changing Peclet number can explain the 
properties of excipients such as L-leucine and trileucine as surface modifiers 
accumulating in the surface of particles. In many studies, L-leucine and 
trileucine have been used as force control agents in spray-dried formulations 
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for inhalation as they have been found to alter the interparticle forces in the 
aerosol powder and thus improving powder dispersibility (Seville et al., 2007; 
Vehring, 2008; Xu et al., 2014).  
 
1.6. Nanoparticles in drug delivery 
 
The use of nanoparticles has gained momentum in drug delivery, and 
research on nanoparticulate formulations is expanding in recent years. This 
is mainly because   many of the new chemical entities (NCEs) arising from 
combinatorial screening (>40%) suffer from poor solubility in aqueous media 
and some of them simultaneously in organic solvents (Lipinski, 2002). Benet 
(2007) puts the figure of NCEs suffering from poor solubility at 90%, while 
only 40% of marketed drugs are poorly soluble. The limitation of poor 
solubility, that constitutes one of the main reasons for the discontinuation of 
development of NCEs, makes their formulation very challenging. In the past, 
the industry considered these compounds as highly risky development 
candidates. However, nowadays mainly due to their prevalence, ‘industry 
consensus has shifted from an attitude of avoidance to one of acceptance 
and increasing research dedication is given to solving solubility challenges’ 
(Brough and Williams, 2013). Nanotechnologies are considered one of the 
most prevalent improvement methods and have been used to overcome the 
problem of poor solubility and thus bioavailability, as well as to achieve 
targeted drug delivery. 
 
Despite the importance of nanoparticles, there is no single definition of 
nanoparticles. This may be due to the highly multidisciplinary nature of 
nanotechnology. The term nanotechnology was first used by the scientist 
Norio Taniguchi in 1974, at the University of Tokyo in Japan, for any material 
in the nanometre size range (Taniguchi, 1974). 
According to the U.S. Food and Drug Administration, materials are classified 
as being in the nanoscale range if they have at least one dimension at the 
size range of approximately 1-100 nm. However, the 100 nm limit is often 
considered constraining and according to a more expanded and inclusive 
definition: particles below 1000 nm in each dimension (sub-micron particles) 
are designated as nanoparticles (Keck and Müller, 2006). The latter definition 
is applicable in the pharmaceutical field as physical behaviour and material 
properties such as aggregation, solubility and dissolution, start to alter once 
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the size of particles is reduced to the sub-micron level, due to the increased 
surface area to volume ratio (Florence and Attwood, 2015).  
Different types of nanotherapeutics have been applied in drug delivery, such 
as nanocomplexes, nanoemulsions, polymeric micelles, liposomes, 
virosomes, polymeric nanoparticles, and nanocrystals (Fig. 1.12). 
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Figure 1.12 Types of nanotherapeutics marketed in the EU (Hafner et al., 2013). 
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1.6.1. Nanocrystals  
Nanocrystals are nanosized drug particles. Nanocrystals are typically 
produced in the form of nanosuspensions, which are submicron, colloidal 
dispersions of nanosized drug particles, stabilised by surfactants, polymers, 
or a mixture of both (Chingunpituk, 2007). According to a stricter definition, 
a formulation should have a volume median diameter (D50) below 1 μm and 
a volume diameter 90% undersize (D90) below 2.5 μm to be classified as a 
nanosuspension (Wong et al., 2008; Yue et al., 2013). The term 
nanocrystals, although implying the particles are in a crystalline state, which 
is true for the majority of reported cases, has been extended to describe 
nanosized suspensions of partially crystalline or even amorphous drugs 
(Lindfors et al., 2007).  
 
From the different types of nanotherapeutics, specific focus will be given on 
nanocrystals in the context of this thesis. Nanocrystals possess a high drug 
loading (close to 100%) in contrast to matrix nanoparticles consisting of 
polymeric or lipid matrices. Thus, the main advantage of nanocrystals is the 
low amount of excipients used allowing high drug concentration at the site of 
action and reduction of the potential toxicity of the excipients in the lungs.  
1.6.1.1. Advantages of nanocrystals in drug delivery 
 
In general, the main advantages of nanocrystals are:  
 
 increased dissolution rate and enhanced saturation solubility with 
consequent bioavailability improvement  
 low toxicity 
 improved chemical stability  
 
The reduced particle size and high surface area per unit mass of the 
nanoparticles lead to a more rapid dissolution as described by the Nernst and 
Brunner equation (Eq.1.7, Nernst, 1904; Brunner, 1904):  
 
𝑑𝑚
𝑑𝑡
=
𝐷∗𝑆
ℎ
(𝐶𝑠 − 𝐶)  . . . Equation 1.7  
 
where 
𝑑𝑚
𝑑𝑡
 is the dissolution rate of non-formulated drug particles, D is the 
diffusion coefficient, S is the surface area of drug particles, h is the thickness 
of the diffusion layer, Cs is the saturation solubility of the drug particles and 
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m is the concentration of the drug in solution. Therefore, by reducing the 
particle size, the total surface area, S, will increase resulting in a more rapid 
dissolution, particularly under sink conditions (C << Cs).  
 
Regarding the saturation solubility, which for drug particles in the 
micrometre size range and above is a constant depending on temperature 
and dissolution medium, in the case of submicron particles, it depends on 
their size and is reported as ‘apparent’ saturation solubility (Buckton and 
Beezer, 1992). The enhanced ‘apparent’ saturation solubility of 
nanosuspensions has been attributed to the increased curvature of 
nanoparticles resulting in increased dissolution pressure and hence drug 
solubility as described by a modified Kelvin and Ostwald-Freundlich equation 
(Eq.1.8) 
 
𝑙𝑛
𝑆
𝑆0
=
2𝛾∗𝑉𝑚
𝑟∗𝑅∗𝑇
=
2𝛾∗𝑀
𝑟∗𝜌∗𝑅∗𝑇
  . . . Equation 1.8 
 
where S is the drug solubility at temperature T, S0 is the solubility of infinite 
big particle material, R is the gas constant, Vm is the molar volume, T is the 
temperature, r is the particle diameter, γ is the surface free energy, M and ρ 
are the molecular weight and density of the compound, respectively.  
 
Due to the increased dissolution rate and enhanced saturation solubility, 
nanosuspensions result in improved bioavailability (Kesisoglou et al., 2007; 
Shegokar and Muller, 2010). More specifically, regarding the oral drug 
delivery, nanosuspensions have been used as a way to address the issue of 
low bioavailability with reduced food effect compared to micronized drug 
(Rabinow, 2004). Nanosuspensions also increase adhesiveness to the 
gastrointestinal mucosa, leading to prolonged gastrointestinal residence and 
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thus enhanced uptake via the gastrointestinal tract (Jacobs et al., 2001). 
Mucoadhesive nanosuspensions of the antiprotozoal drug buparvaquone 
containing chitosan were proposed as a drug delivery system against 
intestinal Cryptosporidium infections due to their increased gastrointestinal 
residence time and thus prolonged action (Kayser, 2001). The high drug 
loading of nanosuspensions compared to other formulation approaches (e.g. 
cyclodextrin formulations) is beneficial as it is associated with reduced 
toxicity due to the very small amounts of stabilisers/excipients used (Verma 
and Burgess, 2010). Recently, there is increasing concern regarding 
nanotoxicology mainly due to the ability of nanoparticles to enter the cells. 
The toxicity of nanoparticles is related to their cellular uptake and 
intracellular fate. According to the nanotoxicological classification system 
proposed by Müller et al (2011), nanocrystals are in the low/non-risk group. 
Their typical size (100 nm < d < 1000 nm) does not allow cell endocytosis 
and their biodegradable nature is associated with low danger of 
biopersistency. However, studies should be conducted on the interaction of 
nanocrystals with cells and their cellular uptake has to be considered when 
developing nanocrystalline-based products.  
 
Formulating a drug as a nanosuspension has also been proposed as a 
method of improving chemical stability with respect to solution formulations. 
For example, quercetin nanosuspensions exhibited no significant change in 
drug content or colour over one month. In contrast, for the solution, a 
28.3% reduction in drug content and discoloration was observed over the 
same period (Gao et al., 2011). Formulating drugs as nanosuspensions may 
change their pharmacokinetic profile and extend their therapeutic use, as in 
the case of melarsoprol, an organoarsenic compound. Melarsoprol as a 
nanosuspension was unable to cross the blood-brain barrier, but rather 
accumulated preferentially in the Mononuclear Phagocyte System, which is a 
family of cells comprising bone marrow progenitors. The high concentration 
of the drug in the bone marrow resulted in reduced arsenic-related 
encephalopathies, due to the inability of the formulation to cross the blood-
brain barrier, and opens the way for the use of melarsoprol against 
refractory leukemias and other cancer diseases (Ben Zirar et al., 2008).  
 
Apart from their superior clinical performance, nanosuspensions have 
attracted the interest of drug formulators as they can extend the life cycle of 
an active pharmaceutical ingredient (API) after patent expiration, as 
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occurred for a fenofibrate nanosuspension launched by Abbott Laboratories 
(Shegokar and Muller, 2010). Nanosuspensions are also suitable 
formulations for preclinical animal studies mainly due to their quantitative 
and easy oral administration (Niwa et al., 2011). Moreover, the techniques 
for the production of nanosuspensions (e.g. wet milling) are easy to scale-up 
and can provide the amount of formulation required (10 mL up to a few 
liters) for toxicological and pharmacokinetic studies in animals and for clinical 
trials under current good manufacturing practices (Möschwitzer, 2013). All 
these characteristics have resulted in the rapid commercialisation of 
nanosuspensions.  
 
1.6.1.2. Stabilisation of nanocrystals 
 
The formation of nanocrystals almost always takes place in a liquid (usually 
water) as a nanosuspension (colloidal system). The nanosuspensions by 
definition are thermodynamically unstable systems due to their large 
interfacial area, and thus they possess high interfacial free energy. The 
surface free energy (ΔG) termed ‘Gibb’s energy’ associated with this area is 
given by Eq.1.9: 
 
𝛥𝐺 = 𝛾𝑆𝐿 ∗ 𝛥𝛢 − 𝑇 ∗ 𝛥𝑆  . . . Equation 1.9  
where ΔA is the change in surface area, γSL is interfacial tension between the 
solid and liquid interface, T is the absolute temperature and ΔS is the change 
in entropy of the system. Therefore, a nanosuspension can spontaneously 
increase its stability by reducing the interfacial area and consequently the 
surface free energy. This can be achieved in several different ways: i) 
aggregation (flocculation), ii) sedimentation or floating and iii) Ostwald 
ripening. 
For a nanosuspension to be stable it must contain a third component known 
as stabiliser additional to the solid particles and liquid, such as a surfactant 
and/or polymer. Several theories have been proposed to explain how 
stabilisers function and contribute to the stability of nanosuspensions: i) the 
lowering of the interfacial tension, ii) the DLVO theory (Derjaguin and 
Landau, 1941; Verwey and Overbeek, 1948) and iii) the steric stabilisation 
theory.  
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Lowering of the interfacial tension: Surfactants are amphiphilic molecules 
having a hydrophilic and a hydrophobic part. The combination of the two 
opposite affinities in the same molecule causes them to orient and adsorb to 
the interface. Thus, in the case of suspensions, they reduce the interfacial 
tension between the continuous (liquid) and disperse (solid) phases. By 
reducing the interfacial tension, the surface free energy of the system is 
reduced resulting in a stable nanosuspension.  
Steric stabilisation theory: Steric stabilisation is a general term that includes 
all the aspects of the stabilisation of uncharged particles in a colloidal 
dispersion system by using non-ionic macromolecules (surfactants or 
polymers), Fig.1.13.  
The non-ionic macromolecules orientate themselves at the solid-liquid 
interface in such a way that the hydrophilic portions are directed towards the 
liquid (water) and the hydrophobic portions towards the solid particle where 
they are adsorbed and adhered on the particle surface. A stabiliser layer is 
formed around the particles and water penetrates into the layer possibly 
allowing the stabiliser macromolecular chains to gyrate. When two particles 
of radius α having adsorbed stabiliser layer with an average thickness δ 
approach one another closely as a result of Brownian motion, two effects will 
lead to repulsion termed ‘steric repulsion’ between the particles. 
The first called the ‘osmotic effect’ occurs if δ ≤ H ≤ 2 δ, where H is the 
distance between particle surfaces. The adsorbed surfactant layers on the 
opposing surfaces of the two particles start to overlap and the 
macromolecular chains will interpenetrate each other. This will cause water 
molecules to be forced out of the overlapped layers and will be a free energy 
change (energy of steric repulsion). The repulsion increases with the chain 
length of the stabiliser, the ability of the liquid to solubilise the chain and with 
the number of chains per unit area of the particle surface (Fischer, 1958). 
The second effect, called the ‘volume restriction effect’ occurs if H < δ; then 
both interpenetration and compression of the macromolecular chains may 
occur. The interpenetration of the chains give rise to the ‘osmotic effect’ 
described above, while their compression may produce two effects: a) 
intermolecular self-interpenetration accompanied by a corresponding ‘osmotic 
effect’ and b) deformation of the adsorbed layer which contributes to the 
‘steric repulsive’ energy of the system (Napper, 1977).  
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Similar to steric stabilisation is the ‘depletion stabilization of colloids’, which 
involves unanchored (free) polymeric macromolecules creating repulsive 
forces between the approaching particles, Fig 1.13. 
 
Figure 1.13 (a) Steric and (b) depletion stabilisation of colloids. 
 
Common pharmaceutical excipients that are suitable as polymeric stabilisers 
are hydroxypropylcellulose (HPC), hydroxypropylmethylcellulose (HPMC), 
polyvinyl pyrrolidone (PVP K30) and poloxamers (Pluronic F68 and F127). 
Tween 80 and sodium lauryl sulfate (SLS) are widely used as non-ionic and 
anionic surfactants, respectively. For nanosuspensions, apart from reducing 
the interfacial tension, it is necessary that a stabiliser acts as wetting agent 
and provides a barrier between the particles (van Eerdenbrugh et al., 2008a). 
It should be noted that currently selection of a suitable stabiliser for a drug 
nanosuspension is based on trial and error. Few studies attempt to develop a 
rational approach for the selection of the appropriate stabiliser based on the 
physicochemical characteristics of the API in question. In this direction, 
George and Ghosh (2013) studied the wet milling of six APIs with four 
different stabilisers in order to identify the material property variables (API 
and stabiliser) that control the critical quality parameters, which play a role in 
nanosuspension stability. They identified, the log P, the melting point and the 
enthalpy of fusion as the key drug properties that have a direct effect on 
nanosuspension stability, proposing a generic formulation strategy for the 
production of nanosuspensions based on the drug properties (Fig. 1.14). The 
most likely candidate for wet milling is a drug with a high enthalpy of fusion 
and hydrophobicity which can be stabilised either electrostatically or 
sterically. 
 
(a) Steric stabilisation (b) Depletion stabilisation 
Polymeric stabilisation of colloids 
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Figure 1.14 Proposed generic formulation of nanosuspension based on drug 
properties (HLB: hydrophilic lipophilic balance, George and Ghosh, 2013). 
 
1.6.1.3. Formation of nanocrystals 
 
Methods for the production of nanosuspensions can be categorised as top-
down and bottom-up methods, depending on the starting material. In top-
down methods, such as wet milling, high-pressure homogenisation (HPH) 
and microfluidisation, the starting material comprises larger solid particles 
than the resulting nanoparticles and mechanical processes are the 
fundamental mechanism causing particle size reduction. In bottom-up 
methods, particles are formed from the molecular level. Such methods are 
further subdivided into solvent evaporation (e.g. spray drying, 
electrospraying, cryogenic solvent evaporation, etc.) and antisolvent 
methods (e.g. liquid antisolvent, supercritical antisolvent, etc.) (Zhang et al., 
2011). 
 
The main advantage of top-down over bottom-up methods is the production 
of nanosuspensions with high drug loading. Moreover, they do not involve 
harsh organic solvents since the solvent in which drug is dispersed, but not 
dissolved, is water for the majority of poorly water-soluble drugs, making the 
top-down methods eco-friendly. This permits the formulation of many poorly 
soluble APIs, characterized as ‘brick dust’, suffering from poor solubility in a 
Any surfactant 
Ionic 
surfactant 
with high HLB 
(e.g. SLS) 
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N/A 
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wide range of solvents. In general, because of the more streamlined process-
flow and the solvent-free feature of top-down methods, the majority of 
marketed and developmental nanosuspension-based pharmaceutical 
formulations have been produced by top-down methods. From the various 
methods for the production of nanocrystals, the method of wet milling will be 
presented in depth, as it is the method used in this thesis for the formation 
of nanosuspensions.  
 
1.6.1.3.1. Wet milling 
 
This process involves feeding the milling chamber with the milling medium 
(water, buffer or organic solvent), the milling beads, the particulate material 
and the stabiliser (Fig. 1.15). The milling chamber is rotated at the desired 
speed generating very high shear forces between the particles and the beads. 
These forces lead to size reduction by breakage and abrasion of the particles 
along the weak points (cracks, crystal imperfections and slip planes) and 
finally yields particles with smaller size.  
Wet milling is an efficient way to produce drug material in the nanosized 
range (nanocrystalline material) with a typical size ranging from 200-500 nm. 
The majority of nanocrystals that have been offered as commercial products 
are produced by this method (Table 1.2). 
 
Figure 1.15 Formation of nanocrystals using a planetary mill showing different 
grinding mechanisms (A- drug-wall, B- drug-bead and C- drug-drug) (Ghosh et al., 
2012). 
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Table 1.2 Commercial products based on nanomilling (Möschwitzer, 2013; Van 
Eerdenbrugh et al.,2008b). 
Trade Name, 
Company 
Active 
substance 
FDA 
approval 
Reasons for the development/ 
reformulation as a nanocrystalline 
dosage form 
Rapamune® a, 
Wyeth 
Sirolimus 2000 
Reformulation of the oral solution, which 
required refrigeration storage and was 
difficult to administer due to special 
dispensing protocol and unpleasant taste 
(Merisko-Liversidge and Liversidge, 2011). 
Emend®, 
Merck 
Aprepitant 2003 
Original dosage form exhibited significant 
food effect (3-fold increase under fed 
conditions). As aprepitant is an antiemetic 
drug, reformulation as a nanosuspension 
and elimination of the food effect is 
significant as patient’s compliance may 
have been limited if the drug should be 
administered with food (Merisko-Liversidge 
and Liversidge, 2011; Brough and 
Williams, 2013).  
Tricor®, 
Abbott 
Fenofibrate 2004 
More flexible dosing regime. Life-cycle 
extension after patent expiration due to 
superior performing product (Shegokar and 
Müller, 2010). 
Megace ES®, 
PAR 
Pharmaceuticals 
Megestrol 
acetate 
2005 
Enhanced solubility, increase in the 
dissolution rate of the oral suspension and 
reduction of its volume and viscosity. 
Reduced bioavailability variation between 
fed/fasted state. 
Invega 
Sustenna®,  
Janssen 
Paliperidone 
palmitate 
2009 
Once monthly intramuscular extended 
release in injectable dosage form with 
physical stability for a two-year shelf life. 
As paliperidone palmitate is an atypical 
antipsychotic, the once monthly 
intramuscular injection facilitates patient 
compliance, a special concern for this  
population (Brough and Williams, 2013). 
a Rapamune® was the first product reaching the market using wet milling technology 
and was a patented technology of Elan® drug technologies (known as Nanocrystals®)  
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Nanomilling is always conducted under controlled temperature, a crucial 
parameter especially for thermolabile drugs or drugs with low melting point. 
The increase of temperature during milling is considered as an additional 
mechanism behind the reduction of particle size. More specifically, the 
temperature-related stress relaxation due to intraparticle crack formation is 
followed by crack propagation and finally particle fracturing (Peltonen and 
Hirvonen, 2010).  
The quality of the final nanosuspension is influenced by several critical 
parameters (Table 1.3), which should be selected carefully during the 
optimisation of the process.  
Table 1.3 Critical process variables in nanomilling. Modified from (Peltonen and 
Hirvonen, 2010). 
Process Variables Range 
 
Drug Amount 
 
2-30% w/w 
Amount of milling beads 10-50% w/v of the slurry 
Size of milling beads 0.1-20.0 mm 
Milling speed and duration 
Low milling speed (80-90 rpm) & 
long milling time (1-5 days) 
 
High milling speed (1800-4800 rpm) & 
short milling time (30-60 min) 
 
 
The milling beads are made of a hard and dense material such as yttrium-
stabilised zirconium oxide, stainless steel, glass alumina, titanium or certain 
polymers as highly cross-linked polystyrene and methacrylate (Verhoff et al., 
2003). The beads size may vary from less than 0.1 mm to 20 mm. As a 
general rule, the smaller the size of the milling beads the finer the 
nanoparticles produced, due to increased collision frequency between drug 
particles and beads. However, it has been reported that too small beads (e.g. 
0.03 mm) may not be suitable for milling as they cannot generate sufficient 
energy for particle breakage when they impact with drug particles due to 
their light weight. Rotation speed is a parameter of critical importance. Low 
rotation speeds will lead to the rolling of the beads inside the milling vessel, 
impacting the material with insufficient force to achieve comminution. On the 
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other hand, too high speeds may result in the sticking of the beads on the 
walls of the milling vessel and therefore no milling will occur.  
Nanomilling is especially beneficial for poorly soluble drugs with less than 200 
μg ml-1 solubility, as well as for materials with high melting point and high 
molecular weight. It is characterised as a reproducible, cost-effective, 
scalable and quick process with little or no batch-to-batch variation (control 
over particle size) once the formulation and the process have been optimised. 
The most significant concern of nanomilling includes the risk of contamination 
of the final product with residues of the milling media. This risk, together with 
the risk of degradation, stability issues and microbial growth becomes even 
more increased when nanocrystals are obtained by low milling speeds and 
extended milling times.  
Another concern associated mainly with dry milling is the mechanical 
activation of the particle surfaces above a critical pressure value or crystal 
defection concentration leading to the formation of local amorphous regions. 
The risk of material amorphisation may be linked with the main mechanism 
of particle size reduction during milling. In particular, friction and fracture are 
dominant phenomena during milling contributing to the transformation of 
about 90% of the mechanical energy into dislocation and distortion energy of 
the crystalline lattice. However, for wet milling unlike dry milling, the concern 
of amorphisation is reduced as the particles are formed in liquid media and 
amorphous regions may undergo recrystallisation (Kayaert and Van den 
Mooter, 2012).  
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1.7. Nanoparticles and pulmonary drug delivery 
 
1.7.1. Applications and advantages of nanosuspensions in pulmonary 
drug delivery 
 
The application of nanosuspensions in pulmonary drug delivery has been 
limited until recently. However, many of the advantages outlined in Section 
1.6.1.1 can be extended to this route of administration. Additionally, 
nanosuspensions have been proposed as a formulation approach to increase 
the dissolution rate and thus absorption of poorly water-soluble inhaled 
corticosteroids such as fluticasone propionate and budesonide (Yang et al., 
2008). Regarding pulmonary drug delivery, drug absorption and local 
bioavailability depends upon the fraction of deposited drug that dissolves in 
the lungs. Mucociliary clearance and absorption are two competing 
mechanisms and this can lead to bioavailability reduction for drug particles 
with low dissolution velocity (Forbes et al., 2015). Nanoparticle-based 
formulations have been found to promote more rapid absorption following 
inhalation of poorly water-soluble drug that have dissolution-limited drug 
absorption (e.g. beclometasone dipropionate, budesonide, itraconazole, 
fentanyl) (Tolman and Williams III, 2010).  Britland et al. (2012) compared 
the bioavailability, emission characteristics and efficacy of a budesonide 
nanoparticulate formulation with those of a proprietary micronised 
suspension of the drug after delivery as a nebulised aerosol to a human 
airway epithelial culture cell line. For an equivalent dose, the budesonide 
nanosuspension achieved improved uptake, retention and efficacy in the 
culture cells. 
 
Furthermore, there are two key advantages in using nanosuspensions 
instead of solution formulations for pulmonary delivery of drugs with poor 
aqueous solubility. Preparation of solutions requires the use of organic co-
solvents while the need for co-solvents is limited or even non-existent for the 
production of nanosuspensions. As a result, the danger of potential co-
solvent related toxicity is reduced (Chiang et al., 2009). In nanosuspensions, 
the drug concentration is not limited by the solubility in the vehicle, as is the 
case for solutions, allowing the delivery of higher doses in the lungs. 
Exploiting this advantage, Rundfeldt et al. (2013) prepared itraconazole 
nanosuspensions which achieved high and long-lasting lung tissue 
concentrations well above the minimum inhibitory concentration against 
Aspergillus species, when administered using standard mesh nebuliser 
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technology. The high concentration achieved indicates the potential of 
itraconazole nanosuspensions as a treatment for allergic bronchopulmonary 
aspergillosis in patients with cystic fibrosis, administered only once daily. 
 
Finally, nanosuspensions can be used as formulations facilitating pulmonary 
drug discovery, as they are easy to dose with a syringe-type delivery device 
in preclinical animal studies (e.g. intratracheal instillation, Yang et al., 2008).  
 
1.7.2. Delivery of nanocrystals as dry powders for inhalation: 
challenges and opportunities 
 
Liquid nanosuspensions are associated with physical instability issues 
including sedimentation, creaming, crystal growth (also known as Ostwald 
ripening), aggregation and solid state transformation. A detailed review of 
the physical and chemical instability issues of drug nanoparticles has been 
provided by Wu et al. (2011). These instability phenomena make it difficult 
to ensure that the particle size of the nanosuspensions will remain the same 
upon storage. Moreover, nanosuspensions, due to their liquid media, are 
prone to microbial growth. On the other hand, solid dosage forms exhibit 
enhanced physical and chemical stability.  
 
For pulmonary delivery the particles should have an aerodynamic diameter 
between 1-5 μm so as to deposit in the lungs. Therefore, delivery of 
individual nanoparticles to the lungs (with the exception of particles below 
100 nm) appears to be problematic, as due to their submicron size, the 
probability of exhalation before deposition is increased (Byron, 1986; 
Rogueda and Traini, 2007). Moreover, nanoparticles tend to strongly 
aggregate upon aerosolisation under the normal airflow rates in passive DPIs 
and their cohesive nature makes their handling extremely difficult (Watts 
and Williams III, 2011). In order to overcome these limitations, the 
controlled agglomeration of nanoparticles to micron-sized clusters has been 
recently proposed as “an approach to harmonise the advantages of 
nanoparticles with the aerodynamics of small microparticles so as to achieve 
an improved bioavailability and aerosolisation behaviour of the drug” (El-
Gendy et al., 2009). It is clear then, that solidifying nanosuspensions to 
respirable nanoparticle agglomerates of 1-5 μm, is a highly desirable 
strategy for administering nanoparticles effectively to the lungs using DPIs.  
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1.7.3. Formation of nanoparticle agglomerates as dry powders for 
inhalation 
 
Spray drying, spray-freeze drying, freeze drying and aerosol flow reactor 
have been applied as solidification approaches for the preparation of 
inhalable micron-sized nanoparticle agglomerates with suitable aerodynamic 
properties for delivery to the lungs using DPIs (Fig. 1.16.). 
 
 
Figure 1.16 Schematic representation of the various solidification approaches for the 
preparation of inhalable micron-sized nanoparticle agglomerates.  
 
1.7.3.1. Spray drying 
 
Spray drying has a long tradition as a fundamental particle engineering 
technique for pulmonary drug delivery and until now the majority of reported 
studies on the development of inhalable particles by this methodology have 
focused on spray drying of drug solutions. But, as spray drying is a rapid 
solidification procedure, the obtained particles (at least from solution feed) 
are usually amorphous with the characteristic example being that of 
salbutamol sulfate after spray drying from aqueous solution (Fig.1.17a, 
Chawla et al., 1994).  Amorphicity is regarded as a disadvantage for 
respirable particles as it is associated with the danger of recrystallisation 
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upon storage, which may influence adversely the stability, dissolution, 
absorption and aerosolisation efficiency of the product (Chow et al., 2007). 
Recently, a few studies on solidified nanosuspensions for the development of 
pulmonary formulations by applying spray drying have been reported.  
 
Pilcer et al. (2009) prepared carrier-free respirable agglomerated 
nanoparticle formulations of tobramycin with enhanced dispersion properties 
by combining high-pressure homogenisation with spray drying. This can be 
considered as an attractive formulation approach for treating lung infections 
as a high dose can be delivered to the site of infection reducing the side 
effects related to systemic antibiotic administration.  
 
Yamasaki et al. (2011) prepared nanosuspensions of ciclosporin A by anti-
solvent precipitation (bottom-up technique) using a multi-inlet vortex mixer. 
The nanosuspensions were spray dried after the addition of different 
amounts of mannitol (Fig.1.17b), resulting in respirable nanoparticle 
agglomerates with enhanced fine particle fraction (FPF> 50%). The drug in 
the nanoparticle agglomerates was found to be in the amorphous state and 
this was attributed to the method of nanosuspension production rather than 
to the spray-drying step. The authors also investigated the effect of 
ciclosporin A to mannitol mass ratio on the dissolution rate and on the 
aerosolisation performance of the solidified nanosuspensions and concluded 
that mannitol, as a hydrophilic excipient, improved the dissolution rate of the 
drug, while it did not influence its aerosolisation behaviour.  
 
 
 
Figure 1.17 SEM images of (a) spray-dried salbutamol sulfate from 10% w/v 
aqueous solution (Chalwla et al., 1994) and (b) spray dried nanosuspension of 
ciclosporin A containing mannitol (1:0.5 mass ratio, Yamasaki et al., 2011). 
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Pomázi et al. (2013) developed respirable nanoparticle agglomerates of 
meloxicam embedded in mannitol and other adjuvants (polymers and L-
leucine), by applying high-pressure homogenisation followed by spray 
drying. The presence of the amino acid L-leucine was found to enhance the 
aerosolisation of the nanoparticle agglomerates due to decreased particle-to-
particle adhesion (Sou et al., 2011). The nanoparticle agglomerates of 
meloxicam were crystalline and exhibited enhanced in vitro aerosolisation 
(FPF > 53%; mass median aerodynamic diameter, MMAD < 3.52 μm) and 
dissolution performance. Similar results have been reported for nanoparticle 
agglomerates of itraconazole as a formulation approach for the treatment of 
pulmonary aspergillosis (Duret et al., 2012). 
 
From the above, it can be summarised that spray drying of nanosuspensions 
has great potential for the production of solid formulations with predefined 
solid state and enhanced dissolution and aerosolisation properties that can 
be administered via a DPI.  
 
1.7.3.2. Spray-freeze drying 
 
Spray-freeze drying is an alternative technique to spray drying, which has 
been used for the preparation of thermolabile inhalable particles, especially 
proteins (Maa et al., 1999). In the spray-freeze drying process, the liquid 
feed is atomised by a nozzle and the atomised droplets are snap frozen in 
liquid N2. The iced droplets are then lyophilized in order to remove the frozen 
solvent (water) via sublimation and obtain a powdery product. In comparison 
to spray drying, the spray-freeze drying is a low-temperature solidification 
process that produces porous particles (Mumenthaler et al., 1991).  
 
Few studies have been published regarding the spray-freeze drying of drug 
nanosuspensions to produce particles suitable for inhalation. Cheow et al. 
(2011) prepared inhalable composite particles by spray-freeze drying 
suspensions of levofloxacin-loaded polycaprolactone (PCL) nanoparticles, in 
order to avoid problems associated with the low melting point of PCL and the 
limitation of elevated temperature use, which is inevitable in spray drying. 
Prior to the spray-freeze drying, adjuvants such as mannitol or polyvinyl 
alcohol (PVA) were added to the nanosuspensions to act as cryoprotectants 
and also to ensure redispersibility of the particles produced. Porous inhalable 
particles with suitable flowability and redispersibility were produced when 
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high adjuvant concentrations were used (Fig.1.18). Regarding pulmonary 
drug delivery, spray-freeze drying allows the preparation of particles with 
large geometric diameters but still having suitable aerodynamic properties 
due to their high porosity/low particle density (Cheow et al., 2011). In this 
way the poor flowability problems usually associated with inhalable particles 
can be overcome.  
 
 
 
Figure 1.18 SEM images of (a) large, spherical and porous morphologies of 
levofloxacin-loaded PCL nanoparticles containing mannitol as an adjuvant, prepared 
by spray-freeze drying and (b) PCL nanoparticles dispersed in the porous mannitol 
matrix (Cheow et al., 2011).  
 
1.7.3.3. Freeze drying 
 
Freeze drying or lyophilisation is a classical process of removing water from 
high value products (e.g. antibiotics, enzymes, vaccines, etc.) without 
excessive damage, enhancing stability on storage and reconstitution by 
adding water, or other suitable aqueous vehicle, prior to use (Tang and Pikal, 
2004). In freeze drying, the liquid solution or suspension is firstly frozen 
under atmospheric pressure and subsequently heated under vacuum to 
remove the ice crystals by sublimation. At the end of the process, a highly 
porous cake with low moisture content is obtained. 
 
For the formation of respirable nanoparticle agglomerates, El-Gendy et al. 
(2009) employed freeze drying for the transformation of the 
nanosuspensions obtained by a controlled flocculation process (protocol 
under the name NanoClustersΤΜ, owned by Savara Pharmaceuticals). 
(a) (b) 
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Budesonide nanoparticle agglomerates prepared by this protocol, exhibited 
enhanced dissolution rate compared to the raw drug and had MMAD 2.1 ± 
1.8 μm (mean ± SD) on aerosolisation, appropriate for deep lung deposition 
of the particles (Fig.1.19). The NanoClustersΤΜ protocol has been applied for 
the preparation of nanoparticle agglomerates of various drugs, such as 
ciprofloxacin, paclitaxel, diatrizoic acid, nifedipine and fluticasone propionate  
(El-Gendy et al., 2009; Plumley et al., 2009; El-Gendy et al., 2011).  
 
 
Figure 1.19 (a) SEM image of budesonide nanoparticle agglomerates prepared by 
the NanoClustersTM technology and (b) dissolution profiles budesonide from 
budesonide stock, nanoparticles and nanoparticle agglomerates (El-Gendy et al., 
2009). 
 
1.7.3.4. Aerosol flow reactor 
 
The aerosol flow reactor, patented by Teicos Pharma (Finland), has been 
used for the solidification of nanosuspensions. It is a one-step continuous 
process involving the atomisation of a liquid feed into a carrier gas (usually 
N2) for drying. More specifically, the liquid feed is atomised by an ultrasonic 
air-jet nebuliser and the droplets produced, suspended in the carrier gas, are 
directed into a heated tubular laminar flow reactor with constant 
temperature where evaporation takes place (Eerikainen et al., 2003). 
 
Using the aerosol flow reactor technology, inhalable microparticles for the 
concomitant pulmonary administration (combination therapy) of budesonide 
and salbutamol sulfate have been prepared (Fig.1.20, Raula et al., 2013). 
Combination therapy has been found to be advantageous for the treatment 
of respiratory diseases by reducing the need for multiple therapies and as a 
(a) (b) 
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result it holds potential to improve patient adherence to medication and 
therapeutic outcomes. Especially for COPD, combination therapy enables 
simultaneous delivery of more than one drug to the same area of the lungs 
where they can exhibit synergistic action (Arun et al., 2012).  
 
 
Figure 1.20 SEM image of L-leucine coated and encapsulated aerosol particles 
composed of budesonide nanocrystals embedded in mannitol matrix with salbutamol 
sulfate, prepared using the aerosol flow reactor (Raula et al., 2013). 
 
The budesonide nanosuspension was prepared by wet milling. It was further 
diluted with an aqueous solution of salbutamol sulfate, mannitol and L-
leucine and then solidified using the aerosol flow reactor. The obtained 
microparticles exhibited improved dissolution properties, with budesonide 
nanocrystals dissolving in 20 min and at the same rate as salbutamol sulfate, 
ensuring that the drugs will have a synergistic effect at the site of 
deposition/action. The microparticles also had enhanced aerosolisation 
efficiency with FPF: ≈ 50%, due to the leucine coating, which reduced the 
adhesion between particles. 
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1.8. RESEARCH HYPOTHESIS 
 
Controlled agglomeration of nanoparticles to micrometre-sized clusters, 
which can “fall apart” once they reach the lung environment so as to reform 
nanoparticles, has been suggested as a way to combine the advantages of 
nanoparticles with the aerodynamics of microparticles for pulmonary drug 
delivery. Spray drying is a suitable technique for producing respirable 
particles. While spray drying of solutions may lead to the production of 
(partially) amorphous materials due to the rapid transition of droplets to the 
solid state, spray drying of material from a suspension often yields crystalline 
particles. Excipients such as mannitol and the endogenous amino acid L-
leucine have been used in many studies for the engineering of dry powders 
for inhalation. Additionally, mannitol has been reported to exhibit excellent 
spray-drying properties as the size and shape of particles can be adjusted by 
changing the process parameters, while L-leucine is a commonly used 
aerosolisation enhancer. Therefore, it is hypothesised that it is possible to 
engineer respirable particles with a tailored crystalline form for a range of 
drugs with different physicochemical properties, by preparing nanoparticles 
and spray drying them in the presence of suitable excipients in order to 
produce inhalable microcomposite particles with predictable performance.  
 
1.9. THESIS AIMS AND OBJECTIVES 
 
The aim of this thesis is to develop a drug delivery platform based on wet 
milling and spray drying for the engineering of crystalline nanoparticle 
agglomerates suitable for inhalation, which can be applicable to a range of 
drugs with different physicochemical properties. To achieve this aim, the 
objectives of the thesis are:  
 
 To engineer nanoparticle agglomerates using wet milling and spray 
drying for three model drugs, namely indometacin, ibuprofen and 
theophylline, which possess different physicochemical properties.  
 To characterise the particles produced regarding their micromeritic 
properties, solid state, dissolution profile and aerosolisation 
behaviour. 
 To investigate in a systematic way the effect of formulation 
parameters on the in-vitro performance of the nanoparticle 
agglomerates.   
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 To develop an initial “road map” to guide the selection of formulation 
and process parameters that should be adjusted in order to engineer 
inhalable nanoparticle agglomerates, by taking into account the 
physicochemical properties of the drug in question.  
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2. NANOPARTICLE AGGLOMERATES OF INDOMETACIN 
 
2.1. INTRODUCTION 
 
Several of the drugs used for the treatment of respiratory diseases exhibit 
poor aqueous solubility (antifungals, corticosteroids, oligopeptides and 
opioids) affecting their availability and retention in the lung tissue and 
subsequently their therapeutic efficacy, safety and dosing (Tolman and 
Williams, 2010).  Reduction of drug particle size to the nano-range is 
considered an appropriate method to overcome the obstacle of poor water 
solubility (Brough and Williams, 2013).  
 
The controlled agglomeration of nanoparticles to micro-sized clusters has 
been recently proposed as “an approach to harmonize the features of 
nanoparticles with the aerodynamics of small microparticles so as to achieve 
an improved bioavailability and aerosolisation behaviour of the drug” (El-
Gendy et al., 2009). 
The formation of nanoparticle agglomerates involves two processing steps: 
a) the preparation of a nanosuspension and b) the removal of liquid from the 
nanosuspension with simultaneous controlled assembling of the nanoparticles 
to micrometer-sized particles (agglomeration). 
Considering the various nanosizing techniques, wet bead milling has been 
characterized as a reproducible, cost-effective and scalable way of producing 
nanosuspension (Möschwitzer, 2013). Especially for poorly water-soluble 
drugs, wet milling can take place in water avoiding the use of organic 
solvents, producing crystalline nanosuspensions due to the plasticizing effect 
of water on the potentially generated amorphous material, triggering 
recrystallisation (Kayaert and Van den Mooter, 2012).  
For the water removal from nanosuspensions and controlled nanoparticle 
agglomeration, processes such as freeze drying and spray drying have been 
evaluated. The high energy consumption, long processing times and reduced 
flowability of freeze-dried products limit the use of freeze drying for the 
preparation of nanoparticle agglomerates in the respirable size range (Zhang 
et al., 2014). On the other hand, spray drying is a manufacturing technique 
of particular interest for respiratory drug delivery as particle characteristics 
(e.g. size, flowability, redispersibility and moisture content) can be controlled 
by formulation and process parameters (Van Oort and Sacchetti, 1996).
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Prior to spray drying, the addition of matrix formers and surface-active 
agents may enhance the dissolution rate and the aerosolisation behaviour of 
the particles, respectively. More specifically, incorporation of mannitol as 
matrix former in nanoparticle agglomerates was found to improve their 
dissolution rate by preventing the irreversible aggregation of nanoparticles 
during drying (Chaubal and Popescu, 2008; Van Eerdenbrugh et al., 2008a; 
Yamasaki et al., 2011; Cerdeira et al., 2013). The amino acid, L- leucine, 
was found to act as an aerosolisation enhancer forming a coat (shell) on the 
dry particle surface, preventing particle fusion and therefore by preserving 
the individual particles as collected from the spray dryer (Seville et al., 2007; 
Sou et al., 2011).  
In this chapter, the use of wet bead milling followed by spray drying was 
investigated for the preparation of inhalable nanoparticle agglomerates. 
Three poloxamers selected as amphiphilic, non-ionic copolymers differing in 
their molecular domains, were used for the production of nanosuspensions. 
In this way the effect of stabiliser characteristics (total molecular weight and 
molecular weight of the hydrophilic polyoxyethylene, EO, moiety) on the 
nanosuspension formation will be elucidated. Besides poloxamers, D-α-
tocopherol polyethylene glycol succinate (TPGS) was selected as a stabiliser 
for comparative purposes, since it has been reported as an efficient stabiliser 
for drugs with different functional groups and for different pharmaceutical 
applications (Van Eerdenbrugh et al., 2008b; Duret et al., 2012;). Moreover, 
the effect of mannitol and L-leucine addition during the spray drying of 
nanosuspensions on the solid state, dissolution rate, redispersibility 
(reformation of nanoparticles after rehydration) and aerosolisation efficiency 
of the nanoparticle agglomerates will be investigated. Indometacin was 
selected as a model, poorly water-soluble drug, prone to polymorphic 
transformations and amorphisation during milling and spray drying (Karmwar 
et al., 2012; Legendre and Feutelais, 2004; Martena et al., 2012). 
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2.2.  MATERIALS  
 
Indometacin (IND, LKT Laboratories, USA) with a volume mean diameter 
D4,3: 54.10 ± 8.12 μm was used. Poloxamers: 407, 188 and 184 (Pluronics®: 
F127, F68, and L64 respectively) from BASF Co. (Ludwigshafen, Germany) 
and D-α- tocopherol polyethylene glycol 1000 succinate (TPGS, Sigma 
Aldrich Co., St. Louis, USA) were used as stabilisers. Mannitol (Pearlitol 
160C, Roquette Freres, Lestrem, France) and L- leucine (Sigma®) were used 
as matrix formers of the nanoparticle agglomerates. The chemical structures 
of indometacin, stabilisers and matrix formers are given in Fig. 2.1. and their 
physicochemical properties are summarised in Table 2.1. HycloneTM water for 
injection quality water (Thermo Scientific, UK) was used for the preparation 
of nanosuspensions. Potassium dihydrogen phosphate and sodium hydroxide 
(from Fisher Scientific UK, Loughborough, UK) and deionised water were 
used for the preparation of the dissolution medium. Ethanol (96% v/v, 
analytical reagent grade) and acetonitrile (HPLC grade) both from Fisher 
Scientific UK, Loughborough, UK and trifluoroacetic acid (TFA, Sigma Aldrich 
Co., St Louis, USA) were used for the HPLC analysis.  
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Figure 2.1 Chemical structures of indometacin, stabilisers and matrix formers. 
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Table 2.1 Physicochemical properties of indometacin, stabilisers and matrix formers. 
Compound Molecular weight  
(g mol-1) 
Melting point  
(oC)  
Aqueous solubility 
  
Indometacin 357.79 159 (γ-form)a 16 ± 1 μg mL-1 b 
Mannitol 182.17 166-168c Solublec 
L-leucine 131.17 
145-148 (sublimation) 
293-295 (decomposition)c  
Solublec 
Stabiliser Properties (provided by the manufacturers) 
 Molecular 
weight  
(g mol-1)  
Melting 
point  
(oC) 
PO units EO units PO/EO PO  
(g mol-1) 
HLB 
Pluronics® F127 12600 56 65 2 × 100 0.33 3780 18-23 
Pluronics® F68 8400 52 29 2 × 76 0.19 1680 >24 
Pluronics® L64 2900 16 30 2 × 13 1.15 1740 12-18 
TPGS 1000 1513 38 - - -  13 
a Legendre and Feutelais, 2004, b Van Eerdenbrugh et al., 2008b, c  Rowe et al., 2012  
PO = propylene oxide, EO = ethylene oxide, HLB = hydrophilic- lipophilic balance
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2.3. METHODS 
 
2.3.1.  Solubility measurements  
 
The solubility of indometacin in 0.5% w/v stabiliser solutions (corresponding 
to that of nanomilling) and distilled water was measured. The solvents were 
placed in stoppered vials and excess indometacin was added and stored at 
25oC, in a shaking water bath for 24 h. The saturated solutions were filtered 
through a 0.1 μm disposable syringe filter (Millex® Durapore®) to separate 
the undissolved drug and the amount of drug dissolved was assayed by 
HPLC as described below in drug content determination. All determinations 
were made in triplicate.  
 
2.3.2.  Preparation of nanosuspensions 
 
Nanosuspensions were prepared by wet bead milling using a planetary micro 
mill (Pulverisette 7 Premium, Fritsch Co., Germany) with two grinding bowls 
of 80 mL (Fig. 2.2). 2 g of IND and the stabiliser (10% w/w of IND) were 
added in each milling bowl containing 100 g of milling beads (YTZ grinding 
beads, 0.4 mm, GSK Comet) and 40 mL of sterile purified water. Rotation 
speed of bowls (600 rpm), milling duration (12 cycles of altered bowl 
rotation direction) and stabiliser concentration (10% w/w of IND) were 
selected based on preliminary experiments. Each milling cycle comprised of 
15 min rotation followed by 3 min pause. In order to cool down the milling 
vessels and avoid overheating of the instrument’s rotors, an additional 30 
min pause followed the completion of 3 milling cycles. At each pause, the 
nanocrystal size was determined and at the end of the milling procedure, the 
nanosuspensions were left to cool to room temperature. The 
nanosuspensions were removed from the milling pots using transfer pipettes 
with openings smaller than the size of the milling beads. In the case of the  
nanosuspensions which were further diluted with an aqueous solution prior to 
spray drying (Section 2.3.4), part of this solution was used to repeatedly 
rinse the beads in order to increase the recovery of the nanosuspensions.  
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Figure 2.2 Planetary micro mill Pulverisette 7 premium line. Adapted from Fritsch, 
2007.  
 
2.3.3. Characterisation of nanosuspensions 
 
Dynamic light scattering (DLS) and transmission electron microscopy (TEM) 
measurements were carried out during the milling process, at each pause, 
for monitoring the particle size reduction and the final size of the 
nanocrystals. Physical short-term stability of the nanosuspensions after 7 
days was also determined by DLS. 
2.3.3.1. Dynamic light scattering (DLS) 
 
Malvern Nano ZS (Malvern Instrument, UK) was used for size measurements 
yielding the intensity-weighted mean diameter of the bulk population (z-
average) and the polydispersity index (PI) as a measure of the width of size 
distribution. 20 μL of nanosuspension was diluted with 10 mL of saturated 
IND solution, prepared by filtration of a suspension through a 0.22 μm 
disposable syringe filter (Millex® sterile) to avoid extensive dissolution and 
then was shaken vigorously for 30 s by hand before being transferred into 
disposable sizing cuvettes. The measuring parameters were: dispersant 
reflective index of 1.338 and viscosity value of the dispersion medium 0.89 
cP. The measurement was performed in triplicate, at 25oC, and mean value 
and standard deviation were calculated.  
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2.3.3.2 Transmission electron microscopy (TEM) 
 
One drop of nanosuspension was placed on a 300 mesh copper grid and 
stained with 1% uranyl acetate. The liquid was then allowed to dry and 
examined by TEM (Philips Electron Optics BV, Netherlands). 
2.3.4. Preparation of nanoparticle agglomerates 
The obtained nanosuspensions were solidified by spray drying either 
immediately after preparation as collected without any further pre- 
treatments or after diluting 25 mL of nanosuspension with 75 mL aqueous 
solution of matrix formers (mannitol and L- leucine at contents of 120% and 
16% w/w of IND, respectively). Spray drying was performed using a 
laboratory scale spray dryer (Mini B-290, Buchi Labortechnik Ab, Flawil, 
Switzerland) fitted with a high performance cyclone (Fig. 2.3). On the basis 
of preliminary ‘one-factor-at-a-time’ experiments, inlet temperature of 130 
oC, outlet temperature of 42 ± 2 oC, feed rate of 5 mL min-1 and atomizing 
gas flow rate of 0.5 L s-1 were selected. The collected nanoparticle 
agglomerates were stored in a desiccator over silica gel until testing. 
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Figure 2.3 (a) Büchi Mini Spray Dryer B-290 and (b) high performance cyclone. 
Adapted from Büchi, 2010.  
 
2.3.5. Characterisation of nanoparticle agglomerates 
The nanoparticle agglomerates were characterized with respect to: surface 
morphology by SEM; particle size distribution (PSD) by laser diffractometry; 
solid state form by X-ray powder diffractometry (XRPD) and differential 
scanning calorimetry (DSC); drug loading and dissolution testing by HPLC 
analysis of indometacin content; redispersibility by DLS after dispersion in 
water; and in- vitro aerosol performance using the next generation impactor 
(NGI). 
2.3.5.1. Scanning electron microscopy (SEM) 
 
Samples were placed on double-side electroconductive adhesive tape, which 
was fixed onto an aluminium stub and then sputter-coated with gold under 
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argon atmosphere to a thickness of 10 nm (Quorum model 150). SEM 
micrographs were taken using a FEI Quanta 200 FEG ESEM (Netherlands), at 
5.00 kV. 
2.3.5.2. Laser diffraction 
 
The particle size distribution of the samples (n=3) was determined using a 
HELOS/ BR laser diffractometer (Sympatec GmbH, Germany) which was 
fitted with the micro-dosing unit ASPIROS and the dry disperser RODOS. 
Samples were placed in the feeder and pressurised air at 4 bar was used to 
disperse them in the measurement chamber while the feeding velocity kept 
constant at 50 mm s-1. A pressure of 4 bar was selected based on 
preliminary studies where increase of the primary pressure from 2 to 4 bar 
did not change the particle size distributions of the samples indicating that 
there is no particle de-agglomeration at elevated pressure. An R2 lens 
detector (0.25- 87.5 μm) and the particle size distribution (PSD) analysis 
software Windox 5 were used. The d10, d50 and d90 particle sizes (i.e. the size 
in microns at which 10%, 50% and 90% of the particles are smaller) were 
recorded.  
The particle size distribution of the starting materials was measured with 
Malvern Mastersizer 3000 equipped with a dry sampling system (Aero S, 
Malvern Instruments, UK), as the particle size range covered by this laser 
diffractometer is 0.1-3500 μm. The standard operating conditions used were: 
refractive index: 1.52, vibration feed rate: 25%, measurement time: 5 s, 
dispersive air pressure: 4 bar.  
 
2.3.5.3. X-ray powder diffractometry (XRPD) 
 
XRPD patterns were obtained with a bench-top diffractometer (Rigaku 
Miniflex 600, Japan) to assess crystallinity. Cu Kα radiation at 15 mA and 40 
kV with a step of 0.02 deg and a speed of 5 deg min-1 was used, covering a 2 
θ of 3-40 o. Miniflex Guidance was the analysis software.  
2.3.5.4. Differential scanning calorimetry (DSC) 
 
DSC was performed using a TA DSC Q200 calorimeter at constant pressure 
previously calibrated with indium. Weighted powder samples (1-3 mg) were 
sealed into crimped standard aluminium pans (TA) and heated under 
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nitrogen flow (50 mL min-1) from 25 oC to 180 oC at a heating rate of 10 oC 
min-1.  
2.3.5.5. Drug loading 
 
5 mg of nanoparticle agglomerates was dissolved in 100 mL ethanol 96% v/v 
and indometacin concentration was assayed using a HPLC system (Agilent 
1100 Series, Agilent technologies, Germany). The stationary phase was a 
Synergi 4u Polar- RP 80 A (250 x 4.60 mm, 4 micron) column (Phenomenex 
Co., California, USA) kept at 40 oC. The mobile phase was composed of 
acetonitrile and aqueous trifluoroacetic acid solution (0.1% v/v) at 60/40 
volumetric ratio. The mobile phase flow rate was 1 mLmin-1, the injection 
volume was 20 μL and the detection wavelength 318 nm. The retention time 
for indometacin was 6.1 min. The correlation coefficient of the calibration 
curve was R2: 0.9995 for a concentration range of 5-350 μg mL-1, indicating 
acceptable linearity. Drug loading measurements were conducted in triplicate 
for each formulation (n=3).  
2.3.5.6. Redispersibility 
 
For the measurement of redispersibility, around 100 mg of each spray-dried 
powder was added in 10 mL of water in a glass vial and vortexed for 30 s. 
Redispersibility index (RDI %) was determined according to Yue et al., 2013: 
      
100*%
0averagez
averagez
RDI


      . . . . Equation 2.1      
where, z-average0 is the intensity-weighted mean particle diameter of the 
nanosuspensions prior to spray drying measured by PCS and z-average is 
the corresponding value of nanosuspension reconstituted from nanoparticle 
agglomerates upon rehydration. A RDI% value close to 100% would mean 
that the spray-dried nanosuspensions can be completely reconstituted to the 
original particle size of liquid nanosuspensions upon rehydration.  
2.3.5.7. In-vitro dissolution testing 
 
A paddle method was employed using the USP apparatus type II (Pharma 
Test, Heinburg, Germany), at 37oC and 100 rpm stirring speed. The 
dissolution medium was 900 mL phosphate buffer BP, pH: 6.8. Weighted 
amounts of formulations corresponding to about 75 mg of IND were filled in  
gelatin capsules (size 2). Sink conditions were maintained during the 
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dissolution tests (solubility of IND in phosphate buffer pH: 6.8 is 0.835 mg 
ml-1, Bahl and Bogner, 2008). At specific time intervals up to 60 min, 5 mL of 
dissolution medium was withdrawn, filtered through 0.1 μm disposable 
syringe filter and placed in HPLC vials for assay, while immediately being 
replaced with 5 mL of fresh medium. The HPLC conditions for the assay were 
as described in section 2.3.5.5. Dissolution tests were made in triplicate for 
each formulation (n=3). The percentage of dissolution efficiency (DE%), as a 
parameter of the extent of dissolution, was calculated from the ratio of the 
area under the curve up to time (t), to that of the rectangle described by 
100% dissolution at the same time as follows: 
100
.
.
% ).(
100
0
ty
dty
DE
t

          . . . .               Equation 2.2 
where, y is the percentage of drug dissolved (Khan, 1975). Also, the mean 
dissolution time (MDT), as a parameter of the rate of dissolution, was 
calculated: 





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n
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t
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1
1
ΔΜ
       . . . .            Equation 2.3 
Where, i is the dissolution sample number, n is the number of dissolution 
times, tmid is the time at the midpoint between times ti and ti−1, and ΔΜ is 
the amount of drug dissolved (mg) between times ti and ti−1. (Brockmeier et 
al., 1983). 
2.3.5.8. In-vitro aerosol performance 
 
Deposition profiles were determined with Ph. Eur. Apparatus E (Next 
Generation Impactor, NGI, Copley Instruments Ltd, UK) connected to a high-
capacity vacuum pump (Model HCP5, Copley Instruments Ltd, UK) (Fig. 2.4). 
Prior to use, the impaction cups in each of the seven stages were coated with 
1% v/v silicone oil in hexane, and allowed to dry for 1 h, in order to 
minimize particle bounce and entrapment of particles between the stages. 
The final stage of the impactor was fitted with a fibreglass filter (nylon 0.45 
μm, Millipore, UK). The actual flow rate was measured using a calibrated flow 
meter (Flow Meter Model DFM 2000, Copley Instrument Ltd, UK) prior to 
each run, to ensure that a flow at 60 L min-1 was achieved. 
CHAPTER 2. NANOPARTICLE AGGLOMERATES OF INDOMETACIN 
   
   
   
   
   83 
 
Figure 2.4 The Next Generation Impactor apparatus (a) closed with induction port 
and pre-separator attached and (b) open showing component parts. Adapted from 
Copley, 2007.  
 
Gelatin capsules (size 3) were filled with accurately weighted amounts of 
product corresponding to about 15 mg of IND and tested at 60 L min-1 for 4 
s. The inhaler device (Cyclohaler®) was connected to the impactor via an 
airtight rubber adaptor. The capsules were discharged into the NGI and after 
dispersion the powder deposited on each inhaler and NGI part was collected 
by exhaustively washing with ethanol 96% v/v, transferred into volumetric 
flasks and made up to volume and assayed. In-vitro aerosol performance 
tests were conducted in triplicate for each formulation (n=3). The HPLC 
conditions for the assay were identical to those for drug content 
determination. To characterise the aerosol performance the following 
parameters were determined: the emitted fraction (EF%) was calculated as 
the ratio of the sum of drug mass depositing in the mouthpiece, induction 
port, pre-separator and impactor stages (1 to MOC) to the loaded dose. The 
fine particle fraction (FPF %) was the ratio of the drug mass depositing on 
stages 2 to MOC to the loaded dose (initial mass of drug loaded in the 
capsules). The fine particle dose (FPD) was calculated as the ratio of mass 
deposited on stage 2 to MOC, to the number of doses (n=3). The mass 
median aerodynamic diameter (MMAD) defined as the median particle 
diameter of the formulation deposited within the NGI; and the geometric 
standard deviation (GSD) determined as the square root of the ratio of the 
particle size at 84.13th percentile to that of 15.87th percentile were 
calculated. Both MMAD and GSD were determined from the linear region in 
the plot of the cumulative mass distribution versus the logarithm of 
aerodynamic diameters. 
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2.3.6. Statistical data analysis 
The analysis of variance (one-way ANOVA) with Tukey’s multiple comparison 
test was carried out to evaluate differences between the mean values using 
Prism 6 (GraphPad Software, Inc., USA). Probability values less than 0.05 
were considered as indicative of statistically significant differences. 
2.4. RESULTS AND DISCUSSION 
 
2.4.1. Preparation and characterization of nanosuspensions 
All the stabilisers used in this study (except Pluronic® L64) generated 
nanosuspensions with a mean particle size around 260 nm after 12 cycles of 
milling (Fig. 2.5). Longer milling times resulted in finer nanosuspensions with 
narrow particle size distribution indicated by smaller polydispersity index (PI) 
values.  Furthermore, the achieved rate of size reduction (breakage rate) 
was reduced with the milling duration but in a manner dependent on the 
nature of the stabiliser used (Fig. 2.6.). TPGS generated nanoparticles of 263 
nm even from the first 45 min of milling, followed by Pluronic® F68 and F127. 
More specifically, Pluronic® F127 with the higher molecular weight, Table 2.1, 
exhibited a slower rate of size reduction (mean particle size of 505 nm after 
45 min of milling) compared to small molecular weight stabilisers such as 
TPGS or Pluronic® F68 (mean particle sizes of 263 and 363 nm after 45 min 
of milling, respectively). This suggests a trend between the molecular weight 
of the polymer and the rate of size reduction which may be explained by the 
less kinetically restricted adsorption process of the low molecular weight 
stabilisers compared to those of higher molecular weight (Lee et al., 2008; 
Rachmawati et al., 2013). 
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Figure 2.5 ΤΕΜ images of liquid nanosuspensions prepared with different stabilisers 
(10% w/w IND) after 180 min milling. 
The initial faster breakage of IND crystals, from 54.10 ± 8.12 μm (volume 
mean diameter of raw indometacin crystals) to below 500 nm during the first 
45 min of milling, for all the nanosuspensions prepared (apart from that with 
liquid Pluronic® L64) can be attributed to the existence of more cracks and 
crystal defects in the larger crystals which propagate breakage relatively 
easily. After this initial fast breakage stage, size reduction continues but at a 
remarkably slower rate until a plateau is reached (Fig. 2.6). The slower size 
reduction rate and achievement of the plateau (steady state) suggests that 
in the later stages of milling, abrasion becomes the main mechanism behind 
size reduction as shear stress of nanosuspensions increases with decreasing 
particle size (Peukert et al., 2003; Plakkot et al., 2011). 
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Figure 2.6 Mean nanoparticle size (hydrodynamic diameter) and polydispersity index 
(PI) of nanosuspensions of indometacin with increasing wet milling time (mean ± SD, 
three samples from one batch of each nanosuspension were analysed). 
The size reduction dependence on the stabiliser’s nature and the existence of 
similar nanoparticle size plateau for different stabilisers (steady state), may 
be explained by the fact that the fracture of drug crystals depends on two 
groups of factors based on: the transfer of mechanical energy and the 
intrinsic physico-mechanical properties of the crystalline material (Lee, 
2003). For the transfer of mechanical energy, factors such as stabiliser type, 
slurry viscosity, size of milling beads and milling speed are involved, 
influencing particle size distribution as a function of time (size reduction rate) 
but not the steady state particle size of the nanoparticles obtained. The latter 
mainly depends on the intrinsic physico-mechanical properties of the drug 
crystals such as brittleness, yield stress, plasticity and elasticity (Lee, 2003; 
Plakkot et al., 2011). 
The inability of Pluronic® L64 to stabilise the indometacin nanosuspensions 
seems to be interesting, especially when compared with the high success 
rate of Pluronic® F68 in stabilising nanosuspensions of indometacin (Fig. 2.5) 
and of other poorly water-soluble drugs. Pluronics® L64 and F68 have 
approximately the same molecular weight of the hydrophobic poly-
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oxypropylene (PO) segment (1680 and 1740 g mol-1, respectively). However, 
L64 has a small hydrophilic poly-oxyethylene (EO) segment of 1160 g mol-1, 
while F68 has a EO segment of 6720 g mol-1, Table 2.1. Therefore the poor 
stabilisation ability of L64 can be attributed to its small EO segment 
indicating the importance of both segments for the stabilisation of drug 
nanocrystals. While the hydrophobic PO segment adsorbs and adheres on the 
hydrophobic drug crystal surface the hydrophilic EO segment has to be of 
sufficient size to protrude from the particle size in order to give suitable 
stabilisation. The difference in stabilisation efficiency of Pluronics® L64 and 
F68, can be explained by considering previous studies on the adsorption and 
coating thickness of different types of Pluronics® on polystyrene latex 
particles (Carstensen et al., 1991; Illum et al., 1987).  According to 
Carstensen et al. (1991) the coating thickness of Pluronic® L64 and F68 on 
polystyrene particles (60 nm hydrophobic particles) was 2.4 and 7.6 nm, 
respectively. The lower coating thickness of Pluronic®L64 was explained by 
the fact that its EO segment protrudes to a smaller extent from the particle 
surface than the EO segment of Pluronic® F68. In the case of indometacin 
nanosuspensions, L64 due to its lower coating thickness cannot make the 
hydrophobic drug surface sufficiently hydrophilic so as to secure steric 
stabilisation and as a result aggregation occurs. Liu et al. (2015) reported 
similar results after studying the affinity of polymers onto drug surfaces 
using surface plasmon resonance and contact angle measurements.  
No significant change (p > 0.05) was found in mean hydrodynamic diameter 
of the nanocrystals after one-week storage at room temperature. The one 
week can be considered as a reasonable time period between the procedures 
of wet bead milling and spray drying and the short term physical stability of 
the nanosuspensions is thus considered adequate. 
 
2.4.2. Characterisation of nanoparticle agglomerates  
For the evaluation of the nanoparticle agglomerates prepared with different 
stabilisers, the particle size distribution results are given in Table 2.2 and 
SEM images in Figure 2.7. Figures 2.8 and 2.9 show the XRPD patterns and 
DSC curves, respectively, of the raw materials used and nanoparticle 
agglomerates prepared, while Table 2.3 summarises the contents of nominal 
components and assayed IND together with the calculated drug loading 
efficiency (%) and the parameters of reconstitution ability. The in-vitro 
CHAPTER 2. NANOPARTICLE AGGLOMERATES OF INDOMETACIN 
   
   
   
   
   88 
dissolution parameters of nanoparticle agglomerates are listed in Table 2.4, 
while Figure 2.10 summarizes the corresponding drug dissolution profiles. 
Finally, the parameters of in-vitro aerosol performance of nanoparticle 
agglomerates are given in Table 2.5 and their drug deposition profiles are 
presented in Figure 2.11. 
2.4.2.1. Particle size and morphology  
 
The SEM images (Fig. 2.7) reveal the spherical and composite structure of 
the nanoparticle agglomerates that consist of micron-sized clusters of 
nanoparticles. Also, they show that the nanoparticles were generally 200-400 
nm in diameter, confirming the results of PCS and TEM for the original 
nanosuspensions.  
 
Figure 2.7 SEM images of nanoparticle agglomerates of indometacin: (a) without and 
(b) with matrix formers prepared with different stabilisers (10 % w/w of IND). 
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From the particle size distribution results (Table 2.2) it is seen that 
nanoparticle agglomerates without matrix formers (mannitol and L-leucine) 
have significantly higher median diameter d50 compared to the nanoparticle 
agglomerates containing matrix formers (p < 0.05). Moreover, the 
nanoparticle agglomerates without matrix formers exhibit d90 values higher 
than the size range that is suitable for pulmonary drug delivery (0.5-5 μm). 
This can be attributed to the presence of some secondary agglomerates 
(nanoparticle agglomerates attached together). 
 
Table 2.2. Particle size distribution (d10, d50 and d90, μm) of nanoparticle 
agglomerates of indometacin prepared with different stabilizers (10% w/w of IND) at 4 
bar dispersion pressure and 50 mm s-1 feeding velocity (mean ±SD, n=3). 
 
Stabiliser 
Matrix 
Formers 
Particle size distribution d10, d50, d90 
 
(4 bar, 50 mm s-1) 
  d10 (μm) d50 (μm) d90 (μm) 
Pluronic® F127 without 1.63 ± 0.02 4.03 ± 0.03 47.96 ± 1.65 
 with 0.89 ± 0.04 2.08 ± 0.02 3.88 ± 0.04 
Pluronic® F68 without 1.35 ±0.05 3.37 ± 0.11 6.96 ± 1.50 
 with 1.06 ± 0.02 2.49 ± 0.02 4.68 ± 0.11 
TPGS without 1.26 ± 0.02 4.03 ± 0.03 18.03 ± 9.3 
 with 0.87 ± 0.02 2.17 ± 0.08 3.98 ± 0.10 
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2.4.2.2. Solid state characterisation 
 
The solid state properties of the nanoparticle agglomerates were examined 
as these are important for drug stability, solubility, dissolution and 
therapeutic efficacy and may change for the drug during milling and for both 
the drug and the matrix formers during spray drying. The XRPD patterns 
(Fig. 2.8) showed that for indometacin raw material the diffraction angles 
observed are characteristic of the γ- form (2 theta: 11.6o, 16.8 o, 19.6 o, 
21.8o, 26.6o) (Legendre and Feutelais, 2004), while for spray-dried mannitol, 
XRDP patterns are characteristic for the β- form (2 theta: 10.6o, 14.7o, 
16.9o, 21.2o, 23.9o, 29.5o) (Hulse et al., 2009). Figure 2.8a did not show any 
apparent difference between pure indometacin and the nanoparticle 
agglomerates prepared with different stabiliser and without matrix formers, 
while for the nanoparticle agglomerates containing matrix formers, the 
diffraction patterns (Fig. 2.8b) were essentially a summation of the patterns 
of indometacin and spray-dried mannitol and L-leucine with the expected 
relative reduction in intensities.  Reduction in the intensities, as well as 
broadening of the peaks observed, for the patterns of both nanoparticle 
agglomerates with and without matrix formers compared to the patterns of 
the starting materials, can be attributed to the smaller size of nanoparticles, 
the dilution of the particles with stabilisers and strain caused by the milling 
process (Hecq et al., 2005; Van Eerdenburgh et al., 2008b). 
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Figure 2.8 XRPD patterns of nanoparticle agglomerates of indometacin prepared with 
different stabilisers: (a) without matrix formers and (b) with matrix formers, 
comparatively to raw indometacin and spray-dried aqueous solution of matrix formers 
(mannitol and L- leucine). 
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The DSC curve of raw indometacin (Fig. 2.9) showed an endothermic melting 
peak at 159 oC (γ- form), while the curves of nanoparticle agglomerates 
without matrix formers containing different stabilisers presented two 
endothermic peaks corresponding to their components; a small peak in the 
range 30 to 50 oC due to the melting of the stabiliser used in each 
formulation and a melting peak at 157 oC due to the melting of indometacin. 
Regarding DSC curves of spray-dried aqueous solution of mannitol and L-
leucine in the same proportion as in the agglomerates, a large endothermic 
melting peak at 165 oC appeared due to the melting of mannitol while for the 
nanoparticle agglomerates containing matrix formers an additional smaller 
melting peak at around 155 oC was observed, due to the melting of 
indometacin. Absence of an endothermic peak for the incorporated stabilisers 
indicated their existence as molecular dispersions in the spray-dried 
nanoparticles. Also, in the DSC curves of all nanoparticle agglomerates, as 
expected, the peaks shifted slightly to lower temperatures compared to the 
starting materials due to the fact that the agglomerates consist of more than 
one substance (Sharma et al., 2009). 
 
 
Figure 2.9 DSC curves of nanoparticle agglomerates of indometacin prepared with 
different stabilizers:  (a) without matrix formers and (b) with matrix formers, 
comparatively to raw indometacin and spray-dried aqueous solution of matrix formers 
(mannitol and L- leucine).  
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According to both XRPD and DSC data, nanoparticle agglomerates with and 
without matrix formers retain their crystallinity. The preservation of the 
crystalline state when wet bead milling and spray drying are coupled is 
advantageous ensuring long-term physical stability during storage, compared 
with other size reduction methods that may result in amorphisation (total or 
partial) of indometacin. More specifically, production of indometacin 
nanocrystals by using a nano-spray dryer and ethanol:water solution 
resulted in a mixture of amorphous indometacin and two polymophs, the 
stable γ- form and the metastable α- form (Martena et al., 2012). The 
production of an entirely ‘X-ray amorphous’ indometacin was also observed 
when cryo-milling in an oscillatory ball mill was employed as size reduction 
method (Karmwar et al., 2012). According to Kayaert and Van den Mooter 
(2012) the absence of drug amorphisation when wet bead milling is 
employed, can be attributed to the function of water as plasticiser on the 
potentially generated amorphous material, lowering the glass transition 
temperature sufficiently to trigger recrystallisation.   
2.4.2.3. Drug loading and redispersibility 
 
The results of assayed indometacin content in the nanoparticle agglomerates 
(Table 2.3) show that the drug content is very close to the nominal content, 
meaning that there was very little indometacin loss or powder segregation 
during the production process. Regarding the redispersibilty, for the 
nanoparticle agglomerates it is desirable that they rapidly redisperse and 
give primary nanoparticles upon contact with biological fluids (Chaubal and 
Popescu, 2008). Comparison of redispersibility index data (Table 2.3) shows 
that nanoparticle agglomerates without matrix formers could not reform 
nanoparticles upon their rehydration. Specifically, rehydration of nanoparticle 
agglomerates without matrix formers resulted in particles with z-average 
size above 1 μm and 2 μm in the case of stabilisation with TPGS and 
Pluronics®, respectively. At this point, it should be noted that while the upper 
limit of dynamic light scattering (DLS) is at 5 μm, the technique is not 
accurate for particles above 1 μm. This means that the z-average values 
above 1 μm should only be used as an indication of the poor redispersibility 
of the nanoparticle agglomerates. This may be because spray drying can 
cause thermal stress, which leads to irreversible aggregation, probably due 
to the inactivation of steric stabilisation provided by the stabiliser in the 
liquid state. More specifically, removal of water between the nanoparticles 
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during spray drying may induce entanglement of the stabiliser chains or 
stabiliser fusion which can lead to irreversible particle aggregation (Yue et 
al., 2013). Another possible explanation for the inability for particles to 
redisperse, is that stabilisers, such as Pluronics®, which are coating 
nanoparticles during spray drying, may recrystallize, compromising their 
ability to prevent aggregation (Chaubal and Popescu, 2008). On the 
contrary, for nanoparticle agglomerates containing matrix formers the 
reformed nanoparticles exhibited a mean z-average size of around 450 nm 
upon their dispersion in water (Table 2.3). The higher z-average size of the 
redispersed nanoparticles compared to the nanoparticles after wet milling 
(Fig. 2.6) indicates that addition of matrix of formers reduced the irreversible 
aggregation induced by spray drying but could not completely prevented. 
However, as the reformed particles are in the nano-range, it can be assumed 
that spray drying in the presence of matrix formers did not comprise the 
advantages of nanosuspensions.  
Previous studies have highlighted the role of mannitol as matrix former 
which enhances the redispersibility of nanoparticle agglomerates by 
decreasing the inter-nanoparticle contacts and as a result preserves the 
rapid dissolution characteristics of the nanoparticles (Van Eerdenbrugh et al., 
2008a). Therefore, the protective action of matrix formers for the 
nanoparticle agglomerates can be attributed to mannitol and particularly to 
its function as a continuous solid matrix where nanoparticles are 
interdispersed. Upon contact with water mannitol is dissolved and 
nanoparticles are reformed.  
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Table 2.3 Nominal component and assayed Indometacin content (%w/w) of nanoparticle agglomerates, together with calculated drug loading 
efficiency (%) and parameters of nanosuspension reconstitution: z-average size, polydispersity index, PI,  and redispersibilidy index, RDI % 
(mean ± SD, n=3). 
 
Formulation Matrix Formers Content (% w/w) 
 
Drug  
loading 
Efficiency (%) 
Reconstituted Nanosuspension 
  Nominal 
 
Assayed 
IND 
z-average size 
(nm) 
PI RDI% 
  IND Stab Man Leu    
Pluronic® F127  Without 90.9 9.1 - - 88.4 ± 0.7 97.2 ± 0.8 2749 ± 773a     
  
0.63   1042 
 With 40.6 4.0 49 6.5 38.3 ± 0.4 94.3 ± 1.0 422 ± 0.8  
 
0.19
  
160 
Pluronic® F68 Without 90.9 9.1 - - 90.7 ± 0.7 99.8 ± 0.8 2460 ± 414a   0.48  918 
 With 40.6 4.0 49 6.5 36.3 ± 0.3 89.4 ± 0.8 417 ± 4   0.20 
  
156 
TPGS  Without 90.9 9.1 - - 91.1 ± 0.9 100.2 ± 1.0 1293 ± 83a   
 
0.33 
  
475 
 With 40.6 4.0 49 6.5 41.0 ± 0.5 101.0 ±  1.3 468 ± 31   0.35 
  
172 
a Large sedimenting particles, Stab= stabilizer, Man= mannitol, and Leu= leucine 
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2.4.2.4. In-vitro dissolution tests 
 
The dissolution profiles of nanoparticle agglomerates (Fig. 2.10), and the 
corresponding dissolution parameters (DE% and MDT; Table 2.4) show that 
% DE60 min is lowest for raw indometacin (47.4%) and increases remarkably 
for its physical mixtures with stabilisers (58.7 – 70.6 %) and furthermore for 
the nanoparticle agglomerates without matrix formers (88.2 – 98.1%) and 
even more for those containing matrix formers (97.1– 99.2%). More 
specifically due to the different stabiliser, the %DE60min increases in the order 
F68 < TPGS < F127, which is the same with that of indometacin solubility in 
aqueous (0.5% w/v) solutions of F68 and F127 (Table 2.5) apart from the 
case of TPGS. The exception of TPGS might be attributed to the slow 
diffusion of surfactant-loaded micelles despite the surfactant enhanced 
solubility (Balakrishnan et al., 2004). The results of %DE at 10 and 30 min 
and MDT are in accordance with %DE60min, with some variation, probably due 
to differences in the dissolution area caused by the differences in the size of 
nanoparticle agglomerates and their primary nanoparticles.  
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Figure 2.10 Dissolution profiles of nanoparticle agglomerates of indometacin prepared with and without matrix formers (MF) and different 
stabilizers: (a) Pluronic® F127, (b) Pluronic® F68 and (c) TPGS, comparatively to raw indometacin (IND) and its physical mixtures with each 
stabilizer (PM) (mean + SD, n=3). 
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The increase in dissolution rate for the nanoparticle agglomerates can be 
attributed to the following reasons: 
i) The action of both Pluronics® and TPGS as solubilisers enhancing 
the saturation solubility of indometacin besides its wetting and 
dissolution rate (Chiappetta and Sosnik, 2007; Guo et al., 2013). 
ii) The increase in surface area as a result of size reduction 
(nanoparticle formation) compared to raw indometacin and physical 
mixtures of indometacin with stabilisers.  
iii) The additional enhancement of dissolution rate by the use of 
mannitol as a hydrophilic matrix former, resulting in quicker 
nanoparticle reconstitution and highest dissolution efficiencies, even 
at 10 min, and lowest mean dissolution times (MDT)  
 
Table 2.4 In-vitro dissolution parameters (dissolution efficiency, %DE at 10, 30 and 
60 min and mean dissolution time, MDT) of NP-agglomerates prepared with different 
stabilisers (10% w/w of IND), raw indometacin powder and its physical mixtures with 
stabilisers (n=3).  
 
Formulation Stabiliser 
Matrix 
Former 
DE10 
(%) 
DE30 
(%) 
DE60 
(%) 
MDT 
(min) 
IND powder - Without 3.61 27.5 47.4 15.2 
Agglomerates F127 Without 65.8 91.6 98.1 4.9 
Agglomerates   With 76.5 93.5 97.5 2.9 
Physical mix  Without 17.3 45.8 64.9 14.0 
Agglomerates F68 Without 27.2 71.1 88.2 10.7 
Agglomerates   With 68.8 92.1 99.2 4.1 
Physical mix  Without 22.8 52.5 70.6 17.1 
Agglomerates TPGS Without 47.4 80.1 91.4 8.7 
Agglomerates   With  72.8 91.8 97.1 4.3 
Physical mix  Without 16.8 39.2 58.7 17.8 
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Table 2.5 Solubility of indometacin in aqueous stabiliser solutions (0.5% w/v) before 
nanocommunition (at 25 oC for 24 hs), (mean ± SD, n=3). 
 
Stabiliser 
 
Indometacin solubility  
(μg mL-1) 
 
Distilled water 12.34 ± 0.70 
Pluronic F127  29.02 ± 1.62 
Pluronic F68  25.76 ± 0.15 
TPGS 1000 185.23 ± 3.47 
 
Dissolution testing indicated that nanoparticle agglomerates achieve a 
higher available amount of drug for absorption, as their dissolution is faster 
compared to the raw indometacin and its physical mixtures with stabilisers. 
This is especially advantageous for indometacin, which according to the BCS 
is a class II drug (poor water solubility, high permeability), meaning that its 
in vivo dissolution is the rate-limiting step in its absorption. Thus, the 
improved in-vitro dissolution of nanoparticle agglomerates may result in 
enhanced in vivo bioavailability of indometacin. This is important in both the 
cases of oral and pulmonary delivery of nanoparticle agglomerates of poorly 
water-soluble drugs as indometacin.  
2.4.2.5. In-vitro aerosol performance 
 
The drug deposition profiles (Fig. 2.11) and the parameters FPF% and 
MMAD, Table 2.6, show significant differences due to incorporation of the 
matrix formers. FPF% becomes higher (48.9 - 61.9 instead of 34.9 - 43.2%) 
and MMAD lower (3.4 - 3.5 instead of 3.8 - 4.5 μm) indicating improved 
aerosolisation. Applying ANOVA has shown significant effects of the matrix 
formers’ incorporation on FPF% and MMAD (p=0.001-0.03, p= 0.001-0.1). 
For the nanoparticle agglomerates with matrix formers, those with F68 and 
TPGS exhibited higher FPF% (p=0.36) compared to those with F127 (p= 
0.001-0.04) while no significant differences were found for the MMAD (p= 
0.97-1.0). The type of stabiliser employed was found to have non- significant 
influence for both FPF% and MMAD (p=0.13-0.49) of nanoparticle 
agglomerates without matrix formers. 
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Table 2.6 Parameters of in-vitro aerosol performance (recovered fraction, RF%, emitted fraction, EF%, fine particle fraction, FPF%, fine particle dose, 
FPD, mass median aerodynamic diameter, MMAD, and geometric standard deviation, GSD) of NP-agglomerates prepared with different stabilizers, 10% 
w/w of IND (mean ± SD, n=3). 
 
Stabiliser 
Matrix 
Formers 
RF (%) EF (%) FPF (%) 
FPD 
(mg) 
MMAD 
(μm) 
GSD 
Pluronic F127 Without 82.3 ± 4.3 70.2 ± 5.3 36.6 ± 3.8 5.5 ± 0.6 4.5 ± 0.2 1.7 ± 0.1 
 With 79.7 ± 4.6 61.2 ± 2.6 48.9 ± 4.2 7.3 ± 0.7 3.4 ± 0.1 1.6 ± 0.1 
Pluronic F68 Without 82.4 ± 1.7  62.1 ± 4.9 43.2 ± 2.4 6.5 ± 0.3 4.1 ± 0.3 1.7 ± 0.1 
 With 81.5 ± 7.5 77.9 ± 2.2 61.9 ± 1.6 9.3 ± 0.1 3.4 ± 0.1 1.8 ± 0.3 
TPGS Without 81.4 ± 5.6 60.7 ± 4.3 34.9 ± 2.5 5.2 ± 0.4 3.8 ± 0.2 1.7 ± 0.2 
 With 83.2 ± 5.4  76.3 ± 3.1 57.0 ± 2.2 8.6 ± 0.4 3.4 ± 0.1 1.6 ± 0.1 
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Figure 2.11 Drug deposition profiles of nanoparticle agglomerates prepared with different stabilizers (10% w/w of IND):  (a) without matrix 
formers and (b) with matrix formers (mean + SD, n=3). 
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The improved aerosolisation indicated by higher FPF% and lower MMAD for 
the nanoparticle agglomerates containing matrix formers, Table 2.6, can be 
attributed to the significantly smaller particle size according to the laser 
diffraction measurements, Table 2.2. On the contrary, the high throat and 
pre-separator deposition of the nanoparticle agglomerates without matrix 
formers (Fig. 2.11a) may be due to the presence of secondary nanoparticle 
agglomerates (agglomerates attached together) observed also by the SEM 
images (Fig. 2.7a). Moreover, the presence of leucine is of benefit to the 
aerosolisation performance of the particles. Leucine as a surface active 
molecule was found to improve the dispersibility of particles by forming a 
coat (shell) on the surface. Also, inclusion of leucine as an additive in a 
precursor solution for spray drying was found to enhance the aerosol 
behaviour of the resulting powders (Lechuga-Ballesteros et al., 2008; 
Rabbani and Seville, 2005; Seville et al., 2007). More specifically, the 
addition of leucine to a mannitol-based spray-dried powder for inhalation, 
was found to enhance the performance of DPI formulations, by forming a 
coating on the dry particle surface preserving the individual particles as 
collected from the dryer, preventing any particle fusion (Sou et al., 2011). 
Therefore, the property of leucine on improving dispersibility of particles and 
thus reducing their cohesiveness may explain the remarkably reduced throat 
and pre-separator deposition (Fig. 2.11b) in the case of nanoparticle 
agglomerates containing matrix formers and particularly those with Pluronic® 
F127 resulting in an approximately 2- fold decrease, compared to 
corresponding formulation without matrix formers. 
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2.5. CONCLUSIONS  
 
Based on the aforementioned results presented in this chapter, it can be 
concluded that: 
1. Nanosuspensions of the poorly water-soluble drug indometacin 
stabilised with different Pluronics® (F127 and F68) and TPGS were 
successfully produced and further spray dried with or without the 
addition of matrix formers (mannitol and L-leucine).  
2. Under the milling conditions applied, the molecular weight of 
stabilisers used influences the rate but not the limit of particle size 
reduction of the nanosuspensions, which is probably determined by 
the physico-mechanical properties of the drug tested (IND).  
3. The nanoparticle agglomerates obtained after spray drying were 
crystalline and IND was of the same polymorphic form as the raw 
drug (γ- ΙΝD), which is beneficial for their long-term physical stability.  
4. Incorporation of matrix formers during the spray-drying step 
improved the aerosol performance, the dissolution rate as well as the 
redispersibility of the formulations.  
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3. NANOPARTICLE AGGLOMERATES OF IBUPROFEN 
 
3.1. INTRODUCTION 
 
Nanosuspensions have been suggested as a beneficial formulation approach 
for class IIa drugs of the Biopharmaceutical Classification System (BCS), for 
which the dissolution rate is the rate-limiting step of absorption (Butler and 
Dressman, 2010). Solidification of the nanosuspensions has been explored to 
combine the advantages of liquid nanosuspensions (i.e. enhanced dissolution 
and solubility) with the benefits of solid formulations (i.e. stability, easier 
handling, enhanced patient compliance) producing nanoparticle 
agglomerates suitable for oral and pulmonary delivery. Preparation of 
nanosuspensions by wet milling followed by solidification, using spray drying, 
has been suggested as a formulation approach for nanoparticle agglomerates 
with enhanced dissolution and aerosolisation efficiency (Yamasaki et al., 
2011). 
 
Compounds with high melting points and poor water-solubility have been 
highlighted as successful candidates for nanomilling. According to the study 
by George and Ghosh (2013) the melting point is one of the key drug 
properties that showed a direct influence on the stability of the 
nanosuspension with respect to the particle size distribution. This may be 
explained by the fact that the higher the melting point, the more stable is 
the drug compound, with no solid state transformations expected. Thus, it is 
evident that low melting point drugs can be challenging candidates to be 
processed by wet milling and spray drying as considerable amount of heat is 
generated in these operations.  
 
The aim of the present work is to study the preparation of nanoparticle 
agglomerates for low melting point APIs. In this way, the use of wet milling 
followed by spray drying as a universal and industrially feasible formulation-
based approach for the nanoparticle agglomerates with tailored properties 
for pulmonary and oral delivery will be evaluated.  
 
Ibuprofen was selected as a poorly water-soluble model drug with low 
melting point. Moreover, it is a drug with challenging mechanical properties 
as it is a ductile material with a high brittle-ductile transition point of 854 μm 
(Leuenberger, 1982). Below this point, it is difficult to reduce the size of 
particles by dry milling, as the particles tend to deform rather than fragment. 
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Despite the high ductility of ibuprofen, it was reported that wet milling using 
a Micros Ring Mill resulted in particles with diameter about 8-11 μm (much 
smaller than the critical diameter of 854 μm). The superior size reduction 
performance of wet milling was attributed to the contribution of shear forces, 
which cause ductile fracture of crystals (Larsson and Kristensen, 2000). 
Besides the ductility of ibuprofen, its low-melting point poses additional 
challenges on the conventional nano-comminution techniques.  
 
According to the ICH Q8 (R2) guideline, quality by design (QbD) is the 
systematic approach to pharmaceutical development with predefined 
objectives emphasizing product and process understanding (ICH, 2009). The 
main tools of QbD are the design of experiments (DoE), risk assessment and 
process analytical technology (PAT). DoE helps in the identification of critical 
versus non-critical parameters affecting product quality attributes and also 
identifies any interactions between critical parameters impacting the quality 
attributes 
 
In this chapter, wet milling of ibuprofen using two different stabilisers, 
namely hypromellose (HPMC) and D-α- Tocopherol polyethylene glycol 1000 
succinate (TPGS), followed by spray drying, after the addition of matrix 
formers, was assessed. The effect of the type of stabiliser on the size 
reduction of nanosuspensions was investigated. The solid state, particle 
morphology and the dissolution profiles were also assessed. A full factorial 
design was employed to understand the critical process parameters as well 
as any interactions between them involved in the wet milling and spray 
drying process. The critical formulation parameters investigated were: type 
of stabiliser, mannitol to drug ratio and leucine to drug ratio. The yield of the 
process, the particle size distribution, the redispersibility (as redispersibility 
index) and the fine particle fraction were investigated as responses. 
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3.2. MATERIALS 
 
Ibuprofen (IBU, Shasun Pharmaceuticals Ltd, India) with a volume mean 
diameter D4,3: 64.5 ± 8.3 μm was used. Pharmacoat 603 (low viscosity 
hypromellose 2910 Shin-Etsu, Chemical Co. Ltd, Japan) and D-α- Tocopherol 
polyethylene glycol 1000 succinate (TPGS, Sigma Aldrich Co., St Louis, USA) 
were used as stabilisers. Mannitol (Pearlitol® 160C, Roquette Frères, 
Lestrem, France) and L-leucine (Sigma) were used as matrix formers of the 
nanoparticle agglomerates (Fig. 3.1 and Table 3.1). HycloneTM water for 
Injections (Thermo Scientific, UK) was used for the preparation of 
nanosuspensions. Methanol and acetonitrile were HPLC grade and all other 
reagents of analytical grade.  
 
Figure 3.1 Chemical structures of ibuprofen, stabilisers and matrix formers. 
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Table 3.1 Physicochemical properties of ibuprofen and stabilisers. 
Compound Molecular 
weight  
(g mol-1) 
Melting point (o C)  Aqueous 
solubility  
Ibuprofen 206.3 76 o C 318.98 μg mL-1a 
Pharmacoat 603 
(HPMC) 
13000 
170-180 oC (glass 
transition temperature) 
225–230 oC (charring)b 
soluble 
TPGS 1000  1513 38 o C soluble 
a Attari et al., 2015 
b Rowe et al., 2012 
 
 
3.3 METHODS 
 
3.3.1. Preparation of nanosuspensions 
Nanosuspensions were prepared by wet bead milling using a laboratory 
planetary mill (Pulverisette 5, Fritsch Co., Germany). 0.5 g of IBU, the 
stabiliser (10% w/w of IBU) and 10 g of milling beads (0.5 mm diameter 
aluminum borosilicate glass grinding beads, Gerhardt Ltd, UK) were weighed 
into each glass vial of 14 mL capacity and suspended in 10 mL water for 
Injections. The vials were placed into a stainless steel milling pot with a 
maximum loading capacity of 8 vials (Fig. 3.2.). 
 
Figure 3.2 Schematic diagram of the wet bead milling process for the production of 
drug nanosuspension using the planetary mill Pulverisette 5. 
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Rotation speed (200 rpm), milling duration (6 cycles) and stabiliser 
concentration (10% w/w of IBU) were selected based on preliminary studies. 
Each milling cycle comprised 30 min rotation followed by 20 min pause to 
cool down the milling vessels and avoid overheating of the instrument’s 
rotors. At each pause the nanocrystal size was determined and at the end of 
the milling procedure, the nanosuspensions were allowed to cool to room 
temperature and collected by withdrawal using a pipette for separation from 
the milling beads. 
3.3.2. Characterisation of nanosuspensions 
3.3.2.1. Nanoparticle size 
 
Measurements were carried out during the milling process, at each pause, for 
monitoring the particle size reduction and the final size of the nanocrystals in 
the nanosuspensions. Dynamic light scattering (DLS) was used as previously 
described in Section 2.3.3.1.  
3.3.3. Preparation of nanoparticle agglomerates 
 
The obtained nanosuspensions were solidified by spray drying immediately 
after preparation. 10 mL of nanosuspension were diluted to 100 mL with an 
aqueous solution of matrix formers (mannitol and/or L- leucine) to obtain the 
proportions reported in Table 3.2. Spray drying was performed using a 
laboratory scale spray dryer (Mini B-290, Buchi Labortechnik Ab, Flawil, 
Switzerland) fitted with a high performance cyclone Section 2.3.4). On the 
basis of preliminary ‘one-factor-at-a-time’ experiments the following 
parameters were employed: inlet temperature of 70 o C, outlet temperature 
of 50 ± 2 o C, feed rate of 5 mL min-1 and atomizing gas flow rate of 0.5 L s-1. 
The collected nanoparticle agglomerates were weighed and stored in a 
desiccator over silica gel for subsequent testing. 
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Table 3.2 Matrix of full factorial design 
Formulation 
number 
Pattern Independent experimental  variables 
 
Stabiliser 
Mannitol to 
drug ratio 
Leucine to 
drug ratio 
1 100 HPMC 0.5 0.25 
2 200 TPGS 0.5 0.25 
3 1++ HPMC 1 0.5 
4 100 HPMC 0.5 0.25 
5 2+− TPGS 1 0 
6 1−+ HPMC 0 0.5 
7 2−− TPGS 0 0 
8 2−+ TPGS 0 0.5 
9 1+− HPMC 1 0 
10 2++ TPGS 1 0.5 
11 200 TPGS 0.5 0.25 
12 1−− HPMC 0 0 
 
 
3.3.4. Determination of yield  
Yield was calculated as the ratio of the mass of the particles collected after 
spray drying to the mass of solids (drug, stabiliser, matrix formers) 
introduced in the feed solution. The drug quantity used in the calculations 
was the amount weighed in the milling pots before the wet milling step.  
 
3.3.5. Characterisation of nanoparticle agglomerates 
The nanoparticle agglomerates were characterized with respect to: surface 
morphology by SEM, particle size distribution (PSD) by laser diffractometry; 
solid state form by X-ray powder diffractometry (XRPD) and differential 
scanning calorimetry (DSC), redispersibility by DLS after reconstitution in 
water.  Details of the methods applied have been described in Sections 
2.3.5.1-4 and 2.3.5.6.  
 
The drug loading and the dissolution testing were assessed by HPLC analysis 
of ibuprofen content and the in-vitro aerosol performance using the fast 
screening impactor (FSI).  
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3.3.5.1. Drug loading  
 
5 mg of nanoparticle agglomerates were dissolved in 50 mL methanol and 
ibuprofen concentration was assayed using an HPLC system (Agilent 1100 
Series, Agilent technologies, Germany). The stationary phase was a Luna® 
(150 x 4.60 mm, 5 micron) column (Phenomenex Co., California, USA) kept 
at 30 o C. The mobile phase was composed of acetonitrile and aqueous 
trifluoroacetic acid solution (0.1% v/v) at 50/50 volumetric ratio. The mobile 
phase flow rate was 1 mL min-1, the injection volume was 10 μL and the 
detection wavelength 214 nm. The retention time for ibuprofen was 7.4 min. 
The correlation coefficient of the calibration curve was R2=0.9999 for a 
concentration range of 5-600 μg mL-1, indicating acceptable linearity. 
 
3.3.5.2. In-vitro dissolution testing 
 
The paddle method was applied by using USP apparatus type II (Pharma 
Test, Heinburg, Germany), at 37 oC and 50 rpm stirring speed. The 
dissolution medium was 500 mL of deionised water (freshly boiled and 
cooled, pH: 6-7). Weighted amounts of formulations corresponding to about 
30 mg of IBU were filled in  gelatin capsules (size 2), thus sink conditions 
were maintained during the dissolution tests. At specific time intervals up to 
120 min, 5 mL of dissolution medium was withdrawn, filtered through a 0.1 
μm disposable syringe filter and placed in HPLC vials for assay, whilst being 
immediately replaced with 5 mL of fresh medium. The HPLC conditions for 
the assay were similar to those for drug content determination (section 
3.3.5.1). Dissolution tests were conducted in triplicate for each formulation 
(n=3).  
 
3.3.5.3. In-vitro aerosol performance 
 
The aerodynamic assessment of the nanoparticle agglomerates was carried 
out using the fast screening impactor, FSI (MSP 185 FSI, Copley Scientific, 
UK, Fig. 3.3). The FSI was developed based on the abbreviated impactor 
measurement (AIM) concept. The use of multistage cascade impactors for 
determining the aerodynamic particle size distribution (APSD) is a laborious 
and time-consuming process that may not be necessarily needed for initial 
screening and development studies of inhalation formulations (Despres-Gnis 
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and Williams, 2010). The AIM concept reduces the 7 or 8 data points 
required for the typical full resolution APSD to two mass fractions; fine (FPF) 
and coarse (CPF). According to the AIM concept, eliminating all stages from a 
multistage cascade impactor apart from those required to establish fine and 
coarse particle fractions can be used as a simpler, faster and more precise 
way with less operator error in order to assess the quality of inhaled drug 
products (Mitchell et al., 2013).  
 
The fast screening impactor, FSI, is a device based around the NGI pre-
separator. Equipped with a fine particle collector and an induction port, it 
focuses on the fine particle fraction  (i.e. the particles with an aerodynamic 
diameter smaller than 5 μm that is considered to deposit in the lung). The 
coarse fraction collector (CFC) is equipped with an insert that enables a cut-
off of 5μm at a specific flow rate. A range of inserts is available, generating a 
5 μm cut-off diameter within the flow rate range of 30-100 L min-1. The 
particles not captured in the CFC follow the airstream and deposit in the fine 
fraction collector (FFC) where they are captured by a filter. The external filter 
holder, with quick release catches allows rapid removal of the filter holder for 
gravimetric or chemical analysis (Copley et al., 2013). The FSI is a valuable 
tool as it reduces the time (up to 40% compared to NGI) and the analytical 
burden required to assess information regarding the aerodynamic particle 
size of inhaled drug products. It is especially useful for process optimization, 
QbD and DoE development, batch release and quality control (Rogueda et 
al., 2010).  
 
Figure 3.3 Model 185 Fast Screening Impactor (FSI). 
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In our study, deposition profiles of all the formulations were determined with 
a FSI connected to a high-capacity vacuum pump (Model HCP5, Copley 
Instruments, Ltd, UK). Based on results from preliminary studies the bottom 
plate of the pre-separator was coated with 1% v/v silicone oil in hexane in 
order to reduce particle bounce that is created from the additional 5 μm cut-
off plate. The actual flow rate was measured using a calibrated flow meter 
(Flow Meter Model DFM 2000, Copley Instrument Ltd, UK) prior to each run, 
to ensure that a flow at 30 L min-1 was achieved. Gelatin capsules (size 3) 
were filled with accurately weighted amounts of product corresponding to 
about 10 mg of IBU, placed in the inhaler device (Cyclohaler®) fitted to the 
impactor via an airtight rubber adaptor and tested at 30 L min-1 for 8 
seconds (total volume of 4L).  
The capsules were discharged into the FSI and after dispersion the particles 
were collected on a glass fiber filter (76 mm, Pall Corporation, USA) and 
extracted in methanol. Analysis of the extracts from the coarse and fine 
particle fractions of the FSI was performed with HPLC. The HPLC conditions 
for the assay were identical to those for drug content determination. Each 
formulation was tested in triplicate (n=3).  
3.3.6. Design of Experiment 
A full factorial design 23 (3 factors at 2 levels) was used allowing the 
estimation of the main effects and the two-way interactions (Table 3.2). The 
three independent variables used at two levels in the design were: type of 
stabiliser (X1), mannitol to drug ratio (X2) and leucine to drug ratio (X3). 
Dependent variables: yield, volume median diameter (D50), redispersibility 
index (RDI%) and fine particle fraction (FPF%), were selected as critical 
quality attributes (CQAs). The design matrix included 8 runs plus four centre 
points. Centre points were added to the design space to identify any non-
linearity in the responses. The design space was constructed and analysed 
using the JMP 12.1.0 software (SAS Institute Inc., USA). To reduce 
systematic errors, all the experiments were completely randomised. The 
standard least squares model (including multiple linear regression analysis 
and ANOVA) was fitted in to model the data and develop a mathematical 
expression. More specifically the data were fitted according to the following 
polynomial equation (Eq. 3.1):  
𝑌 = 𝑎𝑜 + 𝑎𝑖𝑋𝑖 +  𝑎𝑗𝑋𝑗 + 𝑎𝑘𝑋𝑘 + 𝑎𝑖𝑗𝑋𝑖𝑋𝑗 + 𝑎𝑖𝑘𝑋𝑖𝑋𝑘 + 𝑎𝑗𝑘𝑋𝑗𝑋𝑘 + 𝜀     .  .  .   Equation 3.1 
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where 𝑌 is the dependent variable or response,   𝑎𝑜 is the intercept, 𝑎𝑖, 𝑎𝑘, 𝑎𝑗 
are the main effects coefficients, 𝑎𝑖𝑗  , 𝑎𝑖𝑘 , 𝑎𝑗𝑘  are the two-way interactions 
coefficients, 𝑋𝑖, 𝑋𝑖, 𝑋𝑖 are the independent factors and 𝜀 is the noise of the 
measurement. The significance and validity of the model was estimated by 
ANOVA. For the sorted parameter estimates of the effects and two-way 
interactions of each response, the t-ratio and prob>|t| values are given. The 
t-ratio value is the ratio of the estimate to its standard error and prob>|t| 
list the probability value of the test. Probability values less than 0.05 were 
deemed to be statistically significant.   
  
3.4. RESULTS AND DISCUSSION 
 
3.4.1. Preparation and characterisation of nanosuspensions 
In this study, both stabilisers were able to produce nanosuspensions of 
ibuprofen after 180 min of wet milling. The results of hydrodynamic diameter 
and polydispersity index (PI) of nanosuspensions obtained with both 
stabilisers as a function of milling time are presented in (Fig. 3.4). More 
specifically, after 180 min nanosuspensions stabilised with HPMC and TPGS 
exhibited a z-average size of 533 ± 28 nm and 663 ± 12 nm, respectively.  
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Figure 3.4 Nanoparticle size (hydrodynamic diameter) and polydispersity index (PI) 
of ibuprofen nanosuspensions with increasing wet milling time (mean + SD, n=3, i.e. 
three batches of each nanosuspension were produced and analysed). 
 
The starting material, with a volume mean diameter D4,3: 64.5 ± 8.3 μm 
(Fig. 3.5) initially showed rapid size reduction during milling, especially with 
HPMC as stabiliser. In the case of HPMC, submicron particles of ibuprofen 
were produced in 60 min while for TPGS this occurred in 90 min. The 
breakage rate of crystals was high initially and with further milling time the 
size continued to decrease but at a remarkably slower rate for both 
stabilisers. This is a common profile as breakage rate kinetics have been 
found to follow a first-order exponential decay (Afolabi et al., 2014). The 
ability of HPMC to stabilise the ibuprofen nanosuspensions can be attributed 
to the conformation of stabiliser molecules on the ibuprofen surface. The 
polymeric chains were found to be completely uncoiled and adsorbed in an 
open extended conformation on the ibuprofen surface (Verma et al., 2009a).  
 
Various techniques have been employed for the nanocomminution of 
ibuprofen crystals. More specifically, Mauludin et al. (2012) produced 
ibuprofen nanosuspensions with a z-average size of 929 nm after 40 
homogenisation cycles using different stabilisers (sodium dodecyl sulfate, 
Tween 80, Poloxamer 188 and polyvinyl alcohol 90000). Plakkot et al. (2011) 
managed to produce nanosuspensions of ibuprofen around 450 nm using a 
new comminution technology (Dena DM 100 processing system) equipped 
with a heat exchanger. The heat exchanger attached to the size reduction 
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system enables the temperature of the sample suspensions to be controlled 
during processing and thus avoid the melting of thermolabile compounds. 
 
In this study, the results of ibuprofen size reduction are similar to those 
reported by Plakkot et al. (2011) and can be favorably compared with those 
obtained by Mauludin et al. (2012) using high pressure homogenisation and 
by Cristini et al. (2003) using rapid expansion of supercritical solutions.  
 
 
Figure 3.5 SEM image of ibuprofen starting material. 
 
3.4.2. Preparation of nanoparticle agglomerates 
During spray drying, the particles are never heated above the outlet 
temperature of the dryer, despite the fact that the inlet temperature may be 
considerably higher (Anandharamakrishnan and Ishwarya, 2015). However, 
in this study based on preliminary trials an inlet temperature of 70 oC, lower 
than the melting point of ibuprofen, was selected in order to avoid melting 
and irreversible aggregation of nanoparticle agglomerates that would hinder 
their reconstitution upon hydration. Similar results were reported regarding 
the spray drying of fenofibrate nanosuspensions (Zhu et al., 2014).  
 
3.4.3. Yield  
The yield was selected as a response characterising quantitatively the overall 
productivity of the process. For the experimental conditions applied the yield 
ranged from 27.3% to 72.5% (Table 3.3). The generated model was 
significant and the response was modeled with high accuracy (adjusted R2: 
0.96) and low root mean square error (RMSE= 2.4516, Fig.3.6).  
 
100 µm 
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Figure 3.6 Actual vs predicted plot for the process yield of nanoparticle agglomerates 
of ibuprofen. 
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Table 3.3 Yield of process and characteristics of spray dried nanoparticle agglomerates of ibuprofen: volume diameter, 
redispersibility (RDI%) and fine particle fraction (FPF%) (mean ± SD, three samples of one batch of each formulation 
were analysed). 
 
Sample 
number 
Pattern Yield (%) Volume diameter (μm) RDI (%) FPF (%) 
   D10 D50 D90   
1 100 58.2 0.92 ± 0.02 3.02 ± 0.04 7.02 ± 0.23 420 58.20 ± 4.2 
2 200 46.6 0.85 ± 0.01 6.20 ± 0.05 9.02 ± 0.13 250 46.62± 5.6 
3 1++ 72.5 0.85 ± 0.00 3.57 ± 0.03 6.82 ± 0.07 283 68.55 ± 3.8 
4 100 56.4 0.83 ± 0.01 2.27 ± 0.01 6.23 ± 0.16 400 45.11 ± 6.1 
5 2+− 41.1 1.13 ± 0.05 9.88 ± 0.39 24.39 ± 2.70 181 9.32 ± 2.5 
6 1−+ 60.1 0.99 ± 0.02 2.30 ± 0.08 3.83 ± 0.11 751 22.93 ± 1.2 
7 2−− 27.3 1.56 ± 0.04 16.04 ± 0.33 53.22 ± 1.51 765 6.68 ± 2.7 
8 2−+ 53.8 0.88 ± 0.02 2.15 ± 0.02 3.81 ± 0.01 600 40.00 ± 2.3 
9 1+− 47.9 1.02 ± 0.06 3.22 ± 0.04 5.92 ± 0.34 307 29.56 ± 3.4 
10 2++ 60.0 0.77 ± 0.01 2.23 ± 0.04 6.21 ± 0.01 148 43.63 ± 4.1 
11 200 43.2 0.87 ± 0.01 5.20 ± 0.04 7.31 ± 0.30 280 40.23 ± 2.7 
12 1−− 37.7 0.96 ± 0.03 4.29 ± 0.09 6.87 ± 1.01 938 5.84 ± 2.8 
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All the three independent variables (independent formulation factors) were 
identified as significant with a positive effect on the yield of the process (p  < 
0.05, Table 3.4). More specifically, the positive effect of increasing the 
leucine and mannitol to drug ratios may be attributed to the increased 
concentration of the solids dissolved in the feed suspension, prior to the 
spray-drying step. Spray drying of nanosuspensions stabilised with TPGS led 
to the lowest yield of 27.3% yield. This low yield may be attributed to the 
low melting point of TPGS resulting in melting and adhesion of the 
nanoparticle agglomerates to the drying chamber and cyclone. Similar 
results have been reported for spray drying nanosuspensions of indometacin 
containing low glass transition temperature sugars (Kumar et al., 2014). 
Replacing TPGS with HPMC, which is a non-thermolabile stabiliser (Table 
3.1), increased the yield. Furthermore, the yield of the process was found to 
maximize by increasing leucine to drug ratio. This may be explained by the 
fact that leucine accumulates on the surface of the particles forming a 
coating around them and thus protecting them from being exposed to high 
temperatures during the spray-drying step. Similar results were reported by 
Rabbani and Seville (2005) regarding the spray drying of hydroalcoholic 
solutions of β-estradiol. They reported that the powder yield was increased 
with increasing leucine content in the formulation. The explanation proposed 
by the authors was that when increasing leucine content was used, the drug 
was encapsulated in micelle-like structures of leucine and thus it was 
protected from the relative harsh spray-drying conditions.  
 
As shown in the response surface plot (Fig. 3.7) higher yields were obtained 
when HPMC was used as the stabiliser of ibuprofen nanosuspensions and 
when high leucine and mannitol to drug ratios were used in the formulations 
prior to the spray-drying step. 
 
Table 3.4 Sorted parameter estimates of the effects and two-way interactions of 
factors on the process yield of nanoparticle agglomerates of ibuprofen.  
Term t-ratio prob > |t| 
Leucine to drug ratio (0,0.5) 13.33 < 0.0001 * 
Type of stabiliser [HPMC] 7.16 0.0008 * 
Mannitol to drug ratio (0,1) 6.14 0.0017 * 
Mannitol to drug ratio * Leucine to drug ratio -0.78 0.4714 
Type of stabiliser [HPMC] * Mannitol to drug ratio  0.37 0.7231 
Type of stabiliser [HPMC] * Leucine to drug ratio  0.23 0.8267 
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Figure 3.7 Response surface plots showing the influence of the independent 
formulation variables mannitol to drug ratio and leucine to drug ratio on the yield of 
the nanoparticle agglomerates of ibuprofen. The stabiliser is (a) HPMC and (b) TPGS. 
(b) Stabiliser: TPGS 
(a) Stabiliser: HPMC 
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3.4.4. Characterisation of nanoparticle agglomerates  
3.4.4.1. Particle size and morphology 
 
The SEM images of the formulations prepared based on the full factorial 
design are shown in Figs. 3.8 and 3.9. Spray drying of ibuprofen 
nanosuspensions stabilised either by HPMC or TPGS in the absence of matrix 
formers resulted in aggregated particles of irregular morphology with size 
outside the acceptable range for deposition to the respiratory tract. In the 
case of HPMC, the particles exhibit irregular morphology where elongated 
fine crystals of ibuprofen coexist with larger particles (pattern 1--, Fig. 3.8). 
In the case of TPGS, the SEM images at low magnification shows particles 
with size larger than 50 μm. SEM images of the same formulation using 
higher magnification indicate that the lumps may have been created due to 
melting and sintering of smaller particles (pattern 2--, Fig.3.9).  
 
Addition of mannitol and/or leucine resulted in the promotion of spherical 
particles with mean size around 2-3 μm that is suitable for pulmonary drug 
delivery. The surface of the spray-dried particles appears not to be smooth 
and a closer look reveals the presence of nanoparticles indicating the 
composite structure of the particles where ibuprofen nanocrystals are 
embedded in a matrix of mannitol and/or leucine (i.e. nanoparticle 
agglomerates).  
 
The nanoparticle agglomerates containing leucine consist of individual 
particles (e.g. patterns 1-+, 2-+). This may be attributed to the 
accumulation of leucine to the surface of the particles preventing any particle 
fusion. Addition of high leucine to drug ratio resulted in wrinkled particles 
(patterns 1++, 2++). A wrinkled morphology was interpreted as an 
indication of hollow particles as the particle density was found to decrease as 
the “wrinkleness” of the particles was increased (Raula et al., 2010).  
 
Furthermore, the nanoparticle agglomerates appear to be porous with holes 
and dimples in the particle surface. The presence of the holes in the particle 
shell can be attributed to the evaporation of liquid that escapes from the 
inner of the droplet through the solid crust built in the course of the drying 
process on the surface of the droplet (Vehring, 2008; Maas et al., 2011). 
Engineering of porous particles is considered beneficial for pulmonary drug 
delivery as particles with high porosity have smaller aerodynamic diameter 
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compared to nonporous particles of the same size, increasing the probability 
for deposition in the lower respiratory tract (Edwards et al., 1997). 
 
 
Figure 3.8 SEM images of nanoparticle agglomerates of ibuprofen stabilised with 
HPMC included in the full factorial design. 
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10 µm 4 µm 1 µm 
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Figure 3.9 SEM images of nanoparticle agglomerates of ibuprofen stabilised with 
TPGS included in the full factorial design. 
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The particle size of the nanoparticle agglomerates obtained was measured by 
laser diffraction as volume diameter (Table 3.3) The dried powders obtained 
exhibited a median diameter D50 between 2.15 and 16.04μm and the data 
are in good agreement with the particle size observed by SEM. The results 
were analysed in the experimental design performing ANOVA for particle size 
focusing on the D50 value and the model was found significant (p < 0.05, 
Fig.3.10). 
 
                         
Figure 3.10 Actual vs predicted plot for the D50 particle size of the nanoparticle 
agglomerates of ibuprofen.  
 
Leucine to drug ratio and the type of stabiliser were identified as formulation 
variables with the most significant effects on the D50 (Table 3.5). Their 
“negative” effect is interpreted as size reduction that is desirable for 
pulmonary drug delivery. It is likely that increased leucine to drug ratio 
formed a surface coating around the particles which prevented the particles 
from melting and sintering, as observed for the process yield. Moreover, a 
significant interaction was identified between leucine to drug ratio and the 
type of stabiliser with a positive t-ratio, despite the fact that the factors had 
individually negative effects on the D50 (Table 3.5).  
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Table 3.5 Sorted parameter estimates of the effects and two-way interactions on the 
D50 particle size of nanoparticle agglomerates of ibuprofen. 
Term t-ratio prob > |t| 
Leucine to drug ratio (0,0.5) -6.47 0.0013 * 
Type of stabiliser [HPMC]* Leucine to drug ratio 5.55 0.0026 * 
Type of stabiliser [HPMC] -5.25 0.0033 * 
Mannitol to drug ratio * Leucine to drug ratio 2.39 0.0620 
Type of stabiliser [HPMC] * Mannitol to drug ratio  1.75 0.1400 
Mannitol to drug ratio (0,1) -1.64 0.1627 
 
 
This means that the interaction between HPMC and leucine to drug ratio is 
synergistic rather than additive. Use of the non-melting HPMC as a 
nanosuspension stabiliser and the addition of a high leucine to drug ratio 
leads to further particle size reduction than the individual factors alone. 
 
As shown in the response surface plot, spray drying of ibuprofen 
nanosuspensions stabilised with HPMC and containing a high leucine to drug 
ratio was able to produce nanoparticle agglomerates with particle size 
around 2-3 μm that is suitable for pulmonary drug delivery (Fig. 3.11a). On 
the other hand, spray drying of ibuprofen nanosuspensions stabilised with 
TPGS produced larger particles while addition of both high leucine and 
mannitol to drug ratios is required in order to produce particles smaller than 
4 μm (Fig. 3.11b). This indicates that the selection of stabiliser is vital not 
only for the step of nanosuspension production but it may also influence the 
downstream process of spray drying by affecting the properties of the 
nanoparticle agglomerates produced. 
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Figure 3.11 Response surface plots showing the influence of the independent 
formulation variables mannitol to drug ratio and leucine to drug ratio on the quality 
attribute D50 particle size of nanoparticle agglomerates of ibuprofen. The stabiliser is 
(a) HPMC and (b) TPGS. 
(a) Stabiliser: HPMC 
(b) Stabiliser: TPGS 
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3.4.4.2. Redispersibility  
 
Redispersibility is an important quality attribute of nanoparticle agglomerates 
as it is a prerequisite for the reformation of nanoparticles upon rehydration 
and potential enhancement of therapeutic efficacy. Particularly, for 
nanoparticles of low melting point drugs such as ibuprofen, thermal stresses 
during spray drying may lead to phase and composition changes of 
formulations causing irreversible aggregation and loss of the advantages of 
nanoformulations (Chaubal and Popescu, 2008). An RDI% value close to 
100% means that the nanoparticle agglomerates reformed nanoparticles 
with z-average size close to the z-average size of the nanosuspensions prior 
to the solidification step.  For the experimental conditions applied the 
redispersibility index (RDI%) ranged from 148% to 938% (Table 3.3). The 
results were analysed in the experimental design performing ANOVA for 
particle size focusing on the RDI% value and the model was found significant 
(p < 0.05, Fig.3.12). 
 
 
Figure 3.12 Actual vs predicted redispersibility index (RDI%) of the nanoparticle 
agglomerates of ibuprofen.  
 
 
The mannitol to drug ratio was identified as the only significant factor 
affecting redispersibility (p value < 0.05, Table 3.6) with higher mannitol to 
drug ratio leading to RDI% values closer to 100%. The role of mannitol can 
be explained by the formation of a continuous matrix around the 
nanocrystals during the spray-drying step preventing their irreversible 
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aggregation. Upon rehydration, mannitol as a hydrophilic excipient dissolves 
and the nanocrystals are reconstituted. Zuo et al. (2015) reported similar 
results highlighting that a high mannitol to drug ratio is important for the 
redispersibility of nanoparticle agglomerates of fenofibrate.  
 
Table 3.6 Sorted parameter estimates of effects and two-way interactions on the 
redispersibility index (RDI%) of the nanoparticle agglomerates of ibuprofen. 
Term t-ratio prob > |t| 
Mannitol to drug ratio (0,1) -6.46 0.0013 * 
Type of stabiliser [HPMC] 2.16 0.0830 * 
Leucine to drug ratio (0,0.5) -1.24 0.2708 * 
Mannitol to drug ratio * Leucine to drug ratio 0.89 0.4129 
Type of stabiliser [HPMC] * Mannitol to drug ratio  -0.19 0.8561 
Type of stabiliser [HPMC] * Leucine to drug ratio -0.04 0.9699 
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Figure 3.13 Response surface plots showing the influence of the independent 
formulation variables mannitol to drug ratio and leucine to drug ratio on 
redispersibility index of the nanoparticle agglomerates of ibuprofen. The stabiliser is 
(a) HPMC and (b) TPGS.  
(a) Stabiliser: HPMC 
(b) Stabiliser: TPGS 
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As shown in the response surface plot (Fig. 3.13), nanoparticle agglomerates 
of ibuprofen with enhanced redispersibility (RDI% value closer to 100%) are 
obtained only when high mannitol to drug ratios are present in the 
formulations prior to the spray-drying step. 
 
3.4.4.3. Drug loading  
 
The results of assayed ibuprofen content in the nanoparticle agglomerates 
are given in Table 3.7. Spray drying of nanosuspensions without matrix 
formers appeared to have lower drug loading than the nominal. This may be 
attributed to the melting of TPGS or ibuprofen during spray drying that led to 
drug loss due to deposition on the walls of the drying chamber and cyclone. 
For the spray-dried nanosuspensions containing mannitol and/or L-leucine 
the assayed ibuprofen content is close to the nominal content indicating that 
the addition of these excipients prevented ibuprofen loss or powder 
segregation during the production process.  
 
Table 3.7 Nominal content and assayed ibuprofen content (% w/w) of nanoparticle 
agglomerates together with calculated drug loading efficiency (%) (mean ± SD, 
n=3).  
Pattern Content (% w/w) 
Drug Loading 
Efficiency (%) 
 
Nominal Assayed 
IBU 
 
 IBU STAB MAN LEU  
100 54.05 5.41 27.03 13.51 50.8 ± 1.3 94.0 ± 2.4 
200 54.05 5.41 27.03 13.51 51.8 ± 1.7 95.9 ± 3.2 
1++ 38.46 3.85 38.46 19.23 36.7 ± 0.2 95.4 ± 0.5  
100 54.05 5.41 27.03 13.51 49.2 ± 1.3 91.0 ± 2.6 
2+− 47.6 4.76 47.6 - 44.4 ± 0.8 93.2 ± 1.7 
1−+ 62.5 6.25 - 31.25 59.4 ± 1.2 95.0 ± 1.8 
2−− 91 9 - - 77.4 ± 1.4 85.1 ± 1.6 
2−+ 62.5 6.25 - 31.25 58.3 ± 1.1 93.3 ± 2.1 
1+− 47.6 4.76 47.6 - 42.1 ± 2.1 88.5 ± 3.6 
2++ 38.46 3.85 38.46 19.23 35.4 ± 0.7 92.0 ± 1.9 
200 54.05 5.41 27.03 13.51 50.4 ± 2.1 93.2 ± 3.5 
1−− 91 9 - - 80.3 ± 1.9  88.2 ± 2.6 
Statistically significant differences (p < 0.05) between the drug loading efficiency (%) of the 
nanoparticle agglomerates of ibuprofen include 2-- and 100, 2-- and 200, 2-- and 1++, 2-- and 
2+-, 2-- and 1-+, 2-- and 2-+, 2-- and 200, 200 and 1+-, 200 and 1-- and 1++ and 1--. 
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3.4.4.4. Solid state characterisation 
 
The XRPD patterns of the starting materials are shown in Fig. 3.14. Raw 
ibuprofen exhibited sharp peaks in the range of 2theta: 15-25 o that are 
characteristic of the drug.  The peaks are in agreement with detailed studies 
on the ibuprofen peak assignment and location, which already are already 
reported in the literature (Kayrak et al., 2003, Plakkot et al., 2011). Mannitol 
starting material exhibited characteristic peaks of the β- form  (2 theta: 
10.6o, 14.7o, 16.9o, 21.2o, 23.9o, 29.5o) (Hulse et al., 2009) while the 
diffractogram of L-leucine indicated a highly crystalline structure (2 theta:6o, 
12o, 24o, 31o, 37o) (Raula et al., 2007).  
 
 
Figure 3.14 XRPD patterns of starting materials. 
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The diffractograms of all runs prepared according to the DoE are shown in 
Fig.3.15. The diffractograms of patterns 1-- and 2-- (without matrix formers) 
showed peaks at similar 2 theta positions to those of the raw ibuprofen. For 
the nanoparticle agglomerates of ibuprofen containing matrix formers the 
diffractograms were a summation of the patterns of their components. No 
new peaks or halo could be detected in the XRPD patterns indicating the 
absence of generation of amorphous content during the process. 
 
Figure 3.15 XRPD diffractograms of nanoparticle agglomerates of ibuprofen included 
in the full factorial design 
 
The DSC was used to assess the thermal behaviour of the starting materials 
and nanoparticle agglomerates of ibuprofen (Fig. 3.16). The DSC 
thermogram of ibuprofen showed an endothermic peak at 76 oC 
corresponding to the melting of the drug. The nanoparticle agglomerates of 
ibuprofen without mannitol and leucine exhibited the same endothermic peak 
shifted to slightly lower temperature (Fig. 3.16a) while those containing 
mannitol exhibited thermal behaviour depending on the stabiliser.  
 
More specifically, the nanoparticle agglomerates of ibuprofen containing 
mannitol and stabilised with TPGS exhibited two endothermic peaks 
(patterns 2++, 2+-, Fig.3.16b) as expected: the melting peak at around 70 o 
C, which relates to the melting of the drug and a sharp endothermic peak at 
168 o C, which relates to the melting of mannitol (Pearlitol 160C). For the 
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nanoparticle agglomerates of ibuprofen containing mannitol and stabilised 
with HPMC, apart from the melting of ibuprofen, an endothermic peak at 150 
oC was followed by an exothermic event and then an endothermic melting at 
168 oC (patterns 1++, 1+-, Fig. 3.16b).  Mannitol exists in three 
polymorphic forms; alpha (α), beta (β) and delta (δ) (Walter-Levi, 1968). 
Differing findings have been reported regarding the stability of D-mannitol 
polymorphs. According to Kim et al. (1998) both α and β forms are 
considered stable, while in a later study by Willart et al. (2007) it was found 
that form β is the most stable polymorph, δ is the least stable and form α 
exhibits an intermediate stability between the two. The thermal events 
observed in the DSC of patterns 1++ and 1+- could be attributed to the 
formation of the metastable δ-form of mannitol (mp: 150-158 oC) that is 
followed by crystallisation to the α- or/and β-form and the melting of the 
respective crystal form (Burger et al., 2000). Both α- and δ-form of mannitol 
were found to be chemically and physically stable for at least 5 years when 
stored at 25 oC and 43% relative humidity (Burger et al., 2000). Recently, 
co-spray drying of an aqueous solution of mannitol with PVP in a ratio 4:1 
was reported to produce the δ-form of mannitol (Vanhoorne et al., 2016). At 
this point, it should be noted that the presence of the δ-form of mannitol 
could not be observed by XRPD but this may be explained by the small 
difference between the characteristic peaks of the β-form (10.6 o) and δ-
form (9.6 o), while a method such as Raman spectroscopy may be more 
suitable to analyse the polymorphic mannitol composition.  
 
Based on various studies, L-leucine sublimes and then to decomposes. The 
temperatures reported for the sublimation of L-leucine vary from 145 oC to 
295 oC while decomposition occurs at around 300 oC (Lähde et al., 2009; Li 
et al., 2006). However, as ibuprofen decomposes at temperatures higher 
than 200 oC, a heating range from 30 oC to 200 oC was selected so as to 
carry out the DSC of the nanoparticle agglomerates in order to avoid 
decomposition of samples in the DSC cells. Thus, the thermal behaviour of L-
leucine was left out of the scope of our study.  
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Figure 3.16 DSC thermograms of ibuprofen and mannitol starting materials and 
nanoparticle agglomerates included in the full factorial design. 
 
Overall, the XRPD and DSC data suggest that the engineered nanoparticle 
agglomerates retain their crystallinity during wet bead milling followed by 
spray drying. The preservation of the crystalline state is advantageous, 
ensuring the long-term physical stability of the formulations during storage. 
 
3.4.4.5. In-vitro dissolution tests 
 
Dissolution studies of ibuprofen and nanoparticle agglomerates were 
performed in deionised water as it was found to be discriminatory as a 
dissolution media compared to phosphate buffer (pH: 7.2). This may be 
explained by the lower saturation solubility of ibuprofen in water (318.98 μg 
mL-1) compared to phosphate buffer pH:7.2 (1234.09 μg mL-1) (Attari et al., 
2015). The dissolution profiles of the nanoparticle agglomerates prepared 
according to the matrix of the full factorial design are shown in Fig. 3.17. 
Nanoparticle agglomerates stabilised with either HPMC or TPGS exhibited 
enhanced dissolution profiles compared to ibuprofen. In the case of the raw 
ibuprofen, less than 40% was released in the first 20 min, while the 
nanoparticle agglomerates achieved complete dissolution in less than 5 min. 
The exception to this were the spray-dried nanosuspensions of ibuprofen 
without matrix former (patterns 1-- and 2--) which exhibited a higher 
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dissolution rate compared to ibuprofen but slower than the nanoparticle 
agglomerates containing mannitol and/or leucine. In the case of TPGS, this 
may be associated with the formation of large aggregates with size around 
50 μm and poor redispersibility. Thus, the selection of suitable process and 
formulation parameters is of paramount importance in order to ensure that 
the dissolution benefit of nanoparticles is retained after the spray- drying 
process.  
 
Figure 3.17 Dissolution profiles of ibuprofen starting material and nanoparticle 
agglomerates included in the full factorial design (mean + SD, n=3). 
 
In this study no differences could be observed in the dissolution profiles of 
nanoparticle agglomerates containing different amounts of matrix formers. 
At this point, it should be noted that Yamasaki et al. (2011) using a flow-
through setup found that increasing mannitol amounts enhanced the 
dissolution rate of ciclosporin A nanomatrix powders. Even if a comparison 
between the dissolution profiles of the two drugs is not feasible as they 
possess different physicochemical properties and different dissolution media 
were used, it should be highlighted that the dissolution testing method plays 
a significant role as well. A flow-through cell method was found to be 
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unequivocally the most robust method for nanoparticulate systems when 
compared with paddle, basket and dialysis method (Heng et al., 2008). 
 
3.4.4.6.In-vitro aerosol performance 
 
Fine particle fraction (FPF%) was selected as a quality attribute describing 
the aerodynamic performance of a dry powder for inhalation. The FPF% 
values of the nanoparticle agglomerates produced ranged from 5.84 to 
68.55% (Table 3.3) and the model generated was found to be significant (p 
< 0.05, Fig.3.18).  
 
 
Figure 3.18 Actual vs predicted fine particle fraction (FPF%) of the nanoparticle 
agglomerates of ibuprofen. 
 
Leucine to drug ratio and mannitol to drug ratio were identified as the most 
significant factors on the FPF% (Table 3.8.). The positive effect of leucine 
can be linked with its properties as an aerosolisation enhancer. According to 
Sou et al. (2013), the addition of leucine facilitates the formation of spray-
dried particles. More specifically, addition of leucine (≈10% w/w) was found 
to increase the aerosolisation performance of particles by accumulating on 
their surface resulting in the formation of individual spherical particles. When 
leucine was used in higher amounts (≈20% w/w), it was found to produce 
particles of wrinkled morphology. The corrugated surface of the particles 
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increases their dispersibility from the inhalation device by reducing the 
contact points between particles and cohesiveness of the powdered 
nanoparticle agglomerates.  
 
The positive effect of mannitol to drug ratio may be attributed to the good 
spray-drying properties of mannitol which facilitates the formation of 
spherical particles with narrow and unimodal particle size distribution (Li et 
al., 2014). As illustrated in the response surface plot (Fig. 3.19), both 
leucine and mannitol to drug ratio had a significant effect on the 
aerodynamic performance of the nanoparticle agglomerates resulting in large 
FPF% increase from 10% to 50%. Therefore, combination of high leucine and 
mannitol to drug ratios is required in order to maximise the FPF% of the 
nanoparticle agglomerates of the low melting point and ductile ibuprofen.  
 
Table 3.8 Sorted parameter estimates of effects and two-way interactions on the fine 
particle fraction (FPF%) of the nanoparticle agglomerates of ibuprofen. 
Term t-ratio prob > |t| 
Leucine to drug ratio (0,0.5) 4.93 0.0044* 
Mannitol to drug ratio (0,1) 3.01 0.0298 * 
Type of stabiliser [HPMC] * Mannitol to drug ratio (0,1) 2.50 0.0543  
Type of stabiliser [HPMC] 1.06 0.3366 
Mannitol to drug ratio * Leucine to drug ratio 0.90 0.4071 
Type of stabiliser [HPMC] * Leucine to drug ratio -0.46 0.6649 
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Figure 3.19 Response surface plots showing the influence of the independent 
formulation variables mannitol to drug ratio and leucine to drug ratio on the quality 
attribute fine particle fraction (FPF%) of the nanoparticle agglomerates of ibuprofen. 
The stabiliser is (a) HPMC and (b) TPGS.  
(b) Stabiliser: TPGS 
(a) Stabiliser: HPMC 
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3.5. Conclusions 
 
Based on the aforementioned results presented in this chapter, it can be 
concluded that:  
1. Nanosuspensions of the poorly water-soluble, low melting point 
and ductile drug ibuprofen stabilised with HPMC and TPGS were 
successfully produced and were further spray dried with or 
without the addition of matrix formers (mannitol and/or L-
leucine) employing a full factorial design.  
2. Design of experiments is a useful approach in order to gain 
insight and understanding on the formation of inhalable 
nanoparticle agglomerates using wet milling followed by spray 
drying.  
3. Leucine to drug ratio, mannitol to drug ratio and the type of 
stabiliser were found to be significant (p < 0.05) factors affecting 
the yield of the particles obtained by combining wet milling and 
spray drying. The particle size response was mainly dependent on 
the leucine to drug ratio and the type of stabiliser (p < 0.05). 
Mannitol to drug ratio was found as the only critical parameter 
affecting redispersibility of nanoparticle agglomerates (p < 0.05) 
and both leucine to drug ratio and mannitol to drug ratio were 
found as significant factors affecting FPF% (p < 0.05).  
4. The nanoparticle agglomerates were found to be crystalline and 
exhibit enhanced dissolution compared to the ibuprofen starting 
material.  
5. High leucine and mannitol to drug ratio should be incorporated in 
ibuprofen nanosuspensions prior to spray drying in order to 
increase the yield of the process and produce nanoparticle 
agglomerates with enhanced redispersibility and aerosolisation 
efficiency.  
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4. MICROCOMPOSITE PARTICLES OF THEOPHYLLINE 
 
4.1. INTRODUCTION 
 
As described in the previous chapters, preparation of nanosuspensions by a 
wet size reduction technique (e.g. wet milling, high pressure 
homogenisation, antisolvent precipitation) followed by solidification, using 
spray drying, has been suggested as a preparation platform for inhalable 
micrometer-sized composites of nanocrystals with enhanced dissolution and 
aerosolisation efficiency (Bosch et al., 1999; Pilcer et al., 2009; Yamasaki et 
al., 2011). 
 
The majority of such reported applications  (nano-in-micro particle 
engineering approach) has focused on poorly water-soluble drugs and thus 
the size reduction step can take place in aqueous media where the drug is 
dispersed but not dissolved (Duret et al., 2012; Pomázi et al., 2013). 
However, some drugs used for the treatment of respiratory diseases are 
moderately or very water-soluble, such as salbutamol sulfate (albuterol 
sulfate) and terbutaline sulfate, or are prone to hydrate formation, e.g. 
nedocromil sodium. Therefore, water cannot be used as the wet milling 
medium, in the preparation of nanosuspensions for such drugs nor as the 
solvent during the spray-drying step as for poorly water-soluble drugs. 
Instead, an appropriate organic solvent has to be selected, in which the drug 
exhibits a solubility lower than 10 mg mL-1 and ideally lower than 5 mg mL-1 
(Hong and Oort, 2011), to eliminate the possibility of crystallinity changes  
(e.g. amorphisation) during milling and spray drying. 
 
Theophylline has been chosen as the model compound in this study as it has 
a long history of use within respiratory medicine, and its solid-state 
properties have been extensively investigated. More specifically, anhydrous 
theophylline is a challenging molecule with respect to wet milling and spray 
drying due to the following physicochemical properties:  
(i) It is moderately water-soluble (7.36 mg mL-1, at 25 oC, 
Yalkowsky et al., 2010). 
(ii) Its needle-like crystal morphology can affect its 
fracture/breakage behaviour, as reported for other organic 
crystalline materials (Ho et al., 2012).  
(iii) It is prone to process-induced solid-state transformations as it 
exists in four polymorphic forms (forms I-IV) along with a 
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monohydrate form (Fucke et al., 2012). Form II is the stable 
polymorph at room temperature while the monohydrate is the 
stable form in water and at high relative humidity 
environment.  
Theophylline is a widely available and inexpensive methylxanthine that has 
been used in the treatment of airways diseases such as asthma and COPD 
for more than 90 years (Barnes, 2013).  
 
The use of theophylline has been limited by its narrow therapeutic index (TI) 
and the marked inter-subject variability of its clearance. A therapeutic 
plasma concentration of 10 - 20 mg L-1 is required for theophylline to achieve 
bronchodilation comparable with β2-agonists, while side effects (e.g. nausea, 
vomiting, heartburn, diarrhea) become an issue at concentrations above 20 
mg L-1 (Barnes, 2013). Due to its narrow TI, it is administered as oral 
sustained-release (SR) preparations.  
 
There is increasing evidence that theophylline at low doses (plasma 
concentrations < 7 mg L-1) exhibits immunomodulatory properties in the 
pathophysiology of both asthma and COPD (Barnes, 2013). Moreover, it has 
been reported that theophylline has the potential to enhance the anti-
inflammatory effect of corticosteroids and to reverse steroid resistance that 
is common in COPD patients (Hirano et al., 2006; Tilley, 2011). These 
observations may lead to the reevaluation of this old drug in the future, once 
clinical trials of low-dose theophylline therapy are completed (Barnes, 2008; 
2003).  
 
Theophylline applied intratracheally as a dry powder formulation to the 
airways of anaesthetised guinea pigs exhibited smooth muscle relaxant and 
anti-inflammatory properties at very low doses that would be predicted to 
have no systemic toxicity (Raeburn and Woodman, 1994). Thus, developing 
inhalable formulations for theophylline may offer advantages over oral 
administration for the treatment of inflammation in asthma and COPD, 
enhancing the local efficacy of the drug while minimising systemic side 
effects (Raeburn and Woodman, 1994; Zhu et al., 2015a).  
 
There are few published studies on engineering inhalable theophylline 
particles. A low-dose pMDI formulation of theophylline (Zhu et al., 2015a) 
and formulations for DPIs (polymeric composite particles, microspheres, co-
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crystals and nanosized rods agglomerates) have been  produced and 
characterised (Alhalaweh et al., 2013; Kadota et al., 2015; Momeni and 
Mohammadi, 2009; Salem et al., 2011; Zhang et al., 2009; Zhu et al., 
2015b). Blends of theophylline microparticles (63-90 μm) with inhalable 
budesonide and terbutaline particles (< 5 μm) were proposed as a 
formulation approach for concurrent oral and pulmonary drug delivery with 
theophylline acting as a carrier (Salama et al., 2014).  
 
The aim of this chapter is to produce inhalable dry powder formulations of 
theophylline, by coupling wet bead milling in an organic solvent with spray 
drying of the milled suspension. The effect of mannitol addition during the 
wet milling of theophylline on the micromeritic, solid state and aerosol 
performance of the produced spray-dried particles will be investigated. The 
experimental data of this study are complemented with a computational 
study of the interaction between theophylline and mannitol (i.e. crystal 
morphology modelling and lattice matching calculations) in order to elucidate 
the role of mannitol as a co-milling agent.  
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4.2. MATERIALS  
 
Theophylline (THEO), 3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione (LKT 
Laboratories, USA), was used as the drug under investigation. D-mannitol 
(MAN, Pearlitol 160C®, Roquette Freres, France) was used as co-milling agent 
and matrix former of the microcomposites (Fig. 4.1 and Table 4.1). 
Isopropanol (IPA, Thermo Scientific, UK) was used as the milling medium for 
the preparation of suspensions. Methanol and water both from Fisher 
Scientific UK, and trifluoroacetic acid (TFA, Sigma-Aldrich Co., USA) were 
used for the HPLC analysis. All the solvents used were of analytical grade. 
 
Figure 4.1 Chemical structures of theophylline and D-mannitol. 
 
 
 
Table 4.1 Physicochemical properties of theophylline and mannitol. 
Compound 
Molecular weight 
(g mol-1) 
Melting point 
(oC) 
Solubility (mg mL-1) at 25 oC 
   water isopropanol 
Theophylline 180.16 271-274 7.36a 2.45b 
0.01c Mannitol 182.17 166-168 Soluble
c 
a Yalkowsky et al., 2010; b Krasnov, 2011; c Rowe et al., 2012 
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4.3. METHODS 
 
4.3.1. Preparation of suspensions 
Suspensions were prepared by wet bead milling using a laboratory planetary 
mill (Pulverisette 5, Fritsch Co., Germany). 1.0 g of solids (THEO and MAN) 
and 10 g of milling beads (0.5 mm diameter aluminum borosilicate glass 
grinding beads, Gerhardt Ltd, UK) were weighed into a glass vial of 14 mL 
capacity and suspended in 10 mL IPA, as the dispersing medium. The total 
concentration of solids (THEO and MAN) in suspension was kept constant 
(10% w/v) and different THEO to MAN mass ratios (i.e. 25:75, 50:50 and 
75:25) were employed (Table 4.2). The vials were placed into a stainless 
steel milling pot with a maximum loading capacity of 8 pots. Rotation speed 
(300 rpm) and milling duration (6 cycles of altered bowl rotation direction) 
were selected based on preliminary experiments. Each milling cycle 
comprised 60 min rotation followed by a 20 min pause to cool down the 
milling vessels and to prevent overheating of the instrument’s rotors. The 
suspensions were left to cool to room temperature and collected by 
withdrawal with a pipette to separate from the milling beads.  
 
4.3.2. Preparation of spray-dried microcomposite particles  
The suspensions were diluted 1 in 2 with IPA, before spray drying, to obtain 
suspensions with an overall solid concentration 5% w/v in IPA. Spray drying 
was performed with a Gea Niro Spray Dryer SD MicroTM (Gea Process 
Engineering, Denmark, Fig.4.2) operated with nitrogen as the drying gas. An 
inlet temperature of 80 ± 3 oC was selected, and the atomiser gas flow and 
chamber inlet flow were set at 2.5 and 25 kg h-1, respectively. The nozzle 
pressure was set at 1.5 bar and the bag filter pressure at 2.1 bar. The outlet 
temperature control was set at 20%, resulting in an outlet temperature of 60 
± 5 oC.  
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Figure 4.2 Gea Niro Spray Dryer SD MicroTM. Adapted from Gea Process Engineering, 
2013 
 
4.3.3. Characterisation of spray-dried microcomposite particles 
In this chapter, no further characterisation of the produced suspensions was 
carried out due to limitations of the available instrumentation. Regarding 
transmission electron microscopy (TEM), negative staining protocols treat 
the sample with aqueous solution of 1% uranyl acetate. This sample pre-
treatment leads to dissolution of the theophylline and mannitol fine crystals.  
The spray-dried powders were characterised for: particle surface morphology 
and shape by scanning electron microscopy (SEM) and image analysis of the 
SEM images; particle size distribution (PSD) by laser diffractometry; specific 
surface area by the Brunauer-Emmett-Teller (BET) method; solid state by X-
ray powder diffraction (XRPD), Fourier transform infrared spectroscopy (FT-
IR) and differential scanning calorimetry (DSC); drug loading by HPLC 
analysis of theophylline content and in-vitro aerosol performance using the 
next generation impactor (NGI). 
The SEM, laser diffraction, XRPD and DSC methods applied have been 
described in previous chapters (sections 2.3.5.1-2.3.5.4).  
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4.3.3.1. Image Analysis 
 
SEM images were processed with the open source image processing software 
FIJI/Image J (Schindelin et al., 2012) to determine the number-based aspect 
ratio of the particles. The major and minor axis (i.e. primary and secondary 
axis of the best fitting ellipse) of a minimum of 100 particles was measured 
for each spray-dried powder and for the starting materials, and the aspect 
ratio was calculated as the ratio of the minor to the major axis. 
4.3.3.2. Specific surface area and porosity 
 
The specific surface area was measured using the nitrogen adsorption 
Brunauer-Emmett-Teller (BET) method with a Quantachrome Nova 4200e 
multi-station gas sorption surface area analyser (Quantachrome Ltd, UK) 
Approximately 0.1 g of each powder was placed in each sample cell, and the 
outgassing process was conducted at 105 oC over 2 h. The total pore volume 
and the average pore radius were calculated following the t-plot method 
which was introduced by de Boer et al. (1966) and compares comparing the 
isotherm of a microporous material with a standard Type II isotherm. Each 
formulation was tested in triplicate (n=3).  
4.3.3.3. Fourier transform infrared spectroscopy (FT-IR)  
 
Spectra of the starting materials, their physical mixtures and the 
microcomposites were recorded using a Spectrum100 FT-IR spectrometer 
(PerkinElmer, Ιnc., USA) equipped with the attenuated total reflection 
sampling accessory. Samples were scanned at room temperature, at the 
transmission mode, over a wavenumber range of 4000-650 cm-1, 16 
accumulations and 1 cm-1 resolution. Before each measurement, a 
background spectrum of air was acquired under the same instrumental 
conditions. The acquired spectra were processed using the PerkinElmer 
Spectrum Express software.  
4.3.3.4. Drug loading 
 
5 mg of each spray-dried formulation were dissolved in 25 mL water and 
theophylline concentration determined using an HPLC system (Agilent 1100 
Series, Agilent Technologies, Germany) following the method described by 
Alhalaweh et al. (2013). More specifically, the stationary phase was a Luna® 
(150 x 4.60 mm, 5 micron) column (Phenomenex Co., California, USA) kept 
at 40 o C. The mobile phase was composed of aqueous trifluoroacetic acid 
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solution (0.1% v/v) and methanol at 75/25 volumetric ratio. The mobile 
phase flow rate was 1 mL min-1, the injection volume was 10 μL and the 
detection wavelength 273 nm. The retention time for theophylline was 4.8 
min. The correlation coefficient of the calibration curve was R2: 0.9997 for a 
concentration range of 5-400 μg mL-1, indicating acceptable linearity. Each 
formulation was tested in triplicate (n=3).  
 
4.3.3.5. In-vitro aerosol performance  
 
Deposition profiles were determined with Ph. Eur. Apparatus E (Next 
Generation Impactor, NGI, Copley Instruments Ltd, UK) fitted with a 
stainless steel 90O induction port (IP) and a pre-separator (PS) operated as 
specified in European Pharmacopoeia (Ph. Eur. 8th edition, monograph 
2.9.18) and connected to a high-capacity vacuum pump (Model HCP5, 
Copley Instruments Ltd, UK). Prior to use, the impaction cups in each of the 
seven stages were coated with 1% w/v silicone oil solution in hexane, and 
allowed to dry for 1 h, in order to minimise ‘particle bounce’ and entrainment 
of particles between the stages. The final stage of the impactor, known as 
micro-orifice collector (MOC), was fitted with a fiberglass filter (nylon 0.45 
μm, Millipore, UK). The flow rate was measured using a flow meter (Flow 
Meter Model DFM 2000, Copley Instruments Ltd, UK) prior to each run, to 
ensure that a flow of 60 L min-1 was achieved. Gelatin capsules (size 3) were 
filled with accurately weighed amounts of product corresponding to about 10 
mg of THEO. Following filling, capsules were stored in a desiccator over silica 
gel for 24 h prior to performing the deposition study. Storage for 24h 
allowed relaxation of any electrical charge without influencing the brittleness 
of the capsules as their water content in preliminary studies was found to 
comply with the normal moisture specification limits (13-16% for gelatin). 
The inhaler device (Cyclohaler®) was connected to the impactor via an 
airtight rubber mouthpiece adaptor and tested at 60 L min-1 for an actuation 
time of 4 s. The capsules were discharged into the NGI, and after dispersion 
the powder deposited on the capsules, mouthpiece, inhaler and each NGI 
component was collected by exhaustively washing with water (HPLC grade), 
transferred into volumetric flasks and assayed. The HPLC conditions for the 
assay were the same to those for drug content determination (section 
4.3.3.4). To characterise the aerosol performance the following parameters 
were determined: the emitted fraction (EF %) was calculated as the ratio of 
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the drug mass depositing in the mouthpiece, induction port, pre-separator, 
and impactor stages (1 to MOC) to the cumulative mass of drug collected 
following actuation (total drug deposited in the capsule, inhaler, mouthpiece, 
throat, pre-separator and stages). The fine particle fraction (FPF %) of each 
dose was the ratio of the drug mass depositing on stages 2 to MOC over the 
recovered dose. The fine particle dose (FPD) was calculated as the ratio of 
mass deposited on stage 2 to MOC, to the number of doses (n=3). Stage 2 
had a cut-off diameter of 4.46 μm. The mass median aerodynamic diameter 
(MMAD) defined as the median particle diameter of the formulation deposited 
within the NGI, and the geometric standard deviation (GSD) determined as 
the square root of the ratio of the particle size at 84.13th percentile to that of 
15.87th percentile. Both MMAD and GSD were determined from the linear 
region in the plot of the cumulative mass distribution versus the logarithm of 
aerodynamic diameters. Each formulation was tested in triplicate (n=3).  
4.3.4. Statistical data analysis 
An analysis of variance (one-way ANOVA) with Tukey’s multiple comparison 
test was carried out to evaluate differences between the mean values using 
Prism 6 (GraphPad Software, Inc., USA). Probability values less than 0.05 
were considered as indicative of statistically significant differences. 
 
4.3.5. Computational study of the interaction between the crystals of 
theophylline and mannitol  
In order to gain insight into the intermolecular interactions that influence the 
mechanical properties of theophylline and mannitol, the energetic and 
structural aspects of their crystals were investigated following a combination 
of approaches, namely: crystal morphology modelling, semi-classical density 
sums (SCDS-Pixel) and lattice matching calculations. Crystal structure 
coordinates for theophylline form II (CSD-REFCODE BAPLOT01, Ebisuzaki et 
al., 1997) and D-mannitol form β (CSD-REFCODE DMANTL07, Kaminsky and 
Glazer, 1997) were taken from the Cambridge Structural Database (Allen, 
2002).  
 
4.3.5.1. Crystal morphology modeling 
 
The minimisation of the energy of the crystal lattice was performed using the 
General Utility Lattice Program (GULP v.4.3) (Gale and Rohl, 2003). The 
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Dreiding 2.21 force field parameters (Mayo et al., 1990) were used in 
combination with high-quality electrostatic potential-derived atomic point 
charges calculated at the 6-31G**/MP2 level of theory. For the 
determination of the atomic charges the Firefly quantum chemistry package 
was used (A. Granovsky, 
http://classic.chem.msu.su/gran/gamess/index.html), which is partially 
based on the GAMESS (US) source code (Schmidt et al., 1993). Crystal 
morphologies based on Bravais-Friedel-Donnay-Harker (BFDH) theory (which 
assumes that the slowest growing faces are those with the greatest 
interplanar spacing, dhkl) were constructed in order to identify faces more 
likely to occur in the crystal. For the morphology calculations the GDIS 
program was utilized, serving as a graphical front end to the GULP software 
program (Fleming and Rohl, 2005). 
 
4.3.5.2. Semi-classical density sums (SCDS-Pixel) calculations 
 
 The crystal structures were analysed using the PIXEL approach developed 
by Gavezzotti (Gavezzotti, 2005). This method provides quantitative 
determination of crystal lattice energies and pairwise intermolecular 
interactions, with a breakdown of these energies into coulombic, polarisation, 
dispersion and repulsion terms. For the derivation of PIXEL energies, the 
electron density of theophylline and mannitol were calculated at the 6-
31G**/MP2 level of theory using the Firefly quantum chemistry package. 
Finally, energy vector diagrams were constructed according to Shishkin et al. 
(2012) using the processPIXEL package and the results were visualised using 
the Mercury software program (Bond, 2014; Macrae et al., 2008; Shishkin et 
al., 2012). 
 
4.3.5.3. Computational lattice matching calculations 
 
Possible interactions between crystal faces of theophylline and mannitol were 
probed applying a computational lattice matching approach, using the 
Geometric Real-space Analysis of Crystal Epitaxy (GRACE) software (Mitchell 
et al., 2011). Cut-off distances of dc = 0.5 Å and d0 = 0.3 Å were selected. 
The value of θ was varied in the range of −90° to 90° with increments of 
0.5°, and a search area of 400 × 400 Å and a range of overlayer hkl planes 
from −3 ≤ h, k, l ≤ +3 were employed. The epitaxy score, E, was calculated 
using the Gaussian function. The chemical complementarity at the 
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geometrically matching crystal faces was evaluated by visual inspection of 
the crystal structures using the Mercury software program (Macrae et al., 
2008). 
 
 
4.4. RESULTS AND DISCUSSION 
 
4.4.1. Preparation of microcomposite particles 
Isopropanol (IPA) was selected as the wet milling medium based on 
preliminary solubility measurements. The lower solubility of anhydrous 
theophylline in IPA (2.81 ± 0.18 mg mL-1, at 25 oC for 24h) compared to its 
aqueous solubility (7.36 mg mL-1, at 25 oC, Yalkowsky and He, 2003) 
ensured the formation of nanocrystals that will be suspended in the liquid 
medium. Also, it may limit the risk of solution-mediated phase 
transformation that can give rise to increased amounts of amorphous form. 
Moreover, anhydrous theophylline is transformed to monohydrate when 
processed in water, while such hydration transition is not expected to occur 
in IPA. 
Wet bead milling of anhydrous theophylline, in IPA, did not result in the 
production of nanosized particles, even after 6 h milling. By contrast, wet 
milling of mannitol in IPA resulted in submicron-sized particles. The minor 
axis and major axis of the primary mannitol nanocrystals based on image 
analysis of SEM images were 405.44 ± 58.72 nm and 724.24 ± 113.46 nm, 
respectively. Therefore, use of isopropanol as the wet milling medium and 
mannitol as co-milling agent were selected.  
The use of mannitol (MAN) as a co-grinding agent, enhancing the size 
reduction of drug particles and even leading to an increase in their 
bioavailability, has been reported previously (Kubo et al., 1996; Takahata et 
al., 1992). However, in these earlier studies dry grinding techniques were 
used and the authors mainly focused on bioavailability studies in animals 
rather than on the mechanism underlying size reduction of drug particles in 
the presence of mannitol.  
Mannitol is a commonly used matrix former during the solidification of 
aqueous nanosuspensions, for both oral and pulmonary drug delivery. It is 
usually incorporated prior to spray drying due to its high aqueous solubility, 
and forms a continuous matrix around the drug nanocrystals enhancing their 
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redispresibility on rehydration (Chaubal and Popescu, 2008; Yue et al., 
2013). It should be noted that in this study mannitol is not dissolved prior to 
spray drying but rather is added before the wet milling of anhydrous 
theophylline, i.e. both substances are in suspended form due to their 
marginal solubility in IPA. The total concentration of solids (THEO and MAN) 
in suspension was kept constant (5% w/v) and different THEO to MAN mass 
ratios (i.e. 25:75, 50:50 and 75:25) were employed (Table 4.2) in order to 
elucidate the potential effect on the particle size reduction of theophylline, 
and also on the micromeritic, solid state and aerosolisation properties of the 
microcomposite particles produced.  
Table 4.2 Nominal composition and assayed theophylline content (% w/w) of 
microcomposite particles together with the calculated drug loading efficiency (%) 
(mean ± SD, n=3). 
Formulation 
Content (% w/w) 
Drug loading 
efficiency (%) 
Nominal  Assayed  
THEO Mannitol  THEO  
SD susp. THEO 100 -  n/a n/a 
SD susp. THEO:MAN 75:25 75 25  76.2 ± 0.1 101.6 ± 0.1 
SD susp. THEO:MAN 50:50 50 50  53.3 ± 0.1 106.7 ± 0.1 
SD susp. THEO:MAN 25:75 25 75  28.7 ± 0.2 114.1 ± 1.0 
SD susp. MAN - 100  n/a n/a 
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4.4.2. Characterisation of microcomposite particles 
4.4.2.1. Micromeritic properties  
 
The SEM images of starting materials are presented in Fig. 4.3. Anhydrous 
theophylline (THEO) particles consisted of primary crystallites bound 
together to form needle–shaped particles with a D50 of 124.12 ± 18.33 μm. 
Mannitol particles also exhibited an elongated morphology, with a D50 of 
68.07 ± 1.36 μm (Table 4.3).  
 
Figure 4.3 SEM images of theophylline and mannitol starting materials. 
 
SEM images of the microcomposites produced by wet milling and spray 
drying are shown in Fig. 4.4. Wet milling of theophylline in the absence of 
mannitol followed by spray drying resulted in particles with smaller size 
compared to the raw drug, exhibiting a D50 of 4.64 ± 0.87 μm and an aspect 
ratio of 0.41 ± 0.14, with values closer to 1 indicating a more spherical 
shape (Table 4.3).  
100 µm 100 µm 
THEO Mannitol 
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Figure 4.4 SEM images of microcomposite formulations containing theophylline and 
mannitol wet milled alone and in different mass ratios. 
 
Simultaneous wet milling of theophylline and mannitol in isopropanol 
followed by spray drying resulted in microcomposite particles, which 
consisted of theophylline and mannitol crystals assembled together (Fig. 
4.4). They exhibited D50 values ranging from 3.5 to 2 μm, with size 
decreasing as mannitol content increased, and D90 values less than 10 μm, 
making them potentially suitable for pulmonary drug delivery (Table 4.3). 
SD susp. THEO 
SD susp. THEO:MAN 75:25 SD susp. THEO:MAN 50:50 
SD susp. MAN 
SD susp. THEO:MAN 25:75 
4 µm 4 µm 
4 µm 4 µm 4 µm 
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Table 4.3 Particle size distribution data and aspect ratio values of the starting materials and microcomposite formulations containing different 
theophylline to mannitol ratios (mean ± SD, n=3). 
 
Formulation Size distribution: D10, D50, D90 Image analysis 
 
D10 (μm) D50 (μm) D90 (μm) Aspect ratio 
THEO 29.90 ± 1.76 124.12 ± 18.33 352.27 ± 54.75 0.33 ± 0.18 
Mannitol 
12.23 ± 0.34 68.07 ± 1.36 208.13 ± 3.96 0.58 ± 0.21 
SD susp. THEO 
1.17 ± 0.31 4.64 ± 0.87 13.80 ± 4.60 0.41 ± 0.14 
SD susp. THEO:MAN 75:25 0.97 ± 0.06 3.52 ± 0.68 9.72 ± 2.40 0.55 ± 0.15 
SD susp. THEO:MAN 50:50 0.82 ± 0.05 2.95 ± 0.64 7.91 ± 1.95 0.68 ± 0.19 
SD susp. THEO:MAN 25:75 0.61 ± 0.08 2.18 ± 0.30 5.11 ± 1.22 0.71 ± 0.12 
SD susp. MAN 0.58 ± 0.03 2.86 ± 0.12 6.39 ± 0.50 0.85 ± 0.09 
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Inclusion of increasing amounts of mannitol resulted in production of 
particles with increased sphericity and porosity, demonstrated by aspect 
ratios closer to 1 and higher specific surface area and pore volume values, 
respectively (Table 4.3 and 4.4). Thus, addition of mannitol during wet 
milling in isopropanol facilitated the size reduction of theophylline crystals 
and their assembly in microcomposites by forming porous and spherical 
agglomerates of mannitol nanocrystals in which submicron theophylline 
particles are embedded. 
 
Table 4.4 Specific surface area, total pore volume and average pore radius of the 
starting materials and microcomposite formulations containing different theophylline 
to mannitol ratios (mean, n=3)*. 
 
 
Formulation 
 
 
BET 
Surface area 
(m2 g-1) 
 
Total 
pore volume 
(cc g-1) x103 
 
Average 
pore radius 
(Å) 
THEO 0.80  2.31 24.11 
Mannitol 
0.36  1.26 11.39 
SD susp. THEO 
5.23  8.63 21.82 
SD susp. THEO:MAN 75:25 8.97  14.71 32.79 
SD susp. THEO:MAN 50:50 9.64  20.14 41.77 
SD susp. THEO:MAN 25:75 11.57  25.99 44.93 
SD susp. MAN 19.73  39.13 39.67 
* Relative standard deviation <4% 
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4.4.2.2. Solid state characterisation 
 
The solid state of both theophylline and mannitol in the microcomposite 
formulations may change during either milling or spray drying. This was 
examined as different solid forms exhibit different physicochemical and 
mechanical properties, which may influence processability during product 
manufacturing and may also impact drug stability, solubility, dissolution and 
ultimately therapeutic efficacy (Adeyeye et al., 1995; Raw et al., 2004). 
Mannitol is known to be highly crystalline even during milling and spray 
drying. It exists in three polymorphic forms; alpha (α), beta (β) and delta (δ) 
(Fronczek et al., 2003). The β-form is the stable form of mannitol, however 
both α- and δ-forms were found to be chemically and physically stable for at 
least 5 years when stored at 25 oC and 43% relative humidity (Burger et al., 
2000). Preparation of mannitol particles by different methods (e.g. freeze 
drying, spray drying, jet milling or antisolvent crystallisation) as well as 
process parameters during spray drying (i.e. outlet temperature) have been 
reported to influence the solid form of D-mannitol (Kaialy and Nokhodchi, 
2013; Maas et al., 2011; Tang et al., 2009).  
XRPD is a fast and straightforward method for determining basic information 
regarding the solid state of a powdered material with a limit of crystallinity 
detection in amorphous drug compositions around 5-10% (Stephenson et al., 
2001). According to the XRPD diffractograms of the starting materials (Fig. 
4.5), the diffraction peaks of anhydrous theophylline are characteristic of 
form II (2 theta: 7.2 o, 12.6 o, 14.5 o) while for mannitol they are 
characteristic of the β form (2 theta: 14.7 o, 18.8 o, 23.6 o, 29.5 o). Similar 
results regarding the solid state of Pearlitol 160C®, the commercial type of 
mannitol used in our study, have been reported in other studies (Cares-
Pacheco et al., 2015; Hulse et al., 2009).  
 
The XRPD diffractograms of the spray-dried microcomposites of THEO wet 
milled alone (SD susp. THEO) exhibited the same characteristic peaks as the 
starting material, indicating that both processes (i.e. wet milling coupled with 
spray drying) did not alter the polymorphic form of anhydrous theophylline 
(Fig. 4.5). Similarly, the spray-dried microcomposite of mannitol wet milled 
alone (SD susp. MAN) was in the same form as the raw material (β-form) 
(Fig. 4.5). 
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For the microcomposites containing both THEO and MAN wet milled together 
in different mass ratios, the diffraction patterns shown in Fig. 4.5, were 
essentially summations of the patterns of the starting materials. In all cases, 
reduction in the intensities and broadening of the peaks, compared to the 
patterns of the starting materials, can be attributed to the smaller size of the 
primary crystals in the microcomposite formulations and strain caused by the 
milling process (Hecq et al., 2005).  
 
Figure 4.5 XRPD diffractograms of starting materials and microcomposite 
formulations containing different theophylline to mannitol ratios. 
 
DSC was used to assess the thermal behaviour of the starting materials and 
the microcomposite formulations (Fig. 4.6). The DSC curve of the raw THEO 
showed an endothermic melting peak at 273 oC. The same thermal transition 
was observed for the SD susp. THEO formulation. The DSC of mannitol 
starting material (Pearlitol 160C®) and the SD susp. MAN showed one sharp 
endothermic peak at 167 oC that relates to the melting of mannitol crystals. 
Regarding the DSC curves of the microcomposite particles containing both 
THEO and MAN, instead of the expected two endothermic events 
corresponding to the melting of the two components, a change in the 
thermal behaviour of theophylline was observed in the presence of mannitol. 
More specifically, after the melting of mannitol at around 165 oC, 
theophylline appeared to dissolve completely in the melted mannitol when a 
drug load of up to 50 %w/w was used, and partially at higher drug loads 
leading to the broadening of the melting peak of theophylline and a shift 
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towards lower temperature (around 255 oC) compared to the raw THEO 
material.  
 
Figure 4.6 DSC thermograms of starting materials and microcomposite formulations 
containing different theophylline to mannitol ratios.  
 
As the FT-IR spectra of the physical mixtures and spray-dried suspensions of 
THEO and MAN presented the same bands as the raw materials (Fig. 4.7), it 
can be assumed that the interaction between theophylline and mannitol is 
limited to temperatures above the melting point of mannitol (166 ± 2oC). 
Similar results have been reported for the interaction of mannitol with other 
drugs (e.g. carbamazepine and promethazine hydrochloride) indicating that 
DSC should not be used alone to detect any inherent incompatibility between 
substances, but it should be combined with other non-thermal techniques, 
such as XRPD and FT-IR (Flicker et al., 2011; Joshi et al., 2002; Thumma 
and Repka, 2009). 
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Figure 4.7 FT-IR spectra of starting materials, physical mixture (PM) of theophylline 
and mannitol (mass ratio 50:50) and SD susp. THEO:MAN 50:50. 
 
Overall, the XRPD data suggest that the engineered microcomposite 
formulations retain their crystallinity during wet bead milling followed by 
spray drying. The preservation of the crystalline state is advantageous, 
ensuring the long-term physical stability of the formulations during storage. 
At this point, it should be highlighted, that dry milling techniques (e.g. air jet 
milling and ball milling) can induce crystal defects and even cause surface 
amorphisation of the particles (Ward and Schultz, 1995). These phenomena 
seem to be avoided during wet bead milling, as the liquid medium ensures 
rapid recrystallisation of potentially formed amorphous regions (Kayaert and 
Van den Mooter, 2012). Another suggested mechanism is that the liquid 
media allows fast cooling during particle breakage, which can minimise 
formation of local hot spots on particle surfaces and thus reduce the extent 
of surface amorphisation (Monteiro et al., 2012). 
 
4.4.2.3. Drug loading 
 
The value for THEO content in microcomposites are given in Table 4.2. The 
assayed THEO content was close to the nominal value, indicating no 
significant loss or powder segregation during the production processes. The 
small deviation of the assayed THEO amount compared to the theoretical 
value may be attributed to the suspension collection method employed at the 
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end of the milling process. Separation by pipetting cannot achieve total 
suspension recovery with small amounts remaining among the beads. In 
industrial settings this is unlikely to be an issue as mills with separate 
holding and receiving tanks equipped with paddle mixers are used (Monteiro 
et al., 2012). In this way, enhanced suspension homogeneity and recovery 
are ensured leading to the production of formulations with consistent drug 
loading.  
 
4.4.2.4. In-vitro aerosol performance 
 
The drug deposition profiles of the formulations produced are shown in Fig. 
4.8, while parameters of their aerosol performance are given in Table 4.5. 
The SD susp. THEO exhibited a significantly lower emitted fraction (EF%) of 
65.6 ± 0.8 compared to the formulations containing mannitol (p<0.05), 
which may be attributed to the needle-shaped morphology. Elongated 
particles, despite their ability to travel further in the lung airway, were found 
to have poor dispersion from inhaler when administered as dry powders for 
inhalation as they are subject to strong attractive forces when in contact 
along their axis (Crowder et al., 2002). For the formulations containing 
mannitol, reduced capsule and device retention was observed, leading to 
EF% of around 80% for all the various theophylline to mannitol (THEO:MAN) 
ratios examined in this study (Table 4.5). This may be attributed to their 
more spherical size that allows them to leave the capsule and device by the 
additional mechanism of rolling.  
 
Wet milling of theophylline in the presence of mannitol followed by spray 
drying resulted in particles with enhanced aerosol performance as 
demonstrated by the higher fine particle fraction (FPF%) and fine particle 
doses (FPD) achieved compared to the SD susp. THEO. More specifically, the 
SD susp. THEO achieved a FPF of 26.1 ± 7.1 % and a mass median 
aerodynamic diameter (MMAD) of 4.5 ± 1.1 μm while incorporation of 
mannitol resulted in  approximately 2- fold increase in FPF% (p<0.05), 
depending on the drug to mannitol ratio, and in MMADs close to 3 μm for the 
respective formulations (Table 4.5). Increasing the concentration of mannitol 
from 25% to 50% w/w or 75% w/w resulted in slightly higher FPF% however 
the increase was not found statistically significant (p>0.05). Moreover, 
increasing mannitol concentration shifted drug deposition from stages 2 and 
3 to lower stages of the impactor (i.e. stages 4 to 6) (Fig. 4.8).  
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It is known, that the aerodynamic diameter, which is a function of the 
geometric size and particle density, governs the behaviour of a particle in the 
airstream. Thus, the improved aerosolisation efficiency of the formulations 
containing mannitol may be attributed to their smaller particle size and 
increased porosity compared to SD susp. THEO (Table 4.3 and 4.4). 
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Figure 4.8 Drug deposition profiles of microcomposites containing different theophylline to mannitol ratios delivered using the Cyclohaler® at 
60 L min-1 (mean + SD, n=3). St.1-St.7 denote stages 1-7 of the NGI, the aerodynamic cut-off diameter of each stage is given in parenthesis. 
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Table 4.5 Aerodynamic parameters of microcomposite formulations containing different theophylline to mannitol ratios delivered using the 
Cyclohaler® at 60L min-1 (mean ± SD, n=3). 
Formulation 
Emitted fraction 
(EF %) 
Fine particle 
fraction 
(FPF %) 
Fine particle 
dose 
(FPD, mg) 
 
Mass median 
aerodynamic 
diameter 
(MMAD, μm) 
 
Geometric Standard 
Deviation 
(GSD) 
SD susp. THEO 65.6 ± 0.8 26.1 ± 7.1 2.6 ± 0.6 4.5 ± 1.1 1.7 ± 0.1 
SD susp. THEO:MAN 75:25 84.0 ± 0.4 47.9 ± 2.3 4.8 ± 0.2 3.1 ± 0.2 1.6 ± 0.1 
SD susp. THEO:MAN 50:50 78.9 ± 12.9 56.1 ± 0.8 5.6 ± 0.1 3.2 ± 0.3 1.6 ± 0.0 
SD susp. THEO:MAN 25:75 84.1 ± 4.6 56.8 ± 8.7 5.7 ± 0.9 2.9 ± 0.1 1.7 ± 0.1 
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Previously, when mannitol was added as a matrix former in aqueous 
nanosuspensions prior to spray-drying, it was found to have no significant 
influence on the surface roughness and aerosol performance of the nano-
matrix powders produced (Yamasaki et al., 2011). This result, which at first 
sight seems contradictory to the conclusions of this study, can be explained 
by the fact that in the former study mannitol was dissolved in the aqueous 
drug nanosuspensions and during spray drying it formed a continuous matrix 
around the drug nanocrystals. In the current study, mannitol nanocrystals 
were suspended in isopropanol prior to the spray-drying step, and after 
solvent evaporation they formed porous agglomerates wherein theophylline 
particles were embedded.  
 
4.4.3. Computational study of the interactions between theophylline 
and mannitol 
Results of PIXEL calculations for theophylline form II and mannitol form β are 
given in Table 4.6. Results for the mechanical properties of the crystals, 
calculated by molecular mechanics force field methods are presented in Table 
4.7. Regarding the energy decomposition results for theophylline (Table 4.6), 
only the repulsive component is destabilising with all the other energy terms 
to contribute to the crystal lattice stabilisation. More specifically, the 
dispersion and coulombic components have almost equal contributions 
regarding the stabilisation. These results are in agreement with previously 
published data (Dunitz and Gavezzotti, 2005). In the case of mannitol, the 
coulombic component is by far the most important stabilising interaction, 
reflecting the significance of the hydrogen bonds in the stabilisation of the 
crystal structure. 
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Table 4.6 Lattice energy (kJ/mol) decomposition according to the PIXEL scheme, for 
theophylline form II and mannitol form β. ECOUL: coulombic; EPOL: polarisation; EDISP: 
dispersion; EREP: repulsion and ETOTAL: total intermolecular interaction energy. 
Substance ECOUL EPOL EDISP EREP ETOTAL ΔΗSUB 
THEO -95.5 -47.5 -109.0 123.2 -128.9 135.0* 
Mannitol -312.7 -139.7 -132.2 356.7 -227.8 202.0* 
*Sublimation enthalpies (ΔΗSUB) were taken from http://webbook.nist.gov/chemistry 
 
Table 4.7 Calculated mechanical properties of theophylline form II and D-mannitol β-
form. 
 
 THEO Mannitol 
Bulk modulus (GPa) 14.81 10.85 
Shear modulus (GPa) 4.59 4.15 
Compressibility (GPa-1) 0.0675 0.0922 
Young modulus (GPa) 
Ex 18.6 75.6 
Ey 15.5 15.1 
Ez 22.0 20.5 
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The crystal morphologies of theophylline and mannitol, determined according 
to the BFDH theory and energy vector diagrams are shown in Fig. 4.9. From 
Fig. 4.9c, it is seen that, as already described by Dunitz and Gavezzotti 
(2005), theophylline forms stacked dimers, but those do not form layers in 
the crystal structure, and there are strings of N-H···N hydrogen bonds 
between non-coplanar molecules. The direction of (stabilising) coulombic and 
polarisation, as well as the (destabilising) exchange repulsion interaction 
forces, coincides with the hydrogen bonding motif. On the other hand, the 
(stabilising) dispersion interaction forces extend mainly between adjacent 
coplanar purine rings, normal to the plane defined by the N-H···N hydrogen 
bond strings. 
 
The spatial arrangement of the interaction forces in the lattice of theophylline 
defines the (200) plane as the most probable slip direction since no 
significant interaction forces act along or intersect this plane. However, as it 
becomes evident from the calculated crystal morphology in order to cause 
shearing of the crystal along the (200) plane, a force has to act on the much 
smaller (110) or (201) faces (Fig. 4.9a). The small relative surface area of 
these crystal faces, which is expected to get gradually smaller as milling 
proceeds, together with the rather high stiffness of its crystal structure 
(relatively high values of Young’s modulus, (Table 4.7)) is probably the cause 
of the difficulty to break theophylline crystals by milling. 
 
Mannitol exhibits a needle-like habit, with elongation along the a 
crystallographic axis, which is adequately represented by the BFDH 
morphology model, Fig. 4.9b. As demonstrated by the energy vector diagram 
of mannitol (Fig. 4.9d), intermolecular interaction forces extend parallel to 
the c crystallographic axis, clearly defining a slip direction along the (020) 
plane, in agreement with literature data (Al-Khattawi et al., 2015; Ho et al., 
2012). Moreover it has been reported that mannitol crystals also fracture 
along the (011) plane (Ho et al. 2012). According to the energy vector 
diagram of mannitol, strong stabilising forces act along this plane, therefore 
fracture should not be very likely. However, when the elongated habit of the 
crystals is taken into account, it becomes evident that mechanical forces 
normal to the elongation axis eventually prevail and cause fracture. 
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Figure 4.9 Chemical structures and crystal morphologies of (a) theophylline 
anhydrous form II and (b) D-mannitol β form. Crystal morphologies are calculated 
according to the BFDH theory showing the orientation of the unit cell in the bulk 
crystal. Energy vector diagrams of (c) theophylline form II showing the direction of 
coulombic and polarisation (pink) and dispersion (yellow) interactions, and of (d) D-
mannitol β form, showing the direction of combined stabilising (pink) and 
destabilising repulsive (green) interactions. Red surfaces indicate the most probable 
slip planes. 
 
(a) (b) 
a 
d c 
b 
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Regarding the mechanism by which mannitol facilitates the size reduction of 
theophylline, this may be attributed to the interaction between certain crystal 
faces of the two substances, leading to subsequent adsorption-induced 
reduction of strength of a solid (AIRS); a phenomenon of physicochemical 
mechanics also known as the Rehbinder effect (Rehbinder and Shchukin, 
1972). According to Rehbinder, adsorption of additives on the surface of the 
particles can make crack propagation easier by way of a reduction in surface 
energy (Andrade et al., 1950).  
In order to investigate potential interactions between crystal faces of 
theophylline and mannitol, geometric lattice matching calculations were 
employed. It should be noted that geometric lattice matching calculations are 
developed to study epitaxial growth (i.e. growth of one crystal (overlayer) on 
the surface of another crystal (the substrate), on which the growth of the 
overlayer is oriented by the lattice structure of the substrate) (Datta and 
Grant, 2004). However, as the epitaxy score relates to the density and 
precision of lattice coincidence within a predefined search area and the 
higher its value, the larger the area a substrate and an overlayer can 
maintain a favourable low energy interaction, the use of these calculations 
has been extended in this case (Lee et al., 2010).  
No significant geometric matching was found between the (200) plane of 
theophylline and (020) plane of mannitol. On the contrary, a high E value, 
the epitaxy score, indicates good matching between the (200) plane of 
theophylline and the (011) plane of mannitol. The value of the best matching 
theta, the angle between the (200) plane of theophylline and the (011) plane 
of mannitol is -79.5 o with an E value of 5.4895 (Fig. 4.10a). A one-
dimension Moiré plot shows a high degree of superimposed patterns for 
theophylline’s (200) and mannitol’s (011) crystal plane, which is typical of 
registry between the two crystal lattices (Fig. 4.10b). 
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Figure 4.10 (a) Epitaxy score vs rotation angle and (b) Moiré patterns for the geometric matching of the crystal plane of theophylline (100) on 
that of mannitol (011). 
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The geometric matching of the lattice planes provides an indication of 
favourable interactions that could also lead to attachment of one crystal on 
the other, initiating processes involved in the adsorption-induced reduction 
of strength of theophylline particles. These results, together with the 
different physicomechanical properties of the compounds may shed light on 
the mechanisms behind the enhancement of theophylline’s particle size 
reduction by mannitol during wet milling.  
 
4.5. CONCLUSIONS 
 
Based on the aforementioned results presented in this chapter, it can be 
concluded that:  
1. Inhalable-sized particles of theophylline with various amounts of 
mannitol were successfully prepared by wet milling in isopropanol 
followed by spray drying.  
2. The addition of mannitol as a co-milling agent facilitated the size 
reduction of theophylline’s needle-like crystals and resulted in 
microcomposite particles which consisted of theophylline and mannitol 
submicron crystals assembled together. Increasing the proportion of 
mannitol was found to result in the production of smaller, more 
spherical and porous particles with enhanced aerosol performance.  
3. Crystal morphology modelling and geometric lattice calculations were 
useful tools providing an insight into the intermolecular interactions 
that may influence the mechanical properties of theophylline and 
mannitol and the role of the latter as a co-milling agent.  
4. Overall, wet milling of drugs in an organic solvent in the presence of 
mannitol, followed by spray drying, can be used a formulation 
approach for the production of respirable particles of water-soluble 
drugs or drugs that are prone to crystal transformation in an aqueous 
environment (i.e. formation of hydrates). Preservation of the solid 
phase makes this approach preferable to micronisation by dry milling 
techniques, which is associated with limitations, such as drug 
amorphisation and performance variability.  
CHAPTER 5. GENERAL CONCLUSIONS AND FUTURE WORK 
 
 172 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 5      
GENERAL CONCLUSIONS  
AND FUTURE WORK 
CHAPTER 5. GENERAL CONCLUSIONS AND FUTURE WORK 
 
 173 
5. GENERAL CONCLUSIONS AND FUTURE WORK 
 
5.1. INTRODUCTION 
 
Pulmonary delivery is an attractive route of drug administration for the 
treatment of respiratory diseases such as asthma, COPD and cystic fibrosis. 
DPIs constitute one of the main types of inhalation devices for drug delivery 
to the lungs. The inherent stability of the dry powders, the ability to 
administer high doses, the absence of propellants and the easier use 
compared to pMDIs as they are breath-actuated can explain the increasing 
popularity of DPIs (in patients ≥ 5 years old and with adequate inspiratory 
flow), especially in Europe and North America (Geller, 2005). The application 
of inhaled dry powders has started to expand in new therapeutic areas as 
many drugs have shown to be suitable for lung delivery using DPIs including 
antibiotics, nucleic acids, peptides and vaccines (Yang et al., 2014).   
 
Research on drug delivery to the lungs using DPIs has mainly focused on the 
devices (e.g. fabrication of novel inhaler devices with enhanced efficiency) 
and particle-engineering approaches in order to improve the properties of 
the formulation. Regarding the latter approach, the main goal of particle 
engineering is to produce particles with desirable attributes such as narrow 
particle size distribution, enhanced dispersibility and drug stability, optimised 
bioavailability and specific targeting at clinically relevant regions, taking into 
account the specifics of the device design and the drug delivery requirements 
(Chow et al., 2007).  
 
The classical formulation approach for drug delivery to the lungs using DPIs 
is micronising the API and then mixing with a suitable coarse carrier (e.g. 
lactose). Micronisation (e.g. by ball or air-jet milling for particle size 
reduction) is a destructive, high-energy technique and may generate highly 
cohesive particles which suffer from poor physical and chemical stability, 
electrostatic charge and amorphous domains. More specifically, the 
amorphous state tends to revert back to a lower energy and more stable 
crystalline state upon storage that may adversely influence the product 
performance as it affects critical particle properties such as morphology, 
particle size distribution, dissolution and aerosolisation (Brodka-Pfeiffer et 
al., 2003; Chow et al., 2007). Moreover, engineered blends of micronised 
drug with coarse carrier particles do not exist as simple ordered mixtures. 
For example, micronised drug particles may adhere to coarse carrier 
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particles, to fine lactose particles or form large agglomerates indicating the 
complexity and heterogeneity of these formulations that have been described 
by Stewart et al. (2005) as as “multi-particulate nightmares”.   
 
Currently, many particle-engineering techniques have been developed (e.g. 
spray drying, sonocrystallisation, supercritical fluid technology) that offer a 
significant level of control over the key micromeritic and physicochemical 
properties of the particles produced. At the Drug Delivery to the Lungs 25 
Conference, Stewart (2014) highlighted that such engineering techniques 
that produce more homogeneous particles, compared to micronisation, 
should be an integral part of the future research and development of drug 
delivery using DPIs.  Among these particle-engineering techniques, spray 
drying is a well-established technique for pulmonary drug delivery due to its 
simplicity, flexibility and scalability making it an enduring technology.   
 
5.2. SUMMARY 
 
The work presented in this thesis has focused on engineering nanoparticle 
agglomerates (i.e. microparticles consisting of nanoparticles) as dry powders 
with tailored properties for pulmonary drug delivery. A combined approach 
comprising two steps was employed: wet milling of drug to produce 
nanosuspensions followed by the spray drying of such suspensions in order 
to produce nanoparticle agglomerates suitable for inhalation.  
 
In this thesis, the process of wet milling followed by spray drying as a 
particle-engineering strategy was carried out using three model drugs, each 
drug exhibiting different physicochemical properties and thus posing different 
challenges to the formation of nanoparticle agglomerates. The particles 
produced for each drug were characterised in terms of their particle size 
distribution and morphology, solid state, redispersibility, dissolution and in-
vitro aerosolisation performance.  
 
More specifically, in Chapter 2, indometacin was selected as a poorly water-
soluble drug, which is prone to polymorphic transformations and 
amorphisation upon processing (e.g. dry milling, spray drying). In order to 
elucidate the effect of stabiliser characteristics (e.g. total molecular weight, 
hydrophilic/hydrophobic ratio) on the formation of nanosuspensions, three 
members of the Pluronic® family as well as TPGS were used as stabilisers 
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during wet milling of indometacin. Pluronic® F127 and F68 as well as TPGS 
managed to stabilise the nanosuspensions of indometacin, which after 180 
min of wet milling exhibited a mean hydrodynamic diameter in the range of 
200-300 nm and narrow polydispersity. Based on particle size reduction 
kinetics data, it was found that the molecular weight of the stabilisers used 
influenced the rate but not the limit (steady state) of particle size reduction, 
which was probably determined by the physico-mechanical properties of the 
drug. The nanosuspensions of indometacin were spray dried either 
immediately after preparation without any further pre-treatment or after the 
addition of matrix formers (i.e. mannitol and L-leucine). Incorporation of the 
matrix-formers markedly improved the redispersibility of the nanoparticle 
agglomerates (i.e. their ability to reform nanoparticles after rehydration) and 
their dissolution rate. Regarding the aerosolisation performance, the 
nanoparticle agglomerates containing matrix formers were found to 
outperform those without matrix formers (FPF: 48.9 - 61.9%, compared to 
34.9 - 43.2%) as determined by in-vitro aerosol testing.    
 
Chapter 3 builds on the knowledge gained in Chapter 2. In this chapter, 
ibuprofen was selected as a poorly water-soluble drug, which is problematic 
during size reduction due to its low melting point and high mechanical 
ductility. A full factorial design was employed as a systematic approach to 
understand the critical formulation parameters, as well as any interactions 
between them, involved in the combined wet milling and spray drying 
process. In particular, the critical formulation parameters investigated were: 
type of stabiliser (HPMC, TPGS), mannitol to drug ratio and leucine to drug 
ratio. The responses investigated were: the yield of the process, the particle 
size distribution, the redispersibility and the FPF of the nanoparticle 
agglomerates. Both HPMC and TPGS were effective stabilisers. Ibuprofen 
nanosuspensions stabilised by HPMC exhibited a mean hydrodynamic 
diameter of 533 ± 28 nm, while those stabilised by TPGS had a mean of 663 
± 12 nm. By applying Partial Least Squares to the results of the full factorial 
design (significance level α=0.05), leucine to drug ratio, mannitol to drug 
ratio and the type of stabiliser were found to be significant factors affecting 
the yield of the combination of wet milling and spray drying. The particle size 
was mainly dependent on the leucine to drug ratio and the type of stabiliser. 
Mannitol to drug ratio was found as the only critical parameter affecting 
redispersibility of nanoparticle agglomerates and both leucine to drug ratio 
and mannitol to drug ratio were found as significant factors affecting FPF%.  
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In Chapter 4 the approach of coupling wet milling with spray drying as a 
particle-engineering method for inhalable composite particles was expanded 
to drugs that cannot be milled in aqueous media. Theophylline, which has a 
long history in respiratory medicine, was selected as it is a moderately 
water-soluble drug, which transforms to its hydrate form when processed in 
water. Moreover, the crystals of theophylline exhibit a needle-like shape and 
thus it can be used as a model for compounds with strongly anisotropic 
morphology that are known to be more difficult to process, but which 
nevertheless are increasingly commonly encountered during discovery and 
early development. In this chapter, theophylline was milled in isopropanol in 
the presence of various amounts of mannitol, and the suspensions prepared 
were solidified by spray drying. Addition of mannitol as a co-milling agent 
facilitated size reduction of the elongated crystals of theophylline, and 
microcomposite particles consisting of theophylline and mannitol submicron 
crystals assembled together were obtained after spray drying. It was found 
that increasing the ratio of mannitol to theophylline resulted in smaller, more 
spherical microcomposites with enhanced aerosolisation performance.  
 
Solid-state characterisation demonstrated that the inhalable particles 
prepared using the methodology outlined in this thesis retained the 
crystallinity of the starting materials and that was a common finding for all 
the drugs used. More specifically, in the nanoparticle agglomerates obtained, 
indometacin was in the stable γ-form, ibuprofren was in the same crystalline 
state as the raw drug and theophylline was in the form II (stable form at 
room temperature) while no solvate formation was observed. The fact that 
by carefully selecting the milling solvent and by fine-tuning the process 
parameters, the crystallinity of the particles can be retained is beneficial as it 
ensures the long-term physical stability of these formulations.  
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5.3. CONCLUSIONS 
 
In this thesis, it was demonstrated that preparation of nanosuspensions by 
wet milling and then spray drying such suspensions could be used as an 
industrially feasible approach to produce composite microparticles of poorly 
water-soluble drug with properties suitable for inhaler formulation.  
 
The selection of the suitable stabiliser is a key step for the successful 
formation of nanosuspensions. Monitoring the particle size of the suspensions 
at various intervals during wet milling provided information on the particle 
size reduction kinetics of the drug. For both indometacin and ibuprofen, 
breakage rate was high initially but with further milling the size continued to 
decrease but at markedly slower rate. These results corroborate the 
observation that breakage rate kinetics of a drug can be described by a first-
order exponential decay function (Afolabi et al., 2014). For a certain milling 
speed, the duration of milling should be equal to the amount of time required 
for the steady state size to be achieved (plateau region). Milling speed is 
another parameter that should be adjusted especially when wet milling 
equipment without temperature control is used. This was found to be 
particularly important in the case of the low-melting point drug ibuprofen, 
where a milling speed of 200 rpm had to be selected in order to prevent 
melting of the drug nanocrystals. It should be noted that in this thesis, two 
different planetary mills were used for the preparation of suspensions. In the 
case of indometacin, nanosuspensions were produced by a planetary micro 
mill Pulverisette 7 which can reach a maximum of 1100 rpm while for 
ibuprofen and theophylline, wet milling was carried out using a planetary mill 
Pulverisette 5 which can reach a maximum of 300 rpm. In this latter case, a 
replacement of the common milling pot by a stainless steel pot whereby 8 
glass vials could be fitted, allowed the reduction of the amount of time and 
material required for each milling experiment. Therefore, wet milling is a 
versatile technique for the production of nanocrystals that can be applied 
from early development (e.g. pre-formulation stage) when small amounts of 
a compound are available through commercial-scale manufacturing using 
wet milling equipment operating in a recirculation mode.  
 
Nanosuspensions were converted to nanoparticle agglomerates by spray 
drying. The formation of the nanoparticle agglomerates can be explained by 
the one-droplet-to-one-particle (ODOP) principle. More specifically, at high 
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atomisation gas flow, two-fluid nozzles generate droplets with a size of 4-7 
μm, which after drying result in particles around 2-3 μm (Kemp et al., 2013). 
Therefore, during the spray drying of the nanosuspensions, a droplet 
contained many nanocrystals, which after drying formed a composite 
microparticle.  
 
In the case of indometacin and ibuprofen, the matrix formers were dissolved 
in the aqueous nanosuspensions. Based on SEM images and previously 
published studies, it is assumed that in the spray-dried particles, mannitol 
formed a continuous matrix around the nanocrystals while L-leucine 
preferentially accumulated on the surface of the particles (Vehring, 2008). 
The addition of matrix formers enhanced the redispersibility, the dissolution 
rate and the aerosolisation behaviour of the nanoparticle agglomerates. The 
full factorial design employed in the case of ibuprofen provided a systematic 
basis in order to understand the effect of the amounts of both mannitol and 
L-leucine on the production and in-vitro performance of the nanoparticle 
agglomerates. Analysis of the full factorial design results showed that high 
mannitol and L-leucine to drug ratio should be incorporated in the 
nanosuspensions prior to spray drying, with mannitol having a significant 
effect on the redispersibility of the nanoparticle agglomerates, while L-
leucine acted as an aerosolisation enhancer. Moreover, addition of high 
amounts of mannitol and leucine improved the yield of the process, which 
was attributed to the formation of a matrix around the nanocrystals, which 
prevented them from melting. At this point, it should be highlighted that 
while the results of the full factorial design may guide the selection of 
formulation parameters regarding the formation of nanoparticle 
agglomerates, they should not be generalised to other drugs without further 
testing.  
 
The use of wet milling followed by spray drying as a particle-engineering 
approach was extended to the formation of microcomposite particles of 
(moderately) water-soluble drugs, with theophylline as a model drug. Prior 
to the extension of the process, suitable modifications had to be 
implemented including the selection of the milling solvent and the stage at 
which mannitol was incorporated.  
 
In the case of theophylline, the selection of isopropanol as the milling solvent 
was governed by the drug solubility. A rule of thumb is that a milling solvent 
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in which a drug exhibits low solubility should be selected in order to avoid 
the presence of the drug in both a solution and a suspended phase. Having 
the drug partly dissolved and partly suspended in the milling solvent may 
result in the formation of partially amorphous particles during spray drying. 
Using an organic solvent instead of water during wet milling called for a 
further modification of the process, as mannitol cannot be incorporated in 
the suspension before spray drying, due to its limited solubility in 
isopropanol. Instead, incorporation of mannitol during the wet-milling step of 
theophylline resulted in suspensions containing fine particles of both 
compounds. Spray drying of these suspensions resulted in respirable 
microcomposite particles where submicron theophylline were embedded in a 
porous network of mannitol nanocrystals. Increasing the proportion of 
mannitol was found to facilitate the size reduction of theophylline crystals 
and smaller, more spherical and porous microcomposite particles with 
enhanced aerosolisation performance were produced after spray drying. 
Thus, when wet milling takes place in an organic solvent, mannitol can play a 
double role: matrix former and co-milling agent.  
 
In conclusion, the main aim of the thesis was achieved as a drug delivery 
platform based on wet milling and spray drying for the engineering of 
nanoparticle agglomerates suitable for inhalation was developed. The rational 
selection of formulation and process parameters allows the application of this 
platform to a range of drugs with different physicochemical and mechanical 
properties (e.g. water-soluble, low-melting point and ductile drugs). In all 
cases, after the optimisation of the process, the particles produced 
demonstrated enhanced aerosolisation performance and they retained the 
crystalline form of the starting materials. Especially for poorly water-soluble 
drugs, the in-vitro performance of the nanoparticle agglomerates was 
complemented by an improved dissolution profile. The observation that the 
microcomposite particles produced by this platform tend to exhibit a rather 
uniform set of properties may indicate that their in-vitro performance is 
process-related. Furthermore, preservation of the solid state makes this 
approach preferable to micronisation by dry milling techniques, which is 
associated with limitations, such as drug amorphisation and performance 
variability. These conclusions support the hypothesis outlined in the 
beginning of this thesis that it is possible to engineer respirable particles with 
a tailored crystalline form for a range of drugs with different physicochemical 
properties, by preparing nanoparticles and spray drying them in the presence 
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of suitable excipients in order to produce inhalable microcomposite particles 
with predictable performance. 
 
Finally, based on the findings of this thesis, an initial “road map” was 
developed to guide the selection of formulation and process parameters that 
should be considered in order to engineer inhalable nanoparticle 
agglomerates, by taking into account the physicochemical properties of the 
drug in question (Fig. 5.1). As it is depicted in the roadmap, the selection of 
the stabiliser during wet milling is one of the first decisions that should be 
taken. Despite a few studies focusing on this topic, the selection of the 
suitable stabiliser is an empirical decision and an open challenge for future 
research. However, the “road map” presented in this thesis may pave the 
way towards the development of a “universal” delivery system where input 
drugs with different physicochemical properties can be processed by wet 
milling and spray drying in the presence of suitable excipients in order to 
produce inhalable microcomposite particles with predictable performance.   
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Figure 5.1 “Road map” developed in this thesis to guide the selection of formulation 
and process parameters that should be adjusted in order to engineer inhalable 
nanoparticle agglomerates, by taking into account the physicochemical properties of 
the drug in question. 
5.4. FUTURE WORK 
 
There are two main areas that future work could focus upon: i) the 
optimisation of the wet milling and spray drying as well as of the 
combination of these two processes as a particle-engineering approach and 
ii) the application of the approach in new areas inside the field of respiratory 
medicine.  
 
One of the current limitations is the empirical nature of the stabiliser 
selection for the production of nanosuspensions. At present there is no 
systematic approach to guide the choice of stabiliser with respect to the 
active ingredient. Recently, many studies have focused on scaling-down the 
wet-milling process so as to allow the parallel screening of different 
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stabilisers (Juhnke et al., 2010; Romero et al., 2016). While these scaling-
down approaches do not provide a first-principle-based predictive method 
towards the identification of a suitable drug stabiliser, they manage to 
reduce the time, effort and materials required for the development of drug 
nanosuspensions (Li et al., 2016). Focus should be given to approaches such 
as molecular modeling and scanning probe microscopy that can provide 
valuable insight into the way the stabiliser adsorbs to the surface of the 
crystal particles (Konkel and Myerson, 2009; Verma et al., 2009a). In this 
way, these two techniques may be able to prioritise and narrow-down the 
number of stabilisers that need to be screened. Measuring the adsorption of 
stabilisers on the drug surface and constructing adsorption isotherms can be 
a valuable tool for the rational selection of the type and concentration of 
polymeric stabilisers in formulation development (Goodwin et al., 2013). 
Moreover, potential within the areas of nanosuspension preparation and 
solidification can be accelerated with the implementation of the concept of 
quality by design (Verma et al., 2009b). In this way, the knowledge of the 
interplay between formulation, process, and quality attributes will facilitate 
rational design of nanocrystalline-based formulations. 
 
Regarding pulmonary drug delivery, one of the distinct advantages of 
inhalable nanoparticle agglomerates is their enhanced aerosolisation 
performance even without the addition of carrier particles (e.g. lactose). In 
this way, high drug payloads can be administered to the lungs, which are 
difficult with the traditional approach of adhesive mixtures of carrier particles 
and micronised drug. This approach can revolutionise the administration of 
antibiotics to patients with chronic respiratory conditions (e.g. cystic 
fibrosis), as it enables local delivery of higher drug concentration at the lung 
tissue while concentrations elsewhere are kept at a minimum. In this way, 
maximum therapeutic effect can be achieved by administering lower inhaled 
doses compared to those required for systemic administration, and as a 
result side effects can be minimised.  
 
Moreover, as asthma and COPD are multi-factorial diseases, the use of an 
inhaled corticosteroid (ICS) plus a long-acting β2-agonist (LABA) has been 
reported to offer a more effective management in these respiratory diseases 
compared to monotherapy (Kankaanranta et al., 2004). In particular, the 
single inhaler for maintenance and relief therapy (SMART) approach, which 
advocates the administration of an ICS/LABA combination from a single 
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inhaler, is recognised as a simple, cost-effective approach which enhances 
patient adherence and provides more effective asthma and COPD control 
(Barnes, 2007). Currently, available inhalable combination products are 
produced by blending discrete micronised particles of both active compounds 
with a coarse carrier (e.g. lactose) and loading into an inhaler device. Apart 
from the limitations of dry micronisation techniques and adhesive mixtures 
that have been mentioned above, it is a challenge to maintain the ratio of 
micronised actives in the formulation by powder blending, especially taking 
into account that in ICS/LABA combinations, the ICS is present in a five to 
30-fold mass excess (Parikh et al., 2012). Most importantly, the micronised 
particles of the two drugs can exhibit different particle size distributions, 
morphologies and surface characteristics resulting in differences in their 
aerodynamic performance. Thus, it is very challenging to ensure that both 
drugs are deposited at the correct ratio and within the same region of the 
lungs. 
 
Combining both drugs in a single particle has been proposed as a particle 
engineering approach to achieve co-deposition in the same lung region, and 
thus to achieve synergy at the cellular/molecular level (Pitchayajittipong et 
al., 2009; Westmeier and Steckel, 2008). Following this direction, the 
concept of nano-in-micro can be tailored to the preparation of inhalable 
combination particles especially when the poor aqueous solubility of ICSs is 
taken into account. However, when designing inhalable particles containing a 
combination of two or more drugs, it is not always easy to identify a common 
solvent for the preparation of the nanosuspensions. Therefore, advanced 
spray-drying techniques (e.g. multiple-fluid nozzle) may be required in order 
to allow each drug to be milled in a different solvent and thus the final 
combination particle to contain crystalline nanoparticles of both drugs.  
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